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1.1. Colon anatomy 
 
The colon is the last part of the digestive system; it extracts water and salt from solid 
wastes before they are eliminated from the body, and is the site in which flora-aided 
(largely bacteria) fermentation of unabsorbed material occurs. Unlike the small 
intestine, the colon does not play a major role in absorption of foods and nutrients. 
However, the colon does absorb water, potassium and some fat soluble vitamins. 
Anatomically it consists of four sections (Figure 1) [1]: the ascending colon, the 
transverse colon, the descending colon, and the sigmoid colon (the proximal colon 
usually refers to the ascending colon and transverse colon). The colon, cecum, and 
rectum make up the large intestine. 
 
Figure 1. Colon anatomy 
 
Histologically the colon can be divided into four layers (Figures 2A and B) [2,3]: 
mucosa, submucosa, muscularis externa and serosa. 
 
          
Figures 2A and B. Colon structure. 
 
The mucosa is composed by the epithelium, lamina propria and muscularis mucosae 
(Figures 3A and B) [4]. It has a simple columnar epithelium shaped into straight 
B 
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tubular crypts, which are short invaginations of mucosal epithelium and provide 
protected pockets for special cellular functions. There are no villi. In cellular 
composition, the epithelium resembles that of the small intestine, but with a higher 
proportion of goblet cells interspersed among the absorptive cells (enterocytes). 
Goblet cells are specialized for secretion of mucus, which facilitates passage of 
material through the bowel, while enterocytes are specialized for absorption of 
nutrients across the apical plasma membrane and export of these same nutrients 
across the basal plasma membrane. The crypt epithelium also includes stem cells 
which replenish the epithelium every few days, enteroendocrine cells, and Paneth 
cells (secretory epithelial cells located at the ends of intestinal crypts. The function 
for these cells is secretion of anti-bacterial proteins into the crypt lumen, thereby 
providing protection for the stem cells which line the crypt walls). The crypts are 
separated by conspicuous lamina propria, the loose connective tissue in a mucosa. 
 Lamina propria supports the delicate mucosal epithelium, allows the epithelium to 
move freely with respect to deeper structures, and provides for immune defense, it is 
composed by connective tissue infiltrated by many white blood cells, with 
capillaries and thin strands of smooth muscle. 
 
           
Figure 3A and B. Colon mucosa structure. 
 
The muscularis mucosa of the lower tract forms a thin layer (only a few muscle 
fibers in thickness) beneath the deep ends of the crypts. The submucosa is a 
connective tissue layer deep to and supporting the mucosa. The muscularis externa 
of the colon has the standard layers of inner circular and outer longitudinal smooth 
muscle. The outer layer of the colon is a serosa attached to mesentery, ordinary 
connective tissue with a surface of mesothelium. 
B A 
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1.2. Colon specific delivery 
 
The oral route is considered to be the most convenient for administration of drugs to 
patients. The conventional oral dosage forms normally dissolve in the stomach fluid 
or intestinal fluid and are absorbed from these regions of the gastrointestinal (GI) 
tract, which depend upon the physicochemical properties of the drug. Localized 
delivery of the drugs in the colon region is possible only when the drug is protected 
from the hostile environment of upper GI tract. Dosage forms that deliver drugs into 
the colon region rather than upper GI tract proffers number of advantages. Oral 
delivery of drugs to the colon is valuable in the treatment of diseases of colon 
(ulcerative colitis, Crohn's disease, carcinomas and infections) whereby high local 
concentration can be achieved while minimizing side effects that occur because of 
release of drugs in the upper GI tract or unnecessary systemic absorption. Specific 
systemic absorption of drugs and protein/peptides in the colonic region offers 
interesting possibilities for the treatment of disease susceptible to diurnal rhythm 
such as asthma, arthritis or inflammation [5-7]. The colon is considered to be more 
suitable for delivery of peptides and protein in comparison to small intestine because 
proteolytic enzyme activity in the colon, such as digestive enzyme and metabolic 
enzyme activity, is lower than in the small intestine [8-11]. Because of the distal 
location of colon in the GI tract, a colon-specific drug delivery system should 
prevent drug release in the stomach and small intestine, and affect an abrupt onset of 
drug release upon entry into the colon. This necessitates a triggering element in the 
system that can respond to physiological changes in the colon. Three strategies are 
currently being pursued to achieve drug release specifically in the colon [12-14].  
1 ) The fact that the luminal pH of the distal colon is slightly higher than that of the 
proximal small intestine has led to the development of oral dosage forms that are 
intended to release the drug at the colonic pH (pH controlled drug delivery). An 
overview of the pH details of the GIT is shown in Table 1 [15]. 
2) The colonic microflora produce a variety of enzymes that are not present in the 
stomach or the small intestine and could therefore be used to deliver drugs to the 
colon after enzymatic cleavage of degradable formulation components or drug 
carrier bonds (enzyme controlled drug delivery).  
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3) The relatively constant transit time in the small intestine – approximately 3–5 h – 
is another physiological characteristic that can be taken advantage of to achieve 
colon specificity (time-controlled drug delivery). After gastric emptying, a time-
controlled drug delivery system is intended to release the drug after a predetermined 
lag phase. Gastric emptying of dosage forms is highly variable and depends 
primarily on whether the subject is fed or fasted and on the properties of the dosage 
form such as size and density. The transit times of small dosage forms in GI tract is 
shown in Table 2 [15]. 
 
Table 1. Average pH in the GI tract                                     Table 2. Transit time in the GI tract 
 
 
 
 
 
 
1.2.1. pH-dependent systems  
The pH-dependent systems rely on the physiological difference between the luminal 
pH of the acidic stomach and that of the large intestine. The pH of the human GI 
tract increases progressively from the stomach (pH=1-2, which increases to 3 during 
digestion), small intestine (pH=5-6) at the site of digestion and it increases to 7-8 in 
the distal ileum [15]. The coating of pH-sensitive polymers to the tablets capsules or 
pellets provide delayed release and protect the active drug from gastric fluid. The 
polymers used for colon targeting, however, should be able to withstand the lower 
Organ Transit time 
(h) 
Stomach 
 Fasting 
 
 Fed 
 
<1 
>2 
Small intestine 3-4 
Large intestine 20-30 
Location pH 
Oral cavity 6.2-7.4 
Oesophagus 5.0-6.0 
Stomach 
 Fasted condition 
 Fed condition 
 
1.5-3.0 
3.0 
Small intestine 
 Duodenum 
 Jejunum 
 Ileum 
 
4.5-5.0 
5.0-6.5 
6.0-7.0 
Large intestine 7.5 
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pH values of the stomach and of the proximal part of the small intestine and also be 
able to disintegrate at the neutral of slightly alkaline pH of the terminal ileum and 
preferably at the ileocecal junction. These processes distribute the drug throughout 
the large intestine and improve the potential of colon targeted delivery systems. 
Most commonly used pH-dependent coating polymers are methacrylic acid 
copolymers commonly known as Eudragit
®
, more specifically Eudragit
®
 L and 
Eudragit
® 
S (Figure 4) [14]. Eudragit
®
 L 100 and S 100 are copolymers of 
methacrylic acid and methyl methacrilate. The ratio of carboxyl to ester groups is 
approximately 1:1 in Eudragit
®
 L 100 and 1:2 in Eudragit
®
 S 100. The polymers 
form salts and dissolve above pH 5.5 and disperse in water to form latex and thus 
avoid the use of organic solvents in the coating process. The water solubility of the 
Eudragit
®
 S depends on the ratio of free carboxyl groups to the esterified groups. 
The critical factor that influences the performance of these polymers is the pH value 
at which dissolution occurs. 
 
 
Figure 4. Chemical structures of various formulations of Eudragit® 
 
1.2.2. Time-release-dependent systems 
This approach is based on the principle of delaying the release of the drug until it 
enters into the colon. The strategy in designing timed release systems is to resist the 
acidic environment of the stomach and to undergo a lag time of predetermined span 
of time, after which release of drug takes place. The lag time in this case is the time 
requires to transit from the mouth to the colon. The first formulation introduced 
based on this principle was Pulsincap
® 
(Figure 5) [16]. It is similar in appearance to 
hard gelatin capsule; the main body is made water insoluble. The contents are 
contained within a body by a hydrogel plug, which is covered by a water-soluble 
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cap. The whole unit is coated with an enteric polymer to avoid the problem of 
variable gastric emptying. When the capsule enters the small intestine the enteric 
coating dissolves and the hydrogel plug starts to swell, the amount of hydrogel is 
such adjusted that it pops out only after the stipulated period of time to the release 
contents. 
 
Figure 5. Pulsincap® system 
 
A delivery system called Time Clock
® 
has been exploited to deliver the drug to the 
colon. It is composed of a solid dosage form coated with a hydrophobic coating 
layer which consists of wax, Tween-80 and hydroxypropylmethylcellulose (HPMC). 
The lag time observed with this system is caused by slow hydratation of the coating 
layer in a time proportional to the thickness of the film and the core is then available 
for dispersion.  
Pressure controlled drug delivery systems have been developed to target the drugs to 
the colon [17,18]. The OROS-CT can be used to target the drug locally to the colon 
for the treatment of disease or to achieve systemic absorption. The OROS-CT 
system can be a single osmotic unit or may incorporate as many as 5-6 push-pull 
units, encapsulated within a hard gelatin capsule. Each bilayer push pull unit 
contains an osmotic push layer and a drug layer, both surrounded by a 
semipermeable membrane. An orifice is drilled through the membrane next to the 
drug layer. Immediately after the OROS-CT is swallowed, the gelatin capsule 
containing the push pull units dissolves. Because of its drug-permeable enteric 
coating, each push pull unit is prevented from absorbing water in the acidic aqueous 
environment of the stomach and hence no drug is delivered. As the unit enters the 
small intestine, the coating dissolves in this larger pH environment (pH>7), water 
enters the unit, causing the osmotic push compartment to swell and concomitantly 
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creates a flowable gel in the drug compartment. Swelling of the osmotic push 
compartment forces drug gel out of the orifice at a rate precisely controlled by the 
rate of water transport through the semipermeable membrane.  
For treating ulcerative colitis each push pull unit is designed with a 3-4 hours post 
gastric delay to prevent drug delivery in the small intestine. Drug release begins 
when the unit reaches the colon. OROS-CT units can maintain a constant release 
rate for up to 24 hours in the colon or can deliver drug over an internal as short as 4 
hours. The results showed the capability of the system in delaying drug release for a 
programmable period of time and the possibility of exploiting such delay to attain 
colon targeted delivery according to a time-dependent approach. 
 
1.2.3. Enzyme-dependent systems 
The gastrointestinal tract is inhabited by a variant microflora all along. The bacteria 
distribution within the gastro-intestinal tract is different and depends on the part of 
the GIT considered.  
In Figure 6 [19] the concentration of bacterial flora in different regions of the 
gastrointestinal tract is presented. The microflora of the stomach is normally sparse 
and bacterial concentration is less than 10
3
 CFU (colony forming unit) ml
-1
. The 
bacterial concentration in the small intestine is of the order of 10
3–104 CFU ml-1, 
while in the large intestine it increases sharply and the colon has a microflora of 
10
11–1012 CFU ml-1 [20]. 
 
 
Figure 6. Microflora distribution in GI tract 
 
One of the main function of the colonic microflora is the carbohydrate fermentation 
and absorption; bacteria produce a wide range of reductive and hydrolytic enzymes 
(amidase, esterase, reductase, deaminase), that ferment the various types of substrate 
 15 
 
that have been indigested in the small intestine like glucose, bi- and tri-saccharide 
and other polysaccharide (starch, pectin, dextran, chitosan, guar gum). The large and 
specific colonic enzyme concentration, which is not present in the rest of the GI 
tract, can be used to deliver drugs to the large intestine. Enzyme-dependent systems 
can be divided in two groups: prodrugs and biodegradable polysaccharides.  
Prodrug is pharmacologically inactive derivative of a parent drug molecule that 
requires spontaneous or enzymatic transformation in vivo to release the active drug. 
For colonic delivery of drugs, prodrugs are designed to undergo minimal absorption 
and hydrolysis in the upper GI tract and undergo enzymatic hydrolysis in the colon, 
there by releasing the active drug moiety from the carrier. A considerable number of 
linkages susceptible to bacterial hydrolysis specifically in the colon have been 
prepared where the drug is covalently attached to hydrophilic moieties of carriers 
like amino acid, glucuronic acid, monosaccharide, polymers. 
The metabolism of azo compounds by the intestinal bacteria is one of the most 
extensively studied bacterial metabolic processes. Both intracellular and 
extracellular reduction has been observed. In 1942 sulfasalazine (Figure 7) was 
prepared: it is formed by 5-aminosalycilic acid bound with a carrier (sulfapyridine, 
SP) through an azo-bond, which undergoes reduction in the colon. However, due to 
a number of side effects associated with SP studies, other carriers were studied to 
deliver 5-ASA to the large intestine with minimal side effects. This lead to 
formation of ipsalazide, balsalazide, and finally to olsalazide, where two molecules 
of 5-ASA were joined together [21]. 
 
 
Figure 7. Sulfasalazine chemical structure and mechanism of drug release by reductase enzyme 
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Macromolecular prodrugs were also prepared, for istance dextran [22,23] or 
cyclodextrin [24-27] conjugates.  
Newer approaches are aimed at use of polymers as drug carriers for drug delivery to 
the colon. Both synthetic as well as naturally occurring polymers are used for this 
purpose. Use of naturally occurring polysaccharides have also been investigated for 
colonic delivery of drugs, since these polymers of monosaccharide are found in 
abundance have wide availability, are inexpensive and are available in variety of 
structures with varied properties. They can be easily modified chemically and 
biochemically and are highly stable, safe, non- toxic, hydrophilic and gel forming 
and in addition biodegradable. These include naturally occurring polysaccharides 
obtained from plant (guar gum, inulin), animal (chitosan, chondroitin sulphate), 
algal (alginates) or microbial (dextran) origin [28-30]. These are selectively broken 
down by the colonic microflora to simple saccharides.  
Many of the polysaccharide-based delivery systems shield the drug from the hostile 
environments of the upper GIT. When these delivery systems arrive into the colon 
the glycosidic linkages within the polysaccharides are hydrolyzed releasing the drug 
candidate. 
 
 
 
1.2.4. Drugs used to colon delivery 
Drugs which show poor absorption or degrade in the stomach or intestine including 
peptide are most suitable for colon specific drug delivery systems [31-36].  
The drugs used in the treatment of inflammatory bowel disease and colon cancer are 
ideal candidates for local colon delivery [37-39]. 
In addition colonic targeting of drugs would prove useful where an intentional delay 
in absorption is desirable from a therapeutic point of view as for the treatment of 
diseases that have peak symptoms in the early morning and that exhibit circadian 
rhythm, such as nocturnal asthma, angina and rheumatoid arthritis [7]. 
The criteria for the selection of drugs for colon specific drug delivery systems are 
shown in Table 3. 
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Table 3. Drugs used for colon specific delivery. 
 
Criteria 
 
 
Drugs 
 
Drugs for disease that exhibit circardian rhytm Theophylline Ibuprofen      
Verapamil 
Drugs poorly absorbed from upper GIT Cyclosporine 
Desmopressin 
Drugs for colon cancer 5-Fluorouracil 
Drugs that degrade in stomach and small intestine 5-Fluorouracil 
Calcitonin Insulin 
Drugs for targeting 5-Aminosalicylic-acid 
Prednisolone 
Metronidazole 
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1.3. Colon diseases 
 
Site specific drug delivery to the colon is important for the treatment of diseases 
associated with the colon, reducing the side effects of the drug and reducing the 
administered dose. The most important colon-associated diseases are: inflammatory 
bowel disease (Crohn’s disease and ulcerative colitis), colon cancer, irritable bowel 
syndrome, diverticulitis and amoebiasis. 
 
1.3.1. Inflammatory bowel disease 
The term inflammatory bowel disease (IBD) covers a group of disorders in which 
the intestine become inflamed, probably as a result of an immune reaction of the 
body against its own intestinal tissue. Two major types of IBD have been described: 
ulcerative colitis (UC) and Crohn's disease (CD) [40,41].  
 
Table 4. Main differences between Ulcerative colitis and Crohn’s disease. 
  
Ulcerative colitis 
 
Crohn’s disease 
 
Areas of 
involvement 
 
Involves the rectum and extends 
proximally in a continuous 
fashion, and always remains 
restricted to the colon. Is 
sometimes restricted to the 
rectum as ‘ulcerative proctitis. 
 
Most commonly the terminal 
ileum, cecum, perianal area 
and colon, but any part of the 
GI tract can be affected. 
Characterized by segments of 
normal bowel between 
affected regions, known as 
‘skip lesions’. 
 
Histology of 
inflammation type 
 
An inflammation affecting the 
superficial (mucosal) layers of the 
bowel wall, infiltration of 
lymphocytes and granulocytes 
and loss of Goblet cells, 
accompanied by ulcerations and 
crypt abscesses. 
 
A transmural inflammation 
(affecting all layers of the 
bowel wall), dense infiltration 
of lymphocytes and 
macrophages; granulomas in 
up to 60% of the patients; 
fissuring ulceration and 
submucosal fibrosis. 
 
Characterization of 
inflammation type 
 
The inflammation is characterized 
by a more Th2 type response, 
with high levels of IL-5 and IL-13 
(but not IL-4), high levels of 
autoantibodies ( anti-neutrophil 
cytoplasmic antibodies (pANCA), 
indicative of B-cell activation). 
 
The inflammation is 
characterized by a Th1 type 
response, with high levels of 
IL-12, IFN-g and TNF-a. 
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As the name suggests, ulcerative colitis is limited to the colon (large intestine), 
although Crohn's disease can involve any part of the gastrointestinal tract from the 
mouth to the anus; it most commonly affects the small intestine and/or the colon. 
The main differences between them are shown in Table 4 [42]. 
Because inflammatory bowel disease is a chronic disease (lasting a long time), it 
goes through periods in which the disease flares up and is considered to be in an 
active stage and severe inflammation; these periods are followed by remission, in 
which symptoms disappear or decrease and normal conditions return [43]. 
Symptoms may range from mild to severe and generally depend upon the part of the 
intestinal tract involved. They include the following: abdominal cramps and pain, 
bloody diarrhea, severe urgency to have a bowel movement, fever, loss of appetite, 
weight loss, anemia (due to blood loss). 
Researchers do not yet know what causes inflammatory bowel disease [44,45]. 
Therefore, IBD is called an idiopathic disease (disease with an unknown cause). An 
unknown factor/agent (or a combination of factors) triggers the body’s immune 
system to produce an inflammatory reaction in the intestinal tract that continues 
without control. As a result of the inflammatory reaction, the intestinal wall is 
damaged leading to bloody diarrhea and abdominal pain.  
 
 
Figure 8. Mucosal immune response initiated by microbial sensing systems activates adaptive 
immune responses. Pathogenic bacteria or commensal microbes in genetically susceptible hosts 
disrupt epithelial barrier function, triggering the recruitment and activation of innate immune 
responses and colitogenic CD4+ T cells. Depicted cells and cytokines imply that multiple 
components are involved in controlling mucosal immune responses in physiological and 
pathological states of inflammation. NK, natural killer. 
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Genetic, infectious, immunologic, and psychological factors have all been 
implicated in influencing the development of IBD. There is a genetic predisposition 
(or perhaps susceptibility) to the development of IBD. However, the triggering 
factor for activation of the body’s immune system has yet to be identified. Factors 
that can turn on the body’s immune system include an infectious agent, an immune 
response to an antigen, or an autoimmune process. Genetic susceptibility is 
influenced by the luminal microbiota, which provides antigens and adjuvants that 
stimulate either pathogenic or protective immune responses. Environmental triggers 
are necessary to initiate or reactivate disease expression. In inflammatory bowel 
disease, the well-controlled balance of the intestinal immune system is disturbed at 
all levels (Figure 8) [46]. 
Standard treatment for ulcerative colitis depends on extent of involvement and 
disease severity [47-49]. The goal is to induce remission initially with medications, 
followed by the administration of maintenance medications to prevent a relapse of 
the disease. Aminosalicylate, corticosteroids, immunosuppressive drugs and TNF- 
inhibitors are commonly used in the treatment of IBD.  
 Aminosalicylate: 5-ASA compounds (mesalazine, osalazine, sulfasalazine, 
balsalazide) [50] have been shown to be useful in the treatment of mild-to-moderate 
Crohn's disease and ulcerative colitis and as maintenance therapy.  
 Corticosteroids: They are a class of anti-inflammatory drug that are used 
primarily for treatment of moderate to severe IBD. The most commonly prescribed 
oral steroid is prednisone, but the following corticosteroids are also used as immune 
system suppressants in treatment of ulcerative colitis: cortisone, hydrocortisone and 
budesonide [51]. 
 Immunosuppressive drugs. They inhibit the immune system generally. These 
include the cytostatic drugs that inhibit cell division, including the cloning of white 
blood cells that is a part of the immune response. Immunosuppressive drugs used 
with ulcerative colitis include: mercaptopurine (6-MP, it is a cytostatic drug that is 
an antimetabolite, it mimics purine, which is necessary for the synthesis of DNA, 
with mercaptopurine present, cells are not able to make DNA, and cell division is 
inhibited); azathioprine (which metabolises to 6-MP) and methotrexate (which 
inhibits folic acid) [52]. 
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 TNF inhibitors: They are monoclonal antibodies that inhibit the pro-
inflammatory cytokine tumour necrosis factor (TNF). The most important are 
infliximab and adalimubab [53]. 
 Antibiotics: Metronidazole and ciprofloxacin are antibiotics which are used to 
treat IBD. They are also used for treatment of complications, including abscesses 
and other infections. 
 
1.3.1.1. 5-Aminosalycilic acid 
5-Aminosalicylic acid (5-ASA), also known as mesalazine or mesalamine, is an 
anti-inflammatory drug used to treat inflammation of the digestive tract, ulcerative 
colitis and Crohn's disease (Inflammatory Bowel Disease, IBD). It is a bowel-
specific aminosalicylate drug that acts locally in the gut and has its predominant 
actions there [50].
 
 
The precise mechanism of action of 5-ASA is not known, but is likely due to a 
combination of anti-inflammatory properties [54,55]. 
 
Table 5.  5-ASA chemical properties. 
   
 
            
              
It has been shown to block the production of interleukin-1 (IL-1) and tumor necrosis 
factor- (TNF-) [56,57] and it is a potent inhibitor of the cyclooxygenase pathway, 
inhibiting the production of prostaglandin E2 in inflamed intestinal specimens [58]. 
 
 
CHEMICAL STRUCTURE   
 
 
IUPAC name 5-amino-2-hydroxybenzoic acid 
Formula C7H7NO3 
Mol. mass 153,135 g/mol 
 Water Solubility 0.84 mg/ml 
 Log P 1.3 
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Blockage of the lipooxygenase pathway has also been shown [59,60] inhibiting both 
5-lipooxygenase and 5-lipooxygenase-activating protein. It is also one of the most 
potent known free radical scavengers and antioxidants [61-64]. Many of the effects 
of 5-ASA may also be explained by inhibition of activation of nuclear factor-B 
(NF-B), a central transcription regulatory factor involved in mediating the initiation 
and perpetuation of inflammatory processes [65,66]. Activated NF-B has been 
detected in macrophages and epithelial cells in inflamed mucosa from Crohn’s 
disease and ulcerative colitis [67]. 
5-ASA is rapidly and completely absorbed from the upper intestine when 
administered orally, [68,69]. Free 5-ASA undergoes rapid and nearly complete 
systemic absorption from the proximal intestine depending on its concentration and 
the local pH, followed by extensive metabolism to N-acetyl-5-ASA, by the N-
acetyltransferase 1 (NAT 1) enzyme [70,71] in both intestinal epithelial cells and the 
liver, and then excretion in the urine as a mixture of free 5-ASA and N-acetyl-5-
ASA [72,73]. To prevent proximal small intestinal absorption and allow the drug to 
reach the inflamed small bowel and/or colon, a variety of 5-ASA delivery systems 
have been developed [74]. These include: 
1) Creating a larger unabsorbing molecule (prodrug) by binding it to a carrier or 
another 5-ASA via an azo-bond, this subsequently undergoes cleavage in the colon 
releasing the active drug. Examples include sulfasalazine (Azulfidine
®
), olsalazide 
sodium (Dipentum
®
), and balsalazide disodium (Colazalk
™
). 
2) Coating mesalamine with a pH-sensitive polymer, which dissolves in the basic 
environment of the distal ileum and colon (Asacol
®
). 
(3) Coating mesalamine with a moisture-sensitive coating (ethyl-cellulose) to release 
mesalamine upon contact with moisture throughout the GI tract (Pentasa
®
). 
(4) Administrating mesalamine as an enema (Rowasa
®
) or suppository (Canasa
™
), 
effectively by passing the threat of small bowel absorption. 
 
1.3.2. Amoebiasis 
Amoebiasis refers to infection caused by the amoeba Entamoeba histolytica, that is 
an anaerobic parasitic protozoan, part of the genus Entamoeba [75,76]. 
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The active (trophozoite) stage exists only in the host and in fresh loose feces; cysts 
survive outside the host in water, soils and on foods, especially under moist 
conditions on the latter. The cysts are readily killed by heat and by freezing 
temperatures, and survive for only a few months outside of the host. When cysts are 
swallowed they cause infections by excysting (releasing the trophozoite stage) in the 
digestive tract. 
The life cycle of the protozoa [77] is shown in Figure 9 [78]: cysts with four nuclei 
(metacysts) are ingested orally with contaminated food or drinking water. After 
excysting in the small intestine, both the cytoplasm and nuclei divide to form eight 
small amebulae (metacystic trophozoites). Mature trophozoites (minuta forms) 
reproduce by constant binary fission. Some of the minuta forms may grow to magna 
forms, which enter the intestinal wall and, via the bloodstream, other organs such as 
liver, lung, and brain, where they lead to abscesses (amoebomae). 
 
 
Figure 9. Life cycle of protozoa. 
 
Symptoms can range from mild diarrhea to dysentery with blood and mucus in the 
stool. 
E. histolytica is usually a commensal organism.[79] Severe amoebiasis infections 
(known as invasive or fulminant amoebiasis) occur in two major forms. Invasion of 
the intestinal lining causes amoebic dysentery or amoebic colitis [80]. If the parasite 
reaches the bloodstream it can spread through the body, most frequently ending up 
in the liver where it causes amoebic liver abscesses [81]. Liver abscesses can occur 
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without previous development of amoebic dysentery. When no symptoms are 
present, the infected individual is still a carrier, able to spread the parasite to others 
through poor hygienic practices. 
Because of E. histolytica infections occur in both the intestine and in tissue of the 
intestine and/or liver, as a result, two different classes of drugs are needed to treat 
the infection, one for each location [82]. Such anti-amoebic drugs are known as 
amoebicides. Both tissue and lumenal drugs must be used to treat infections, with 
metronidazole usually being given first, followed by paromomycin or diloxanide.  
 Tissue amebicides: Metronidazole [83], or a related drug such as tinidazole [84], 
secnidazole or ornidazole, is used to destroy amoebae that have invaded tissue. 
These are rapidly absorbed into the bloodstream and transported to the site of 
infection. Because they are rapidly absorbed there is almost none remaining in the 
intestine.  
 Luminal amebicides: Since most of the amoebae remain in the intestine when 
tissue invasion occurs, it is important to get rid of those also or the patient will be at 
risk of developing another case of invasive disease. Several drugs are available for 
treating intestinal infections, the most effective of which has been shown to be 
paromomycin [85], diloxanide furoate and iodoquinol. 
 
 
1.3.2.1. Metronidazole 
Metronidazole is a nitroimidazole compound active in the treatment of anaerobic 
protozoan and bacterial infections [86,87]. 
Metronidazole is bactericidal against the majority of anaerobic bacteria like 
Gardnerella, Bacteroides fragilis, Fusobacterium, Clostridium, Peptococcus, 
Peptostreptococcus, Clostridium difficile [88,89] and against some microaerophilic 
organisms and anaerobic protozoa [90,91]. These include Entamoeba histolytica, 
Giardia lamblia, and Balantidium coli.  
It is used in the treatment of: Trichomoniasis, pseudomembranous colitis, bacterial 
vaginosis, upper genital tract infections, Amoebiasis and Giardiasis.  
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Table 6.  Metronidazole chemical properties. 
 
 
CHEMICAL  STRUCTURE 
 
N
N
NO2
OH
 
IUPAC name 2-(2-methyl-5-nitro-1H-
imidazol-1-yl)ethanol 
Formula C6H9N3O3 
Mol. mass 171,15 g/mol 
Water solubility  10.0 mg/ml 
Log P -0.1 
 
The proposed mechanism of action of metronidazole consists of a four-step process 
[86]: entry into a target cell, activation, generation of free radicals, and, finally, cell 
death resulting from damage to DNA. Metronidazole enters aerobic and anaerobic 
bacteria, protozoa, and mammalian cells through passive diffusion. In anaerobic 
bacteria, metronidazole is converted to an active metabolite that has not been 
characterized completely. This conversion creates a concentration gradient, 
promoting the further diffusion of the parent compound into the cell. In aerobic 
organisms, conversion does not occur, and the concentration of metronidazole 
within the cell equilibrates with the serum concentration. Activation of 
metronidazole in anaerobic organisms occurs through reduction of the nitro group 
[92]. The reduction is thought to be mediated through donation of electrons by 
ferredoxin-like transport proteins. These proteins are an integral part of the normal 
metabolism of anaerobic organisms but have a limited role in aerobic organism 
metabolism. The intermediate compounds generated by activation of metronidazole 
are free radicals, which are believed to be the source of the cytotoxicity of this 
compound. These free radicals consist of nitro, nitroso, and hydroxylamine 
derivatives. These compounds are short lived and are quickly metabolized to 
inactive end products. The free radical intermediate compounds are thought to 
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interact with and/or destroy directly cellular DNA. The generation of free radicals is 
the source of concern regarding the teratogenic and carcinogenic potential of 
metronidazole. 
The use of metronidazole in the treatment of amoebiasis (amebic dysentery) requires 
high drug doses: 750 mg orally 3 times daily for 5-10 days, because it is completely 
absorbed before it reaches the site of action (colon). For this reason it is necessary to 
develop a new drug delivery system that protects the drug from the absorption in the 
upper part of the gastrointestinal tract and releases metronidazole in the colon.  
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1.4. Carrier systems 
 
1.4.1. Chitosan 
Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-linked 
D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) 
(Figure 10). Chitosan is produced commercially by deacetylation of chitin, which is 
the second most abundant polysaccharide in nature and the structural element in the 
exoskeleton of crustaceans (crabs, shrimp) and cell walls of fungi [93,94].  
Chitosan refers to a large number of polymers, which differ in their degree of N-
deacetylation (40-98%) and molecular weight (50,000-2,000,000 Dalton). These two 
characteristics are very important to the physic-chemical properties of the chitosan 
and hence, it has a major effect on the biological properties.  
Chitosan is a weak base with a pka value of the D-glucosamine unit of about 6.5 and 
therefore is insoluble at neutral and alkaline pH values. It is insoluble in water and 
organic solvent but it dissolves at acidic pH. Indeed in acidic medium the amine 
groups of the polymer are protonated resulting in a soluble positively charged 
polysaccharide. 
 
 
Figure 10. Chitosan structure. 
 
Because chitosan has favorable biological properties such as biodegradability [95] 
and biocompatibility [96] it has attracted a lot of attention in the pharmaceutical and 
medical fields. Chitosan’s main properties are as follows: gel-forming behaviour, 
mucoadhesion, absorption enhancer [97].  
Chitosan has been shown to possess mucoadhesive properties [98-100] due to 
molecular attractive forces formed by electrostatic interaction between positively 
charged chitosan and negatively charged mucosal surfaces. These properties may be 
attributed to: strong hydrogen bonding groups like –OH, –COOH, sufficient chain 
flexibility and positive charge on chitosan polymer gives rise to strong electrostatic 
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interaction with mucus or negatively charged sialic acid residues on the mucosal 
surface.  
Chitosan hydrogels have been prepared [101] with a variety of different shapes, 
geometries, and formulations that include liquid gels, powders, beads, films, tablets, 
capsules, microparticles, textile fibers, and inorganic composites. In each 
preparation chitosan is either physically associated or chemically cross-linked to 
form the hydrogel [102,103]. There are four major physical interactions (ionic, 
polyelectrolyte, interpolymer complex, and hydrophobic associations) that lead to 
the gelation of a chitosan solution.  
Chitosan can be chemically modified in a lot of different ways, since it provides 
functional groups as primary amine as well as a secondary hydroxyl groups in its 
monomers [104,105]. Quaternized derivatives [106,107], carboxymethyl chitosan 
[108], N-Acyl derivatives (for instance N-Succinyl-chitosan) [109], thiolated 
chitosans [110,111] were prepared. Due to its favourable properties chitosan-based 
systems have gained a lot of attention in pharmaceutical field [112,113]. They are 
widely used for ophthalmic [114], nasal [115], buccal [116], intestinal [117], vaginal 
[118], vaccine [119] and colon delivery.  
Chitosan is used in oral drug formulations to provide sustained release of drugs. It 
was found that chitosan is degraded by the microflora, which is available in the 
colon. As a result, this compound could be promising for colon-specific drug 
delivery. Enteric coated capsules have been prepared [120]. Different salts of 
chitosan were synthesized and evaluated [121,122], pH sensitive based chitosan 
hydrogels drug delivery system have been developed [123]. Chitosan-based 
microspheres [124] and polyelectrolyte complexes [125] were also prepared for 
colon targeted drug delivery. Chitosan derivatives were prepared and proved for 
colon-specific, orally administered drug delivery systems [126]. 
 
1.5.2. Cyclodextrin 
Cyclodextrins are cyclic oligosaccharides containing at least 6 D-(+) glucopyranose 
units attached by α-(1, 4) glucosidic bonds (Figure 11) [127]. The three natural CDs: 
α-, β-, and γ-CD possess 6, 7, or 8 glucose units respectively [128]. They are 
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produced from starch by means of enzymatic conversion; commonly cyclodextrin 
glycosyltransferase (CGTase) is employed along with α-amylase [129].  
 
 
Figure 11. -cyclodextrin structures. 
 
The three kinds of cyclodextrin differ from ring size, number of glucopyranose 
units, molecular weight and solubility in water [130]. -CD has 6 glucopyranose 
units, its molecular weight is 972 g/mol and the solubility in water at 25°C is 14.5 % 
w/w. -CD has 7 glucopyranose units, the molecular weight is 1135 g/mol and the 
solubility is 1,85 %w/w. -CD is the most soluble (23.2% w/w) and has 8 
glucopyranose unit, the molecular weight is 1297 g/mol. 
They can be topologically represented as toroids with the larger and the smaller 
openings of the toroid exposing to the solvent secondary and primary hydroxyl 
groups respectively. The interior of the toroids is not hydrophobic, but considerably 
less hydrophilic than the aqueous environment and thus able to host other 
hydrophobic molecules. In contrast, the exterior is sufficiently hydrophilic to impart 
cyclodextrins (or their complexes) water solubility.  
These properties make CD capable to form complexes with lipophilic molecules 
called inclusion complex [130]. The formation of the inclusion complex greatly 
modifies the physical and chemical properties of the guest molecule, mostly in terms 
of water solubility and stability. This is the reason why cyclodextrins have attracted 
much interest in many fields, especially pharmaceutical applications [131].  
Moreover CD–drug conjugates, in which a drug is covalently bound to CD, were 
prepared because they could be used as colon-targeting. CDs are known to be barely 
capable of being hydrolyzed and only slightly absorbed in passage through the 
stomach and small intestine, while they are specifically degraded by the enzymatic 
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microflora [132-134]. This property of CDs may be exploited for the formation of 
colon targeted drug delivery system. Several drug-CD conjugates have been 
prepared and studied. Orally administered drug-CD conjugates can survive passage 
through the stomach and small intestine. However drug release will be triggered by 
enzymatic degradation of CDs in the colon [24-27]. 
 
 31 
 
1.6. References 
[1] http://www.wanitaindonesia-ifs.com/2009_10_01_archive.html 
[2] http://adam.about.com/reports/Structure-of-the-colon.htm 
[3] http://histology-world.com/photoalbum/displayimage.php?album=5&pos=52 
[4] http://www.siumed.edu/~dking2/erg/GI111b.htm 
[5] B.C. Youan. Chronopharmaceutics: gimmick or clinically relevant approach to drug 
delivery? J. Controlled Release 98 (2004) 337– 353. 
[6] A.S. Mandal, N. Biswas, K.M. Karim, A. Guha, S. Chatterjee, M. Behera, K. Kuotsu. 
Drug delivery system based on chronobiology-A review. J. Controlled Release 147 (2010) 
314–325. 
[7] V.S. Mastiholimath, P.M. Dandagi, S.S. Jain, A.P. Gadad, A.R. Kulkarni. Time and pH 
dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int. J. 
Pharm. 328 (2007) 49–56. 
[8] M. Mackay, J. Phillips, J. Hastewell. Peptide drug delivery: Colonic and rectal 
absorption. Adv. Drug Deliv. Rev. 28 (1997) 253-273. 
[9] M. Katsum, S. Watanabe, H. Kawai, S. Takemura, K. Sako. Effects of absorption 
promoters on insulin absorption through colon-targeted delivery. Int. J. Pharm. 307 (2006) 
156–162. 
[10] P. Langguth, V. Bohner, J. Heizmann, H.P. Merkle, S. Wolffram, S. Amidon, S. 
Yamashita. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Controlled 
Release 46 (1997) 39-57. 
[11] J.A. Fix. Oral controlled release technology for peptides: status and future prospects. 
Pharm. Res. 13 (1996) 1760–1764. 
[12] C. S. Leopold. Coated dosage forms for colon-specific drug delivery. PSTT 2(5) (1999) 
197-204. 
[13] L. Yang, J.S. Chu, J.A. Fix. Colon-specific drug delivery: new approaches and in 
vitro/in vivo evaluation. Int. J. Pharm. 235 (2002) 1–15. 
[14] M.K. Chourasia, S.K. Jain. Pharmaceutical approaches to colon targeted drug delivery 
systems. J. Pharm. Pharm. Sci. 6 (2003) 33-66.  
[15] R. Kumar, M.B. Patil, S.R. Patil, M.S. Paschapur. Polysaccharides Based Colon 
Specific Drug delivery: A Review. Int. J. Pharm. Tech. Res. 2 (2009) 334-346. 
[16] S.M. Reddy, V.R. Sinha, D.S. Reddy. Novel oral colon-specific drug delivery systems 
for pharmacotherapy of peptides and nonpeptide drugs. Drugs Today 35 (1999) 537-580. 
[17] T. Takaya, K. Niwa, M. Muraoka, I. Ogita, N. Nagai, R. Yano, G. Kimura, Y. 
Yoshikawa, H. Yoshikawa, K. Tajada. Importance of dissolution process on systemic 
 32 
 
availability of drugs delivered by colon delivery system. J Controlled Release 50 (1998) 111-
122. 
[18] M. Muraoka, Z. Hu, T. Shimokawa, S. Sekino, R. Kurogoshi, Y. Kuboi, Y. Yoshikawa, 
K. Takada. Evaluation of intestinal pressure controlled colon delivery capsule containing 
caffeine as a model drug in human volunteers. J. Controlled Release 52 (1998) 119-129. 
[19] R.B. Sartor. Microbial Influences in Inflammatory Bowel Diseases. Gastroenterol. 134 
(2008)577–594. 
[20]V.R. Sinha, R. Kumria. Microbially triggered drug delivery to the colon. Eur. J. Pharm. 
Sci. 18 (2003) 3-18. 
[21] C.P. Willoughby, J.K. Aronson, H. Agback, N.O. Bodin, S.C. Truelove S.C. 
Distribution and metabolism in healthy volunteers of disodium azodisalicylate a potential 
therapeutic agent for ulcerative colitis. Gut 23 (1982) 1081–1087. 
[22] S. Ahmad, R.F. Tester, A. Corbett, J. Karkalas. Dextran and 5-aminosalicylic acid (5-
ASA) conjugates: synthesis, characterization and enzymic hydrolysis. Carbohydr. Res. 341 
(2006) 2694–2701. 
[23] J. Varshosaz, J. Emami, Naser Tavakoli, A. Fassihi, M. Minaiyan, F. Ahmadi, F. 
Dorkoosh. Synthesis and evaluation of dextran–budesonide conjugates as colon specific 
prodrugs for treatment of ulcerative colitis. Int. J. Pharm. 365 (2009) 69-76. 
[24] K. Uekama, K. Minami, F. Hirayama. 6
A
-O-[(4-Biphenylyl)acetyl]--, --, and --
cyclodextrins and 6
A
-Deoxy-6
A
-[[(4-biphenylyl)acetyl]amino]--,--, and --cyclodextrins: 
Potential Prodrugs for Colon-Specific Delivery. J. Med. Chem. 40 (1997) 2755-2761 
[25] H. Yano, F. Hirayama, M. Kamada, H. Arima, K. Uekama. Colon-specific delivery of 
prednisolone-appended -cyclodextrin conjugate: alleviation of systemic side effect after 
oral administration. J. Controlled Release 79 (2002) 103–112. 
[26] A.H. El-Kamel, A.A.-M. Abdel-Aziz, A.J. Fatani, H.I. El-Subbagh. Oral colon targeted 
delivery systems for treatment of inflammatory bowel diseases: Synthesis, in vitro and in 
vivo assessment. Int. J. Pharm. 358 (2008) 248–255. 
[27] M. Zou, H. Okamoto, G. Cheng, X. Hao, J. Sun, F. Cui, K. Danjo. Synthesis and 
properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific 
delivery systems. Eur. J. Pharm. Biopharm. 59 (2005) 155–160. 
[28] L. Liu, M.L. Fishman, J. Kost, K.B. Hick. Pectin-based systems for colon-specific drug 
delivery via oral route. Biomaterials 24 (2003) 3333–3343. 
[29] S.F. Ahrabi, G. Madsen, K. Dyrstad, S.A. Sande, C. Graffner. Development of pectin 
matrix tablets for colonic delivery of model drug ropivacaine. Eur. J. Pharm. Sci. 10 (2000) 
43–52. 
 33 
 
[30] P. Sriamornsak, J. Nunthanid. Calcium pectinate gel beads for controlled release drug 
delivery:I. Preparation and in vitro release studies. Int. J. Pharm. 160 (1998) 207–212. 
[31] A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima. pH-sensitive microsphere 
delivery increases oral bioavailability of calcitonin. J. Controlled Release 98 (2004) 1– 9. 
[32] P. Nykanen, K. Krogars, M. Sakkinen, J. Heinamaki, H. Jurjensson, P. Veski, M. 
Marvola. Organic acids as excipients in matrix granules for colon-specific drug delivery. Int. 
J. Pharm. 184 (1999) 251–261. 
[33] G.V. den Mooter, C. Samyn, R. Kinget. In vivo evaluation of a colon specific drug 
delivery system: an absorption study of theophylline from capsules coated with azo polymers 
in rats, Pharm. Res. 12 (1995) 244-247. 
[34] H. Tozaki, J. Nishioka, J. Komoike, N. Okada, T. Fujita, S. Muranishi, S. Kim, H. 
Terashima, A. Yamamoto. Enhanced Absorption of Insulin and (Asu1,7) Eel-Calcitonin 
using Novel Azopolymer-Coated Pellets for Colon-Specific Drug Delivery. J. Pharm. Sci. 90 
(2001) 89–97. 
[35] M.L. Lorenzo-Lamosa, C. Remunan-Lopez, J.L. Vila-Jato, M.J. Alonso. Design of 
microencapsulated chitosan microspheres for colonic drug delivery. J. Controlled Release 52 
(1998) 109–118. 
[36] , W. Kalala, R. Kinget, G. Van den Mooter, C. Samyn. Colonic drug-targeting: in vitro 
release of ibuprofen from capsules coated with poly(ether-ester) azopolymers. Int. J. Pharm. 
139 (1996) 187-195. 
[37] V.R. Sinha, B.R. Mittal, K.K. Bhutani, Rachna Kumria. Colonic drug delivery of 5-
fluorouracil: an in vitro evaluation. Int. J. Pharm. 269 (2004) 101–108. 
[38] Y.S.R. Krishnaiah, V. Satyanarayana, B. Dinesh Kumar, R.S. Karthikeyan. In vitro drug 
release studies on guar gum-based colon targeted oral drug delivery systems of 5-
fluorouracil. Eur. J. Pharm. Sci. 16 (2002) 185–192. 
[39] K. Philip, B.Philip. Colon Targeted Drug Delivery Systems: A Review on Primary and 
Novel Approaches A. Oman Medical Journal 25 (2010) 70-78. 
[40] R.B. Sartor. Mechanisms of Disease: pathogenesis of Crohn’s disease and ulcerative 
colitis. Gastroenterol. Hepatol. 3 (2006) 390-407. 
[41] D.C Baumgart, S.R Carding. Inflammatory bowel disease: cause and immunobiology. 
Gastroenterol. 369 (2007) 1627–1640. 
[42] M.E.A. Borm, G. Bouma. Animal models of inflammatory bowel disease. Drug 
Discovery Today 4 (2004) 437-443. 
[43] D.C. Baumgart, W.J. Sandborn. Inflammatory bowel disease: clinical aspects and 
established and evolving therapies Lancet 369 (2007) 1641–57. 
 34 
 
[44] T. Hibi, H. Ogata. Novel pathophysiological concepts of inflammatory bowel disease J. 
Gastroenterol. 41 (2006) 10–16. 
[45] W. Strober, I. Fuss, P. Mannon. The fundamental basis of inflammatory bowel disease J. 
Clin. Invest. 117 (2007) 514–521. 
[46] R.J. Xavier, D.K. Podolsky. Unravelling the pathogenesis of inflammatory bowel 
disease. Nature 448 (2007) 427-434. 
[47] B.E. Sands. Therapy of Inflammatory Bowel Disease. Gastroenterol. 118 (2000) S68–
S82. 
[48] C. Xu, S. Meng, B. Pan. Drug therapy for ulcerative colitis. World J Gastroenterol 10 
(2004) 2311-2317. 
[49] M Campieri. New steroids and new salicylates in inflammatory bowel disease: a critical 
appraisal. Gut 50 (2002) 43–46. 
[50] R. Bergman, M. Parkes. Systematic review: the use of mesalazine in inflammatory 
bowel disease. Aliment. Pharmacol. Ther. 23 (2006) 841–855. 
[51] S.V. Kane, P. Schoenfeld, W.J. Sandborn, W. Tremaine, T. Hofer, B.G. Fegan. 
Systematic review: the effectiveness of budesonide therapy for Crohn’s Disease. Aliment. 
Pharmacol. Ther. 16 (2002) 1509–1517. 
[52] P.M. Choi, S.R. Targan. Immunomodulator therapy in Inflammatory bowel disease. 
Dig. Dis. Sci. 39 (1994) 1885-1892. 
[53] A. Noble, R. Baldassano, P. Mamula. Novel therapeutic options in the inflammatory 
bowel disease world. Dig. Liver Dis. 40 (2008) 22–31. 
[54] N.A. Punchard, S.M. Greenfield, R.P.H. Thompson. Mechanism of action of 5-
aminosalicylic acid. Mediators Inflamm. 1 (1992) 151-165. 
[55] S.M. Greenfield, N.A. Punchard, J.P. Teare, R.P.H. Thompson. Review article: the 
mode of action of the aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. 
Ther. 7 (1993) 369-383. 
[56] D. Rachmilewitz, F. Karmeli, L.W. Schwartz, P.L. Simon. Effect of aminophenols (5-
ASA and 4-ASA) on colonic interleukin-1 generation. Gut 33 (1992) 929–932. 
[57] Y.R. Mahida, C.E. Lamming, A. Gallagher, A.B. Hawthorne, C.J. Hawkey. 5-
Aminosalicylic acid is a potent inhibitor of interleukin 1 production in organ culture of 
colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32 (1991) 50-
54. 
[58] J.R.S. Hoult, P.K. Moore. Effects of sulfasalazine and its metabolites on prostaglandin 
synthesis, inactivation and actions on smooth muscle. Br. J. Pharmac. 68 (1980) 719-730. 
 35 
 
[59] W.F. Stenson, E. Lobos. Sulfasalazine inhibits the synthesis of chemotactic lipids by 
neutrophils, J. Clin. Invest. 69(1982) 494–497. 
[60] W.F. Stenson. Role of eicosanoids as mediators of inflammation in inflammatory bowel 
disease. Scand. J. Gastroenterol. Suppl. 172 (1990) 13–18. 
[61] J.G. Williams, M.Hallett. Effect of sulphasalazine and its active metabolite, 5-amino-
salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut 30 (1989) 1581-
1587. 
[62] S.M. McKenzie, W.F. Doe, G.D. Buffinton. 5-Aminosalicylic acid prevents oxidant 
mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells. 
Gut 44 (1999) 180–185. 
[63] P. Gionchetti, C. Guarnieri, M. Campieri, A. Belluzzi, C. Brignola, P. Iannone, M. 
Miglioli, L. Barbara. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine 
on superoxide radical generation. Dig. Dis. Sci. 36 (1991) 174-178. 
[64] N.J. Simmonds, A.D. Millar, D.R. Blake, D.S. Rampton. Antioxidant effects of 
aminosalicylates and potential new drugs for infammatory bowel disease: assessment in cell-
free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther.13 (1999) 
363-372. 
[65] P.A. Baeuerle, D. Baltimore. NF-B: ten years after. Cell 87 (1996) 13– 20. 
[66] H. Bantel, C. Berg, M. Vieth, M. Stolte, W. Kruis, K. Schulze-Osthoff. Mesalazine 
Inhibits Activation of Transcription Factor NF-B in Inflamed Mucosa of Patients With 
Ulcerative Colitis. Am. J. Gastroenterol. 95 (2000) 3452-3457. 
[67] G. Rogler, K. Brand, D. Vogl, S. Page, R. Hofmeister, T. Andus, R. Knuechel, P.A. 
Baeuerle, J. Scholmerich, V. Gross. Nuclear factor B is activated in macrophages and 
epithelial cells of inflamed intestinal mucosa, Gastroenterol. 115 (1998) 357-369. 
[68] S.Y. Zhou, D. Fleisher, L.H. Pao, C. Li, B. Winward, E.M. Zimmermann. Intestinal 
metabolism and transport of 5-aminosalicylate. Drug Metab. Disp. 27 (1999) 479-485. 
[69] W.J. Sandborn, S.B. Hanauer. Systematic review: the pharmacokinetic profiles of oral 
mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative 
colitis. Aliment. Pharmacol. Ther. 17 (2003) 29-42. 
[70] E. Sim, N. Lack, C. Wang, H. Long, I.Westwood, E. Fullam, A. Kawamura. Arylamine 
N-acetyltransferases: Structural and functional implications of polymorphisms. Toxicol. 254 
(2008) 170–183. 
[71] R.F. Minchin, P.E. Hannab, J.M. Dupret, C.R. Wagner, F. Rodrigues-Lima, N.J. 
Butcher. Arylamine N-acetyltransferase I. Int. J. Biochem. Cell Biol. 39 (2007) 1999–2005. 
 36 
 
[72] H. Goebell, U. Klotz, B. Nehlsen, P. Layer. Oroileal transit of slow release 5 
aminosalicylic acid. Gut 34 (1993) 669–675. 
[73] P.H. Layer, H. Goebell, J. Keller, A. Dignass, U. Klotz. Delivery and fate of oral 
mesalamine microgranules within the human small intestine, Gastroenterol. 108 (1995) 
1427–1433 
[74] A.I. Qureshia, R.D. Cohen. Mesalamine delivery systems: do they really make much 
difference? Adv. Drug Deliv. Rev. 57 (2005) 281-302. 
[75] S.L. Stanley. Amoebiasis. Lancet 361 (2003) 1025-1034 
[76] J. Harries. Amoebiasis: a review. J. R. Soc. Med. 75 (1982) 190-197. 
[77] H. Seneca. Amebiasis. a review II. Laboratory diagnosis, differential diagnosis and 
therapy. Am. J. Dig. Dis. 7 (1956) 310-322. 
[78] http://en.wikipedia.org/wiki/File:Entamoeba_histolytica_life_cycle-en.svg 
[79] R. Haque, D. Mondal, P. Duggal,
 
M. Kabir, S. Roy,
 
B.M. Farr,
 
R.B. Sack, W.A. Petri. 
Entamoeba histolytica infection in children and protection from subsequent amebiasis. 
Infect. Immun. 74 (2006) 904-909. 
[80] K.L. Chan, J.Y. Sung, R. Hsu, C.T. Liew. The association of amoebic colitis and 
chronic ulcerative colitis. Singapore Med J. 36 (1995) 303-305. 
[81] C.D. Wells, M. Arguedas. Amebic Liver Abscess. Southern Medical Journal 97 (2004) 
673-682. 
[82] S.J. Powell. New developments in the therapy of Amoebiasis. Gut 11 (1970) 967-969. 
[83] E.D. Everett. Metronidazole and Amoebiasis. Digestive Diseases 19 (1974) 626-636. 
[84] H.B. Fung, T. Doan. Tinidazole : a nitroimidazole antiprotozoal agent. Clinical 
Therapeutics 27 (2005) 1859-1884. 
[85] C.F. Villamil, H.A. Dolcini, J.T. Arabehety, N.M. Stapler. Treatment of Intestinal 
Amebiasis with paromomicyn, Am. J. Dig. Dis. 9 (1964) 426-428. 
[86] J.S. Simms-Cendan. Metronidazole. Infectious Diseases Update 3 (1996) 153-156. 
[87] C.D. Freeman, N.E. Klutman, K.C. Lamp. Metronidazole. A therapeutic review and 
update. Drugs 54 (1997) 679-708. 
[88] F.P. Tally, V.L. Sutter, S.M. Finegold. Metronidazole Versus Anaerobes In Vitro Data 
and Initial Clinical Observations. Calif. Med. 117 (1972) 22-26. 
[89] F.P. Tally, B.R. Goldin, N. Sullivan, J. Johnston, S.L. Gorbach. Antimicrobial Activity 
of Metronidazole in Anaerobic Bacteria. Antimicrob. Agents Chemother. 13 (1978) 460-465. 
[90] H.N. Prince, E. Grunberg, E. Titsworth, W.F. Delorenzo. Effects of 1-(2-Nitro-1-
Imidazolyl)-3-Methoxy-2-Propanol and 2-Methyl-5-Nitroimidazole-1-Ethanol Against 
Anaerobic and Aerobic Bacteria and Protozoa. Appl. Microbiol. 18 (1969) 728-730. 
 37 
 
[91] J. Samuelson. Why Metronidazole Is Active against both Bacteria and Parasites. 
Antimicrob. Agents Chemother 43 (1999) 1533–1541. 
[92]A. Schmid, H. Schmid. Pharmaco-Toxicological Mode of Action of Antimicrobial 5-
Nitroimidazole Derivatives. J. Vet. Med. A 46 (1999) 517–522. 
[93] P.K. Dutta, J. Dutta, V.S. Tripathi. Chitin and chitosan: chemistry, properties and 
applications. J. Sci. Ind. Res. 63 (2004) 20-31. 
[94] M.N.V.R Kumar. A review of chitin and chitosan applications. React. Funct. Polym. 46 
(2000) 1–27. 
[95] C.L. Vernazza, G.R. Gibson, R.A. Rastall. In vitro fermentation of chitosan derivatives 
by mixed cultures of human faecal bacteria. Carbohydr. Polym. 60 (2005) 539–545. 
[96] T. Kean, M. Thanou. Biodegradation, biodistribution and toxicity of chitosan. Adv. 
Drug Deliv. Rev. 62 (2010) 3–11. 
[97] M. Rinaudo. Chitin and chitosan: Properties and applications. Prog. Polym. Sci. 31 
(2006) 603–632. 
[98] I. Fiebrig, S.E. Harding, A.J. Rowe, S.C. Hyman, S.S. Davis. Transmission electron 
microscopy studies on pig gastric mucin and its interactions with chitosan. Carbohydr. 
Polym. 28 (1995) 239-244. 
[99] V. Grabovac, D. Guggi, A. Bernkop-Schnurch. Comparison of the mucoadhesive 
properties of various polymers. Adv. Drug Deliv. Rev. 57 (2005) 1713–1723. 
[100] P. He, S.S. Davis, L. Illum. In vitro evaluation of the mucoadhesive properties of 
chitosan microspheres. Int. J. Pharm. 166 (1998) 75–88. 
[101] N. Bhattarai, J. Gunn, M. Zhang. Chitosan-based hydrogels for controlled, localized 
drug delivery. Adv. Drug Deliv. Rev. 62 (2010) 83–99. 
[102] J. Berger, M. Reist, J.M. Mayer, O. Felt, R. Gurny, Structure and interactions in 
chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur. 
J. Pharm. Biopharm. 57 (2004) 35–52. 
[103] N. Boucard, C. Viton, A. Domard. New aspects of the formation of physical hydrogels 
of chitosan in a hydroalcoholic medium.  Biomacromol. 6 (2005) 3227–3237. 
[104] V.K. Mourya, N.N. Inamdar. Chitosan-modifications and applications: Opportunities 
galore. React. Funct. Polym. 68 (2008) 1013–1051. 
[105] J. Vinsova, E. Vavrikova. Recent Advances in Drugs and Prodrugs Design of 
Chitosan. Curr. Pharm. Des. 14 (2008) 1311-1326. 
[106] M.M. Thanou, A.F. Kotze, T. Scharringhausen, H.L. Lueben, A.G. de Boer, J.C. 
Verhoef, H.E. Junginger. Effect of degree of quaternization of N-trimethyl chitosan chloride 
for enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers 
Journal of Controlled Release 64 (2000) 15–25. 
 38 
 
[107] A.B. Sieval, M. Thanou, A.F. Kotzé, J.C. Verhoef, J. Brussee, H.E. Junginger. 
Preparation and NMR characterization of highly substituted IV-trimethyl chitosan chloride. 
Carbohydr. Polym. 36 (1998) 157-165. 
[108] V.K. Mourya, N.N. Inamdar. Chitosan-modifications and applications: Opportunities 
galore. React. Funct. Polym. 68 (2008) 1013–1051. 
[109] R. Yamaguchi, Y. Araj, T. Itoh, S. Hirano, Preparation of partially N-succinylated-
chitosan and their cross-linked gels, Carbohydr. Res. 88 (1981) 172-175. 
[110] K. Kafedjiiski, A.H. Krauland, M.H. Hoffer, A. Bernkop-Schnurch. Synthesis and in 
vitro evaluation of a novel thiolated chitosan. Biomaterials 26 (2005) 819–826. 
[111] A. Bernkop-Schnurch, D. Guggi, Y. Pinter. Thiolated chitosans: development and in 
vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J. 
Controlled Release 94 (2004) 177–186. 
[112] V. Dodane, V.D. Vilivalam. Pharmaceutical applications of chitosan. PSTT 6 (1998) 
246-253. 
[113] H. Park, G. Saravanakumar, K. Kim, I.C. Kwon. Targeted delivery of low molecular 
drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 62 (2010) 28–41. 
[114] A.M. De Campos, A. Sanchez, M.J. Alonso. Chitosan nanoparticles: a new vehicle for 
the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. 
Int. J. Pharm. 224 (2001) 159–168. 
[115] S. Türker, E. Onur, Y. Özer. Nasal route and drug delivery systems. Pharm. World Sci. 
26 (2004) 137–142. 
[116] S. Miyazaki, A. Nakayama, M. Oda, M. Takada, D. Atwood. Drug release from oral 
mucosal adhesive tablets of chitosan and sodium alginate. Int. J. Pharm. 118 (1995) 257-263. 
[117] M. Ramdas, K.J. Dileep, Y. Anitha, W. Paul, C.P. Sharma. Alginate encapsulated 
bioadhesive chitosan microspheres for intestinal drug delivery. J. Biomater. Appl. 13 (1999) 
290-206. 
[118] C.E. Kast, C. Valenta, M. Leopold, A. Bernkop-Schnurch. Design and in vitro 
evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J Controlled 
Release 81 (2002) 354-374. 
[119] L. Illum, I. Jabbal-Gill, M. Hinchcliffe, A.N. Fisher, S.S Davis. Chitosan as a novel 
nasal delivery system for vaccines. Adv Drug Deliv Rev. 23 (2001) 81-96. 
[120] H. Tozaki , T. Odoriba , N. Okada , T. Fujita, A. Terabe, T. Suzuki, S. Okabe, S. 
Muranishi, A. Yamamoto. Chitosan capsules for colon-specific drug delivery: enhanced 
localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-
induced colitis in rats. J. Controlled Release 82 (2002) 51–61. 
 39 
 
[121] I.Orienti, T. Cerchiara, B. Luppi, F. Bigucci, G. Zuccari, V. Zecchi. Influence of 
different chitosan salts on the release of sodium diclofenac in colon-specific delivery. Int. J. 
Pharm. 238 (2002) 51-59. 
[122] J. Nunthanid, K. Huanbutta, M. Luangtana-anan, P. Sriamornsak, S. Limmatvapirat, S. 
Puttipipatkhachorn. Development of time-, pH-, and enzyme-controlled colonic drug 
delivery using spray-dried chitosan acetate and hydroxypropyl methylcellulose. Eur. J. 
Pharm. Biopharm. 68 (2008) 253–259. 
[123] Y. Xu, C. Zhan, L. Fan, L. Wang, H. Zheng. Preparation of dual crosslinked alginate-
chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery 
system. Int. J. Pharm. 336 (2007) 329–337. 
[124] K. Mladenovska, R.S. Raicki, E.I. Janevik, T. Ristoski, M.J. Pavlova, Z. Kavrakovski, 
M.G. Dodov, K. Goracinova Colon-specific delivery of 5-aminosalicylic acid from chitosan-
Ca-alginate microparticles. Int. J. Pharm. 342 (2007) 124–136. 
[125] O. Munjeri, J.H. Collett, J.T. Fell. Hydrogel beads based on amidated pectins for 
colon-specific drug delivery: the role of chitosan in modifying drug release. J. Controlled 
Release 46 (1997) 273–278. 
[126] K. Aiedeh, M.O. Taha. Synthesis of Chitosan Succinate and Chitosan Phthalate and 
Their Evaluation as Suggested Matrices in Orally Administered, Colon-Specific Drug 
Delivery Systems. Arch. Pharm. Pharm. Med. Chem, 332 (1999) 103–107. 
[127] M.E. Davis, M.E. Brewster. Cyclodextrin-based pharmaceutics: past, present and 
future. Nat. Rev. Drug Discov. 3 (2004) 1023-1035. 
[128] J. Szejtli. Past, present, and future of cyclodextrin research. Pure Appl. Chem. 10 
(2004) 1825–1845. 
[129] N. Szerman, I. Schroh, A.L. Rossi, A.M. Rosso, N. Krymkiewicz, S.A. Ferrarotti. 
Cyclodextrin production by cyclodextrin glycosyltransferase from Bacillus circulans DF 9R. 
Biores. Technol. 98 (2007) 2886–2891 
[130] E.M.M Del Valle. Cyclodextrins and their uses: a review. Process Biochem. 39 (2004) 
1033–1046. 
[131] F. Hirayama, K. Uekama. Cyclodextrin-based controlled drug release system. Adv. 
Drug Deliv. Rev. 36 (1999) 125–141. 
[132] R.N. Antenucci, J.K. Palmer. Enzymic degradation of - and -cyclodextrins by 
Bacteroides of the human colon. J. Agric. Food Chem. 32 (1984) 1316-1321. 
[133] B. Flourie, C. Moris, L. Achour, H. Dupas, C. Hatat, J.C. Rambaud Fate of -
Cyclodextrinin the Human Intestine. J. Nutrit. 123 (1993) 676-680  
 40 
 
[134] A.T.H.J. De Bie, B.V. Ommen, A. Bar. Disposition of [
14
C]-Cyclodextrin in Germ-
Free and Conventional Rats. Reg. Tox. Pharm. 39 (2004) S57–S66. 
 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. AIM OF THE WORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
 
Colon specific drug delivery has gained increased importance not only for drug 
delivery in  treatment of local colonic diseases but also as potential site for the 
systemic delivery of therapeutic peptides and proteins. To achieve successful colon 
targeted drug delivery, a drug needs to be protected from degradation, release and/or 
absorption in the upper portion of the GI tract and then ensure abrupt or controlled 
release in the proximal colon.  
The aim of this work was to develop different colon specific delivery systems by 
using two model drugs for the treatment of colon diseases: 
 5-ASA,  
 metronidazole. 
Two different types of colon drug delivery systems were chosen: 
 enzyme-dependent system,  
 pH-dependent system.  
Different 5-ASA pH-dependent systems were developed as colon specific delivery 
formulations for the treatment of IBD, and their properties were studied and 
compared. 
N-Succinyl-chitosan was chosen as carrier system and was obtained by introducing 
succinyl groups into chitosan NH2-terminals of the glucosamine units. (It presents 
good solubility at neutral and alkaline pH, but it is insoluble at acidic pH. It also has 
favorable properties as drug carrier such as biocompatibility and low toxicity. Due 
to the presence of carboxyl groups it exhibits pH-dependent swelling behaviour).  
5-ASA loaded N-succinyl-chitosan and chitosan were prepared.  
To increase 5-ASA water solubility and stability, β-CDs were loaded into the 
polymers and the influence of CD on the system characteristics was studied. These 
systems were chemically and analytically characterized; in vitro swelling and release 
studies were performed.  
5-ASA loaded N-succinyl-chitosan microparticles were also prepared and 
characterized.  
5-ASA loaded N-succinylchitosan microparticles and physical mixture were also 
prepared and characterized; mucoadhesion studies were performed and their 
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effectiveness for the treatment of IBD was finally examined in vivo using TNBS rat 
model. 
 
Macromolecular prodrugs of metronidazole and α-, β- and γ-cyclodextrin or chitosan 
were prepared by linking the drug with a covalent bond to the macromolecule (CD 
or CHT).  
The strategy for the prodrugs production consisted of linking the drug through a 
spacer to the macromolecule. The spacers utilized were succinyl or glutaryl moieties 
and they were used because a free carboxylic group was necessary to couple the 
drug to the hydroxyl group of CD or to the amino moiety of CHT.  
Three ester conjugates were prepared with metronidazole and CD:  
metronidazole-succinyl-α-cyclodextrin,  
metronidazole-succinyl-β-cyclodextrin,  
metronidazole-succinyl-γ-cyclodextrin.  
Two amide conjugates were synthesized by linking MTZ to chitosan:  
metronidazole-succinyl-chitosan,  
metronidazole-glutaryl-chitosan.  
All the prodrugs were chemically and analytically characterized. In vitro stability 
and ex vivo release studies were performed to investigate their usefulness as colon 
delivery systems. 
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Abstract 
The aim of this work was to develop new formulations to achieve colon-specific 
delivery of 5-aminosalicylic acid (5ASA). 5ASA was loaded into three-dimensional 
amorphous matrices, prepared by freeze drying, using either chitosan (CH) or its 
N-Succinyl derivative (SucCH). Matrices containing -cyclodextrins (CDs) were 
also prepared to study their influence on the 5ASA release. 5ASA-loaded matrices, 
with or without CDs, were characterized by several methods and their properties 
compared. Infra-Red (IR) and Differential Scanning Calorimetry (DSC) analyses 
were carried out to study interactions between drug, CDs, and polymer. The systems 
were evaluated for morphology, drug loading capacity, ex vivo mucoadhesive 
properties, swelling behaviour, and in vitro drug release studies. Overall results 
showed that SucCH is good candidate for colon targeting of 5ASA. In fact, SucCH 
matrix led to a low drug release in acid medium (pH=1.2,  15%) while, in alkaline 
medium, 5ASA was almost completely released (>90%). 
 
3.1. Introduction 
5-Aminosalicylic acid (5ASA) is an anti-inflammatory drug used for the long term 
therapy of inflammatory bowel disease, a group of inflammatory conditions that 
affect colon and small intestine and among which ulcerative colitis and Crohn’s 
disease are the most diffuse and important [1]. 5ASA has been shown to block the 
production of interleukin-1 and tumour necrosis factor- (TNF-) [2,3]. It is also 
one of the most potent known free radical scavenger and antioxidant [4,5], and 
inhibits the activation of nuclear factor-B (NF-B), a central transcription 
regulatory factor involved in mediating the initiation and perpetuation of 
inflammatory processes [6]. 
Orally administered it is easily absorbed in the stomach and in the small intestine, 
but therapeutic concentrations are not reached in the distal tract. Moreover, the 
absorbed drug is rapidly inactivated by acetylation in gut epithelium and liver [7,8]. 
Its efficacy in inflammatory bowel disease depends on its presence at high 
concentration in the colon. To achieve a colon specific delivery and to obtain a long 
term maintenance therapy, it is necessary to develop new modified release 
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formulations. Different approaches have been evaluated to target 5ASA to the colon, 
such as: pH-dependent, enzyme-dependent and time-dependent systems. These 
formulations are designed to reduce systemic absorption and to achieve high levels 
of 5ASA in the colon lumen [9-14]. 
Chitosan (CH) has been largely studied as pharmaceutical excipient for colon 
specific delivery [15,16]. It is a biocompatible, atoxic and biodegradable polymer 
that could be used to increase the retention time of a drug delivery system in the 
colon due to its ability to adhere to the mucous layer [17]. CH has favourable 
biological properties but it rapidly dissolves in the gastric cavity. In fact, it is soluble 
in acidic solution below pH 6.5 and one limit for its pharmaceutical application is its 
insolubility at high or neutral pH [18]. To improve its solubility a chemical 
modification is required and N-Succinyl-chitosan (SucCH) was synthesized by 
introducing succinyl groups into chitosan N-terminals of the glucosamine units thus 
conferring it good solubility properties at both neutral and alkaline pH [19-21].  
5ASA is slightly soluble in water and is light and oxygen sensitive [22]. Drug 
solubility is a key factor in the drug release from inert as well as swellable delivery 
systems where diffusion, preceded by the drug dissolution, controls the release. For 
poorly soluble drugs, their low dissolution rate is the actual limiting factor of drug 
delivery [23]. One approach to increase 5ASA solubility and stability consists in its 
inclusion in cyclodextrins (CDs) [22]. As well known, CDs are oligosaccharides that 
are largely employed in pharmaceutical formulations for their capability to form 
inclusion complexes with poorly soluble drugs to improve their water solubility and, 
therefore, their bioavailability. In the last decade, CDs have also been proposed as 
modulators of drug release from different polymeric delivery systems [24] that 
include hydrogel, gels, and erodible hydrophilic matrices as well as biodegradable 
microspheres. 
In this research, aiming at developing new colon specific delivery systems for 
5ASA, three-dimensional amorphous matrices made with CH or SucCH, were 
prepared and characterized by using several methods (SEM; DSC; FT-IR, swelling 
behaviour, and drug release). Moreover, in this first part of our research, we have 
particularly focused on the influence of -CDs on the 5ASA release. Therefore, 
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matrices including these cyclic oligosaccharides were also prepared, characterized 
and their properties compared to those of the free-CDs formulations.  
 
3.2. Experimental 
 
3.2.1. Materials 
Chitosan (CH) of average molecular weight (75,000 Da), succinic anhydride and 5-
aminosalicylic acid (5ASA) were obtained from Sigma-Aldrich, (Milan, Italy). -
cyclodextrin (CD) was kindly supplied by Roquette Co. (Lestrem, France). All the 
products and solvents were of analytical grade. Spectra-Por
®
 dialysis membrane 
(cut-off 12000-14000 Dalton, regenerated cellulose) was purchased from Spectrum 
Lab Inc. (CA, USA). 
 
3.2.2. Preparation and characterization of N-Succinyl-chitosan 
Chitosan was succinylated according to the method reported by Hirano et al. (1981) 
[25] with some modifications. Briefly 0.64 g of CH were dissolved under stirring in 
a 5% (v/v) aqueous acetic acid solution (50 ml), and the resulting solution was 
slowly diluted with 50 ml of methanol. Then 4.22 g of succinic anhydride, 
previously dissolved in a minimum amount of acetone (30 ml), added dropwise to 
the CH solution. The reaction was maintained under stirring overnight at room 
temperature. The obtained viscous gel was diluted with a NaOH 2 M solution, which 
was added dropwise until pH=10 was reached and a clear solution was formed. The 
solution was concentrated by a rotary evaporator (Rotavapor Büchi R110, 
Switzerland) and immediately dialyzed for three days against distilled water. Then, 
the solution was freeze-dried to obtain a white cotton-like material. The product was 
characterized by CHN (Fisons model EA 1108 Elemental Microanalyser), IR 
spectrum (Bruker Equinox 55) and DSC spectrum (Toledo model 821e). 
IR (KBr mull) 3319 cm
-1
 (-NH2 and -OH stretching), 1731 cm
-1
 (carboxylic acid 
C=O stretching), 1668 cm
-1
 (amide I) 1585 cm
-1
 (amide II), 1162 cm
-1
 1072 cm
-1
 
1035 cm
-1
 (sugar structure). 
CHN: found C: 36.96; H: 6.62; N: 4.30; calculated from [C6H10O4N (HCOCH3)0.15 
(H2)0.17 (HCOC2H4COONa)0.68] C: 37.91; H: 6.11; N: 4.88. 
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The degree of succinylation, defined as the average number of succinyl groups per 
repeating units of glucosamine, was calculated from the elemental analysis data and 
chemically determined also using 2,4,6-trinitrobenzenesulfonic method [26]. 
 
3.2.3. Preparation of chitosan or N-Succinyl-chitosan matrices 
CH and SucCH were dispersed in distilled water (0.5% w/v). 5ASA or 5ASA and -
CD (4:1 molar ratio) were added to the dispersion, which was homogenized using an 
ultraturrax, then frozen at −15°C/−20°C and freeze-dried for 24 hours at −70°C and 
60 mmHg, using a Freeze-Dryer Criotecnica, (MMCOTA, Rome, Italy).  
 
3.2.4. Determination of 5ASA content in matrices 
The amount of 5ASA loaded into the freeze-dried matrices was determined by a 
dissolution method. Briefly 10 mg of dried powder was dissolved in a 
hydroalcoholic solution (methanol-pH 1.2 buffer, 1:1, v/v for CH matrices; 
methanol-pH 7.4 buffer, 1:1 v/v for SucCH matrices). The mixture was vigorously 
shaken for 2 hours in order to dissolve the matrix into the solution. After 
centrifuging, the supernatant was withdrawn and the 5ASA content was analyzed by 
HPLC (see below). The drug loading capacity was expressed as the ratio of actual-
theoretical 5ASA content. 
 
3.2.5. Quantitative determination of 5ASA 
5ASA content was quantified at 300 nm by HPLC using a chromatograph Alliance 
2695 (Waters, Italy) equipped with a photodiode array detector 996 and a computer 
integrating apparatus (Empower 2). The column was an X bridge-Waters C18 
column (60 Å, 5 μm, 4.8 x 150 mm, Waters). The mobile phase was a mixture of 
acetonitrile, water, and acetic acid (72:20:8, v/v), which was filtered through a 0.45 
m membrane filter before use, and was delivered at a flow rate of 1.0 ml/min. The 
injected sample volume was 10 µl. Sample preparation and analyses were performed 
at room temperature. A standard calibration curve (peak area of 5ASA versus known 
drug concentration) was built up by using working, standard solutions (0.5-0.005 
mg/ml). Calibration graphs were plotted according to the linear regression analysis, 
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which gave a correlation coefficient value (R
2
) of 0.9996. The 5ASA retention time 
(tr) was 3.0 minutes and the minimum detectable amount was 25 g/ml. 
 
3.2.6. Evaluation of the polymer-drug interaction using Fourier Transform Infra-
Red measurements (FTIR) and Differential Scanning Calorimetry (DSC) 
FTIR measurements were carried out at room temperature using Bruker Equinox 55. 
About 2 mg of the samples were ground thoroughly with KBr and pellets were 
formed under a hydraulic pressure of 600 kg/cm
2
. Spectra of 5ASA, CH, SucCH, 
5ASA loaded polymer matrices were performed.  
DSC studies were performed using a DSC Mettler Toledo model 821e. The samples 
(2-5 mg) were scanned in sealed aluminum pans under nitrogen atmosphere. DSC 
thermograms were scanned in the first heating run at a constant rate of 10°C/min and 
a temperature range of 0-325°C. DSC thermograms of pure substances and drug 
loaded polymer matrices were recorded. 
 
3.2.7. Scanning electron microscopy 
The surface morphology of the polymer matrices were examined using a scanning 
electron microscope (SEM), Hitachi S4100 (Madrid, Spain). Powder samples were 
dispersed on an aluminium stub with a self-adhered carbon film. The samples were 
made electrically conductive by coating with gold/palladium under vacuum. The 
SEM images were taken at an excitation voltage of 20 kV. 
 
3.2.8. In vitro swelling studies 
The swelling of freeze-dried matrices was performed in a membrane dialysis bag 
that contained 100 mg of each systems; the membrane bag was placed in a closed 
flat bottom tube with 40 ml of a buffer solution that was maintained at 37° C for 24 
hours. The test was carried out in 2 different solutions: pH 1.2 and pH 7.4. To 
simulate the gastro-intestinal transit it was also performed with a pH gradient 
method by placing the membrane for 2 hours at pH 1.2 and then replacing the acidic 
solution with pH 7.4 buffer (mixed buffer). At specific time intervals, samples were 
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removed, blotted with a piece of paper for 5 s to absorb excess water on surface and 
then weighted. 
The swelling ratio (SW %) was calculated using the following equation: 
[ 100%
0
0 


t
tt
w
W
WW
S ] (1)  
where Wt represents the weight of the system at a certain time and Wt0 represents the 
original dry weight. 
 
3.2.9. In vitro release studies 
Each matrix was placed in a dialysis bag and in a closed flat bottom tube, 40 ml of 
pH 1.2 or pH 7.4 solutions were loaded. The release study was carried out for 24 h 
under magnetic stirring in a thermostatic bath at 37° C. In order to simulate the 
passage through the stomach and the intestine, tests were performed also using a pH 
gradient method as seen for the swelling studies. During the experiments, at regular 
time intervals, 20 ml of the medium were withdrawn and replaced with the same 
amount of fresh solution to ensure sink conditions. The withdrawn samples were 
analyzed for 5ASA content by HPLC as described before (see paragraph 3.6). 
 
3.2.10. Mathematical modelling of release kinetics 
In order to describe the drug release mechanism, the in vitro drug release mean data 
(cumulative drug release up to 60%) were fitted to the power law equation (Equation 
2) 
[
nt tK
M
M


] (2)  
where Mt and M are the absolute amount of drug released at t and infinite time, 
respectively; K is a constant reflecting structural and geometric characteristic of the 
device, and n is the release exponent characterizing the diffusion mechanism. 
According to the criteria for release kinetics from swellable systems, release 
exponent values n=0.45, 0.45<n<0.89 and 0.89 indicate, respectively, Fickian (Case 
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I) diffusion, non-Fickian (anomalous) transport, and diffusion and zero-order (Case 
II) transport [27-29]. 
 
3.2.11. Preparation of GI tissues and mucoadhesive test 
Male Wistar rats (13-weeks old) had been fasted for 24 h. The fasted conditions 
were set to minimize the contents in the GI tract, which disturbed the washing 
process for the following use. The intestine tissues (i.e. duodenum, jejunum, ileum 
and colon) were excised from sacrificed rats. Each section of tissues was slowly 
washed with a large amount of normal saline solution (0.9% NaCl w/v). The 
intestine tissues (duodenum, jejunum, ileum and colon) were immediately used for 
this study. 
Swelling of samples was simulated putting the matrices in a flat bottom tube with 
the buffer solution and thermostated at 37° C. At scheduled time intervals buffer 
solution was withdrawn and mucoadhesion studies were done using different part of 
rat intestine tissue. The mucoadhesion studies were done using a universal tensile 
tester (Lloyd Instruments, LR 50K model, UK). The stainless steel plate (L-shape) 
was fitted by one of its side into the upper and lower jaws of the instrument so as the 
other surfaces of the plates were facing each other. The rat intestine tissue was stuck 
at the upper plate surface with the glue, while matrix was placed on the lower plate. 
PBS, pH 7.4, was used as a medium and 20 L were spread on the contact surface 
between matrix and tissue. Then the upper jaw with tissue stuck on the plate was 
lowered slowly so that it just touched the matrix surface. No external force was 
applied. The matrix was kept in contact with the tissue for 5 min and then the upper 
jaw was slowly moved upward at the speed of 10 mm/min. 
All the experiments were done in triplicate. The maximum detachment force (FMAX), 
i.e. the force required for separating the system from the tissue surface was obtained 
directly from NimaST518.vi software (Nima Technology Ltd, Coventry, England) 
and the total amount of forces involved in the probe withdrawal from the tissue 
(work of adhesion, Wad) was then calculated from the area under the force versus 
distance curve. These parameters were used to compare the different prepared 
matrices. 
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3.2.12. Statistical analysis of data 
Data analysis was carried out with the software package R, version 2.10.1. Results 
are expressed as the mean ± standard deviation. Multiple comparisons of means 
(Tukey test) were used to substantiate statistical differences between groups, while 
Student’s t-test was applied for comparison between two samples. Significance was 
tested at the 0.05 level of probability (p). 
 
3.3. Results and Discussion 
3.3.1. Preparation of N-Succinyl-chitosan 
N-Succinyl-chitosan was successfully synthesized following methods reported in the 
literature (Scheme 1). Polymer derivatization was confirmed by FTIR analysis 
(Figure 1). Chitosan FTIR spectrum shows: at 2912 cm
-1
 the stretching vibration of 
–OH and –NH2; at 1658 and 1602 cm
-1
 stretching respectively of amide I and II; 
-NH2 bending at 1650 cm
-1
. The absorption bands at 1159 cm
-1
 (asymmetric 
stretching of the C-O-C bridge), 1095 and 1039 cm
-1
 (skeletal vibration involving 
the C-O stretching) are characteristic of its saccharide structure [30,31]. Moreover, 
the FTIR spectrum of N-Succinyl-chitosan shows: stretching vibrations of –OH and 
–NH2 at 3319 cm
-1
; the C=O stretching of amide I band at 1668 cm
-1 
and the amide 
II band at 1585 cm
-1
. Peaks at 1162, 1072, and 1035 cm
-1
 are typical of the sugar 
structure. Peaks at 1731 and 1417 cm
-1
 denote the presence of carboxyl groups thus 
confirming chitosan derivatization and N-Succinyl-chitosan formation. In particular, 
the peak at 1731 cm
-1
 is the stretching band of C=O and the peak at 1417 cm
-1
 
belongs to –COOH symmetric stretching vibration [32]. 
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Scheme 1. Synthesis of N-Succinyl-chitosan. 
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The degree of succinylation, defined as the average number of succinyl groups per 
repeating units of glucosamine, was 68%. 
 
3.3.2. Preparation of chitosan or N-Succinyl-chitosan matrices 
The rational of this work was to exploit the promising bioadhesive properties of CH 
or SucCH freeze-dried matrix and to evaluate their possible combination with the 
excellent biopharmaceutical properties of CDs. Anionic succinyl groups of SucCH 
can interact electrostatically with remaining cationic amino groups on the C2 
position of SucCH to form intra- and inter-molecular polyelectrolyte complexes 
capable of controlling drug release. Moreover, the incorporation of CDs into these 
polyionic polymer matrices may allow interaction between the polymer and the 
hydrophilic outer surface of the CDs as well as interaction between 5ASA and CDs, 
with a consequent greater degree of drug release control. 
Freeze-drying was used to prepare CH or SucCH matrices including either 5ASA or 
5ASA and CDs. This procedure gave rise to highly fluffy cotton-like powders. The 
found drug loading capacity was high for all the samples, as shown in Table 1, but 
no statistical differences could be found between matrices with or without -CDs.  
Table 1. 5ASA loading capacity %. 
Systems 5ASA/CH 5ASA/SucCH 5ASA/CD/CH 5ASA/CD/SucCH 
Loading Capacity % 89±8 92±7 94±9 95±5 
 
3.3.3. Evaluation of the polymer-drug interaction using Fourier Transform Infra-
Red measurements (FTIR) and Differential Scanning Calorimetry (DSC) 
The FTIR spectra of pure compounds and obtained matrices are shown in Figure 1. 
In the FTIR spectrum of pure 5ASA, the assignments of the observed absorption 
bands are as follows: -COOH stretching (hydrogen bonded) associated with the 
hydroxyl groups at 3008 cm
-1
, C=O stretching of the -COOH at 1650 cm
-1
,-NH2 
bending at 1622 cm
-1
, C-O stretching at 1137 cm
-1
 and in plane C-O-H bending at 
1190–1267 cm-1 [13]. Band at 1456 cm-1 belongs to the –OH bending, while C-N 
stretching appears at 1357 cm
−1
 and bands at 1490 and 1382 cm
-1
 refer to C=C 
phenyl group stretching. 
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Both CH and 5ASA characteristic peaks are observed in the FTIR spectrum of 
5ASA loaded chitosan system (5ASA/CH), which indicates that the drug was filled 
in the polymeric network. The absorption band at 1658 and 1602 cm
-1
 of C-H 
(amide I and II respectively) shifted to 1660 and 1589 cm
-1
. Bands at 1157, 1097 and 
1051 cm
-1
 are characteristic absorption bands of the chitosan (sugar structure), while 
those at 1496, 1459, and 1380 cm
-1
 are typical of 5ASA. 
5ASA/SucCH system presents typical bands of 5ASA and SucCH, confirming the 
presence of both molecules in the system. SucCH bands: 1722, 1656, 1577, 1411, 
1114, 1074, and 1039 cm
−1
; 5ASA bands: 1502, 1452 and 1396 cm
−1
. CD-
containing matrices do not show any significant difference. 
 
 
Figure 1. FTIR spectra of 5-ASA (5ASA), chitosan (CH), N-Succinyl-chitosan (SucCH), 5-ASA 
and chitosan (5ASA/CH), 5-ASA and N-Succinyl-chitosan (5ASA/SucCH), 5-ASA/-
cyclodextrin/chitosan (5ASA/CD/CH), 5-ASA/-cyclodextrin/N-Succinyl-chitosan 
(5ASA/CD/SucCH) freeze-dried matrices. 
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Shift of the peaks and reduced intensity of the bands in the 5ASA/polymer systems 
confirmed the loading of the drug into the polymers as well as interactions between 
the two components. 
In the calorimetric study, thermal curve of the pure drug exhibits an endothermic 
peak at 277 °C and an enthalpy of 24 mW mg
-1
, corresponding to its melting point 
(Figure 2). The CH and SucCH thermograms show typical polysaccharide behaviour 
with two degradation steps: a wide endotherm around 100 °C and an exotherm at 
315°C that is less evident in SucCH. The first peak in the polymer thermograms 
corresponds to water evaporation, while the second one refers to polymer 
degradation. 
 
 
Figure 2. DSC curves of 5-ASA (5ASA), chitosan (CH), N-Succinyl-chitosan (SucCH), 5-ASA and 
chitosan (5ASA/CH), 5-ASA and N-Succinyl-chitosan (5ASA/SucCH), 5-ASA/-
cyclodextrin/chitosan (5ASA/CD/CH), 5-ASA/-cyclodextrin/N-Succinyl-chitosan 
(5ASA/CD/SucCH) freeze-dried matrices. 
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In thermograms of 5ASA containing matrices, with and without CDs, 5ASA fusion 
peak disappears indicating the presence of solid-state interactions between the drug 
and both polymers. In addition, the thermogram of 5ASA/SucCH shows esotherm-
endotherm peaks around 210°C, which denotes an interaction between anionic 
succinyl groups of the polymer and cationic amino groups of 5ASA. These signals 
are not present in the termograms of the pure SucCH as well as in that of 
5ASA/CD/SucCH matrix, where an inclusion complex between 5ASA and -CD 
could have formed during the freeze-drying procedure. 
 
3.3.4. Scanning electron microscopy (SEM) 
SEM images of CH and SucCH matrices are reported in Figure 3. No differences in 
morphology between matrices prepared with and without CD were observed. All the 
prepared polymer systems showed a three-dimensional structure. The surface pattern 
of CH matrix was slightly rougher and tightly packed in (Fig. 3a), whereas SucCH 
matrix appeared highly porous with small, flat, and folded sheets, with a large 
surface area (Fig. 3b). This three-dimensional structure might be due to interactions 
between the carboxyl and amino groups of SucCH. 
 
 
                      
Figure 3. SEM photographs of (a) 5ASA/CH, (b) 5ASA/SucCH systems. 
 
 
(a) (b) 
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3.3.5. In vitro swelling studies 
Swelling degree is a characteristic of hydrogels that controls drug loading as well as 
drug release. Swelling of the studied matrices was studied as weight evolution of the 
freeze-dried systems and was assayed at pH 1.2 (Figure 4a), pH 7.4 (Figure 4b), and 
also in a mixed buffered medium (pH 1.2 for 2 hours and pH 7.4 until 24 hours; 
Figure 4c). Swelling degree is represented as swelling ratio (Sw). Swelling behaviour 
of the samples was in accordance with their physico-chemical properties. In fact, 
CH, a cationic polymer, easily swelled and jelled at pH 1.2 but it did not at pH 7.4. 
When swelling experiments were performed in the mixed buffer, CH swelled only 
during the first two hours, in the acid medium, where it reached a maximum Sw that 
did not vary further (Figure 4c). When CDs were mixed with 5ASA and chitosan 
(5ASA/CD/CH), the swelling ratio decreased using acid and mixed buffers because 
of the presence of the hydrophilic but no-swellable CDs. On the contrary, CDs did 
not affect the CH swelling in alkaline medium where the system behaved as an inert 
matrix. 
SucCH had an opposite behaviour: it showed low swelling activity in acidic medium 
at pH 1.2 (Figure 4a), while it swelled and jelled at pH 7.4 (Figure 4b). This is due 
to the SucCH modification: succinyl groups (and consequently –COOH moiety) are 
predominant in this polymer and their ionization at alkaline pH made the matrix to 
swell. Swelling studies in mixed buffer confirmed SucCH behaviour in acid and 
alkaline media: the system started to swell only when the buffer medium was 
changed from acid to alkaline (Figure 4c). Also in this case, the presence of CDs 
(5ASA/CD/SucCH) decreased the polymer swelling at pH 7.4 and in mixed buffer, 
while at pH 1.2 no differences were observed. 
Therefore, obtained results point out that influence of -CDs on CH and SucCH 
swelling is also dependent on the medium pH. Indeed, when the polymers can 
easily interact with the aqueous medium, -CDs reduce the polymer swelling 
probably as a consequence of a preferential water uptake by the hydrophilic CDs. 
On the contrary, no influence at all can be found when the polymer does not 
interact with the aqueous medium.  
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Figure 4. Swelling ratio (Sw) of 5ASA freeze-dried systems at (a): pH 1.2, (b): pH 7.4, and (c): 
mixed medium (2 h at pH 1.2 and up to 24 h at pH 7.4). Error bars represent standard deviation, 
n =3. 
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3.3.6. In vitro release studies 
As for the swelling experiments, in vitro release studies were carried out for 24 
hours at pH 1.2, 7.4, and in mixed buffer. Release of 5ASA from matrices 
containing only the drug appears to be substantially determined by the swelling 
kinetics (Figures 5a, b and c). As soon as the matrices swelled and the water could 
penetrate into, the drug was solubilised and released from the system. When the 
systems were not able to interact with the aqueous medium, only a small amount of 
5ASA was released.  
Therefore, at pH 1.2, drug release from 5ASA/CH was quite fast and, after 6 hours, 
82% drug release was obtained (Figure 5a). On the contrary, in alkaline buffer the 
process was slower and only 35% drug release was obtained at the end of the 
experiments (Figure 5a). An opposite behaviour was shown by the SucCH matrix: 
drug release was fast and higher than 90% at pH 7.4 while the release rate decreased 
at pH 1.2. 
Interesting results were obtained when CD containing matrices were tested. In fact, a 
faster drug release was obtained from the “inert” matrices, while the presence of the 
CDs led to a slightly slow release rate in the presence of the swollen CH (pH=1.2) 
and SucCH (pH=7.4). According to literature, in the “inert” matrices the increased 
drug release rate is mostly probably due to the ability of CDs to form an inclusion 
complex with 5ASA with a consequent enhanced drug solubility that improves drug 
delivery [23-24]. When CDs are dispersed in the swollen matrices, on the contrary, 
the complexing capability of the CDs is less effective in the release rate promotion 
probably because of a limited diffusivity of the formed 5ASA/CD complex through 
the swollen polymer [23,33]. 
Drug release in the mixed buffer was always quite fast in the first six hours although 
the 5ASA release profile from SucCH was slower than from all the other samples. In 
fact, drug release rate from CH was very fast in the first 4 hours (50% released drug) 
but then it slowed down and only 70% total drug amount was released at the end of 
the experiments. On the contrary, SucCH led to a slow but constant drug release rate 
during the first 8 hours and, at the end of the experiments, 92% 5ASA release was 
obtained. The highest drug release after 24 hours was obtained from the SucCH and 
the CD-containing CH matrices. Consequently, -CDs in the cationic polymer CH 
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were able to improve 5ASA release in the alkaline conditions. However, SucCH 
alone was capable of better controlling drug release that in acidic medium was lower 
( 15%) than all the other formulations that released more than 49% of 5ASA (Fig. 
5c). Therefore, results from the release experiments showed that SucCH is a 
potential candidate for targeting 5ASA to colon. 
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Figure 5. Drug release (%) from 5ASA or 5ASA/CD from chitosan or N-Succinyl-chitosan freeze-
dried systems at: (a) pH 1.2; (b) pH 7.4 and (c) in mixed medium (2 h at pH 1.2 and up to 24 h at 
pH 7.4). Error bars represent standard deviation, n =3. 
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3.3.7. Mathematical modelling of release kinetics 
To deduce the mechanism of drug release from the matrices, the release data were 
fitted to general power law equation (2) [27], generally used to describe drug release 
from swellable matrices, and results related to experiments in the mixed buffer are 
shown in Table 2. As can be seen from the obtained correlations coefficient values 
(R0.99), the release data fit well to the empirical equation. The n exponent 
obtained from the release studies ranged from 0.69 to 0.91 (Table 2), thus indicating 
a non-Fickian (anomalous) transport (0.45<n<0.89) for all the tested samples [27-
30].  
Mechanism of drug release from hydrophilic and erodible matrices is rather complex 
as a consequence of the several physical process involved especially when CDs are 
present together with a poor soluble drug. In fact, the involved processes regard: 
penetration of water into the matrix with consequent swelling and solubilization 
/erosion of the matrix, dissolution of both the drug and CDs in the swollen matrix, 
CD/drug complex formation, and counterdiffusion of drug, CD, and complex in the 
swollen layer [34]. Therefore, all these process are responsible of an anomalous non-
Fickian diffusion mechanism. 
 
Table 2. Regression analysis and correlation coefficient values for release data from different 
systems according to Ritger-Peppas kinetic equation. 
Systems n k R
2
 
5ASA/CH 0.72±0.05 0.38±0.11 0.9954 
5ASA/SucCH 0.91±0.03 0.12±0.01 0.9920 
5ASA/CD/CH 0.69±0.05 0.30±0.15 0.9948 
5ASA/CD/SucCH 0.70±0.04 0.35±0.09 0.9958 
 
3.3.8. Mucoadhesion study 
Mucoadhesion is becoming an important strategy to improve the highly variable 
residence time experienced by drugs and dosage forms at various sites in the gastro-
intestinal tract and consequently to reduce variability and improve efficacy. In the 
treatment of inflammatory bowel disease, the intimate contact with the colonic 
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mucosa should improve local therapy. The interaction between mucus and 
hydrophilic polymers is a result of physical entanglement and secondary bonding, 
mainly H-bonding and van der Waals attraction. These forces are related to the 
chemical groups of the polymeric chain, and in particular hydroxyl, carboxyl, amine, 
ester and amide groups generally contribute to good adhesion properties. Moreover, 
the polymer swelling ability, increasing molecule mobility, facilitates 
interpenetration and interaction with the mucus layer. Chitosan shows hydroxyl, 
amide, and amine groups able to give hydrogen bonds and its linear molecules 
express good chain flexibility and thus a good physical entanglement [35]. 
Furthermore, it exhibits strong mucoadhesive properties due to the formation of 
hydrogen and ionic bonds between the positively charged amino groups of chitosan 
and the negatively charged sialic acid residues of mucin glycoprotein. It is known 
that negatively charged polymers bearing –COOH group (e.g., Carbomers) interact 
with mucus by hydrogen and van der Waals bonds, created between their carboxylic 
groups and the sialic acid residues of mucin glycoprotein [36]. SucCH contains 
carboxylic group, hydroxyl, and amino groups and, therefore, good mucoadhesive 
ability can be hypothesized due to ionic, hydrogen and van der Waals bonds. 
In this study ex vivo mucoadhesive properties of the studied systems were evaluated 
using different part of rat intestine. The maximum detachment force (FMAX), i.e. the 
force required for separating the sample from the tissue surface, and the total amount 
of forces involved in the probe withdrawal from the tissue (work of adhesion, Wad) 
on different GI mucosa are shown in Table 3.  
All the tested systems showed good mucoadhesion for the colon: Wad mean value 
was higher for SucCH but no statistical differences could be found in the 
mucoadhesive properties of the matrices both with and without CDs. Although the 
polymer ability to swell is a prerequisite for mucoadhesion, since it concerns wetting 
uncoiling and spreading of the polymer over the mucus [37], results of table 3 show 
that the CH systems were as mucoadhesive as SucCH in the last portion of the GI 
tract.  
However, also these results highlight the highest potential of the SucCH matrix as 
delivery system for targeting 5ASA to colon.  
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Table 3. Ex vivo mucoadhesive performance of 5ASA freeze-dried systems. Effect of GI mucosa 
on maximum detachment force and (FMAX) and work of adhesion (Wad). 
 
Systems  Duodenum jejunum ileum colon 
5ASA/CH FMAX (mN) 2.2±0.5 3.3±0.3 3.3±0.4 3.8±0.5 
 Wad(mN mm) 0.9±0.2 1.3±0.2 1.3±0.1 1.5±0.2 
5ASA/SucCH FMAX (mN) 2.7±0.3 2.4±0.2 2.7±0.3 4.0±0.5 
 Wad(mN mm) 1.1±0.3 0.9±0.2 1.1±0.2 1.5±0.3 
5ASA/CD/CH FMAX (mN) 2.0±0.4 3.2±0.4 3.5±0.5 3.6±0.5 
 Wad(mN mm) 0.8±0.2 1.1±0.2 1.4±0.3 1.5±0.2 
5ASA/CD/SucCH FMAX (mN) 2.9±0.4 2.3±0.3 2.8±0.4 3.9±0.5 
 Wad(mN mm) 1.1±0.2 0.9±0.1 1. ±0.3 1.5±0.4 
 
3.4. Conclusions 
Overall obtained results showed that SucCH matrix might be a good candidate for 
colon specific delivery of 5ASA. Indeed, SucCH matrix was able to better control 
drug release, which was quite low in acidic medium and almost complete in alkaline 
environment, in comparison with CH and CD-containing polymeric matrices. CDs 
showed a dual effect on drug release, which was always reduced from the swollen 
polymeric matrices. On the contrary, CDs improved drug release from the inert 
polymers. Further studies are in progress to evaluate new drug delivery systems for 
5ASA by using SucCH.  
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Abstract 
The objective of this study was to prepare two different systems for the delivery of 
5-aminosalicylic acid (5-ASA) to the colon. N-Succinyl-chitosan (SucCH) was 
chosen as carrier system because of its excellent pharmaceutical properties. It was 
prepared by introducing succinic group into chitosan N-terminals of the glucosamine 
units. Due to the presence of carboxyl groups it exhibits pH-dependent swelling 
behavior and good mucoadhesivness. 5-ASA loaded SucCH microparticles and 
freeze-dried systems were prepared using spray-drying and freeze-drying techniques 
respectively. FTIR, DSC, X-ray diffraction studies were carried out to characterize 
the systems and to evaluate drug-polymer interactions. Morphology studies, size 
distribution, zeta potential, swelling properties and drug release were also performed 
in order to understand the potential of the systems to be effective to deliver the drug 
to the site of action. By imaging with SEM, acceptable spherical non porous 
microparticles were obtained. In vitro swelling and drug release studies were in 
accordance with the polymer properties, showing the highest swelling ratio and drug 
release at pH=7.4 (colonic pH). 
 
4.1. Introduction 
 
Ulcerative colitis and Crohn’s disease are chronic, immunologically mediated 
disorders that are collectively referred to as inflammatory bowel disease (IBD). 
Although their exact etiologies remain uncertain, results from research indicate that 
IBD are heterogeneous diseases characterized by various genetic abnormalities that 
lead to overly aggressive T-cell responses to a subset of commensal enteric bacteria 
[1]. Ulcerative colitis is limited to the colon, although Crohn's disease can involve 
any part of the gastrointestinal tract from the mouth to the anus, it most commonly 
affects the small intestine and/or the colon. Standard treatment for ulcerative colitis 
and Crohn’s disease depends on extent of involvement and disease severity [2]. 
5-Aminosalicylic acid (5-ASA) is an anti-inflammatory drug commonly used in the 
treatment of IBD. It is effective for use in mild to moderate disease and as 
maintenance therapy [3]. The precise mechanism of action of the drug is not known, 
but is likely due to a combination of anti-inflammatory properties. It is able to block 
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the production of interleukin-1 (IL-1) and tumor necrosis factor- (TNF-) [4,5]. 
5-ASA is a potent inhibitor of the cyclooxygenase pathway, inhibiting the 
production of prostaglandin E2 in inflamed intestinal specimens [6] and it is also 
one of the most potent known free radical scavengers and antioxidants [7,9]. 
Moreover 5-ASA has been shown to inhibits of activation of nuclear factor-B 
(NF-B), a central transcription regulatory factor involved in mediating the initiation 
and perpetuation of inflammatory processes [10,11]. When pure 5-ASA is taken 
orally, however, the stomach and upper small intestine absorb most of the drug 
before it reaches the colon [12]. Therefore, to be effective as an oral agent for IBD 
and reach the site of action at therapeutic levels, 5-ASA has to escape absorption by 
the stomach and upper intestines. For this purpose different approaches have been 
developed and studied. The most important systems can be divided into three 
groups: time-dependent, enzyme-dependent and pH-dependent systems [13,14]. 
Time-dependent systems are based on the principle of delaying the release of the 
drug until it enters to the colon. Enzyme-dependent systems take advantage of the 
colonic microflora that has a large amount of specific enzymes that are not present 
in the rest of GI tract. They make the drug to be released specifically in the colon by 
breaking covalent bonds between a drug and its carrier (prodrugs) or by eroding 
biopolymers [15]. pH-dependent systems exploit the generally accepted view that 
the pH of the human GI tract increases progressively from the stomach (pH 1-2) to 
small intestine (pH 5-6) and colon (pH 7-8). 
pH-sensitive hydrogels have attracted increasing attention due to their unique 
properties. Swelling of such hydrogels in the stomach is minimal and thus the drug 
release is also minimal. Due to increase in pH, the swelling degree increases as the 
hydrogels pass down the intestinal tract. The use of natural polymers in the design of 
pH sensitive hydrogels has received much attention due to their excellent 
biocompatibility and biodegradability. Among them chitosan and its derivative are 
very promising [16]. N-Succinyl-chitosan (SucCH) is a new chitosan derivate that 
could be obtained by introducing succinyl groups into chitosan N-terminals of the 
glucosamine units [17-19]. It exhibits good solubility properties at neutral and basic 
pH. It is reported to have favorable drug carrier properties such as biocompatibility, 
low toxicity, long-term retention in the body and pH-dependent swelling behaviour. 
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The presence of carboxyl groups and other hydrophilic moiety makes the polymer 
mucoadhesive; these groups adhere to the mucosal tissue via hydrogen bonding 
between carboxyl groups of the polymer and hydroxyl groups of the 
oligosaccharides present in the glycoproteins of the intestinal mucosa [20]. 
In a previous work 5-ASA loaded SucCH freeze-dried systems were prepared [21], 
in this study with the aim to increase the drug loading and evaluate the influence of 
particle size on the delivery system propeties, 5-ASA loaded SucCH microparticles 
(MP) and freeze-dried system (FD) were prepared using spray-drying and freeze-
drying technique respectively. Physicochemical characterizations, including 
microparticle size, morphology, zeta potential, drug loading were performed. 
Swelling and drug release studies from both the systems were carried out at different 
pH values. 
 
4.2. Materials and Methods 
 
4.2.1. Materials 
Chitosan (CH) of medium molecular weight, succinic anhydride and 5-ASA were 
obtained from Aldrich, (Milan, Italy). Spectra-por
®
 dialysis membrane (MWCO 
12000-14000 Dalton, regenerated cellulose) was purchased from Spectrum Lab (Inc, 
USA). All the products and solvents were of analytical grade. 
 
4.2.2. Preparation of N-Succinyl-chitosan 
Chitosan medium molecular weight was succinylated according to the method 
reported in a previous work [21]. 
 
4.2.3. Preparation of 5-ASA/N-Succinyl-chitosan freeze-dried system (FD) 
5-ASA/SucCH system was prepared at 1:1 molar ratio. The appropriate amount of 
N-Succinyl-chitosan were weighted and solubilized in 70 ml of distilled water, when 
it was completely solubilized 5-ASA was added to the solution. The dispersion was 
homogenized using an ultraturrax, then frozen at −80°C and freeze-dried for 24 
hours at −50°C and 60 mmHg, using a Freeze-Dryer Criotecnica, (MM Cota, Rome, 
Italy). 
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4.2.4. Preparation of microparticles (MP) 
5-ASA loaded SucCH microparticles (MP) were prepared using spray-drying 
method. Briefly 400 mg of 5-ASA was dispersed in 100 ml of distilled water and 
then 500 mg of SucCH was added and let solubilize under magnetic stirring. The 
mixture was infused into a spray dryer nozzle unit of Minispray Dryer (Büchi B-
290, Switzerland). The conditions of the spray-drying process were: nozzle diameter 
0.7 mm, aspiration: 80%, inlet temperature: 150°C, outlet temperature: 100°C. 
Blank SucCH microparticles were prepared using the same conditions as for the 
drug-loaded particles. Microparticles were collected and stored at 25°C, 60% Hr. 
 
4.2.5. Characterization of MP and FD 
 
4.2.5.1. Evaluation of the polymers-drug interaction using Fourier transform infra-
red measurements (FTIR) 
FTIR measurements were taken at an ambient temperature using Bruker Equinox 55 
(Germany). About 2 mg of the samples were ground thoroughly with KBr and 
pellets were formed under a hydraulic pressuse of 600 kg/cm
2
. 5-ASA, chitosan, 
SucCH, MP and FD spectra were performed. 
 
4.2.5.2. Evaluation of the polymers-drug interaction and physical state of 5-ASA 
using differential scanning calorimetry (DSC) and X-ray diffraction studies 
DSC studies were performed using a DSC Mettler Toledo model 821e 
(Switzerland). The samples (2-5 mg) were scanned in sealed aluminium pans under 
nitrogen atmosphere. DSC thermograms were scanned in the first heating run at a 
constant rate of 10°C/min and a temperature range of 0-325°C. DSC thermograms of 
pure substances, drug loaded SucCH MP and FD were recorded. 
X-ray diffractogram pattern for 5-ASA alone was recorded with Bragg–Brentano 
geometry on a Bruker AXS D5005 (DRXP, Germany) in the 2θ range from 5° to 
45°, in steps of 0.02° at 6 s per step. 
4.2.5.3. Scanning electron microscopy (SEM) 
Shape and surface morphology of the empty and 5-ASA loaded SucCH 
microparticles were examined using a scanning electron microscope (SEM, S-4100 
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Hitachi, Madrid, Spain). The samples were mounted on an aluminum stub using 
double-sided tape. The samples were made electrically conductive by coating under 
vacuum with gold-palladium. The SEM picture was taken at an excitation voltage of 
20 kV. 
 
4.2.5.4. Particle size analysis 
Measurement of the particle size of MP was carried out with Analysette 22 Micro 
tec plus (Fritsch, Germany) after suspending the particles in distilled water and 
sonicating the suspension for 10 min in ultrasonic bath. The average particle size 
was expressed as the volume surface diameter, dvs (m). 
 
4.2.5.5. Zeta potential 
Suspension of microparticles in distilled water previously sonicated for 10 min in 
ultrasonic bath was used to determine the zeta potential of MP. The zeta potential of 
the particles was recorded using Malvern Zeta Sizer apparatus (model Zen 3600, 
Malvern, UK). Each sample was analysed at least six times to obtain an average 
value and a standard deviation. Samples of blank SucCH microparticles and FD 
were also submitted to this study. 
 
4.2.5.6. Content of 5-ASA in the systems 
The actual content of 5-ASA in MP and FD was determined by dissolving an exactly 
weighed amount of the systems at pH 7.4 with magnetic stirring at room temperature 
for 30 hours. 5-ASA concentration was assayed by HPLC, using a Perkin Elmer
®
 
Series 200 equipped with a UV detector Waters 484
®
 (=300 nm). The mobile phase 
consisted of Acetic Acid solution 0.1 M: Acetonitrile (80:20) and was filtered 
through a 0.45 m membrane filter before use. The mobile phase was eluted at a 
flow rate of 0.5 ml/min. The column was a Kromasil
®
 C-18, 5.0 m (150 cm x 4.6 
mm) [22]. 
 
4.2.6. In vitro swelling 
Swelling studies were performed in a membrane dialysis bag that contained 100 mg 
of each systems; the membrane bag was placed in a closed flat bottom tube with 200 
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ml of a buffer solution that was maintained at 37°C up to 24 hours. It was carried out 
in three different solutions with different pH values in order to simulate the gastro-
intestinal tract: stomach (pH=2), small intestine (pH=5.5) and large intestine 
(pH=7.4). At specific time intervals, samples were removed from the swelling 
medium and blotted with a piece of paper for 5 s to absorb excess water on surface 
and were weighted. 
The Swelling ratio (Sw) was calculated using the following equation:   
 100(%)
0
0 


t
tt
w
W
WW
S                                             (1) 
where Sw represents the swelling ratio, Wt andWt0 represent weights of the sample at 
a certain time and  the original dry weight, respectively. 
 
4.2.7. Drug release studies 
Drug release studies were carried out into a diffusion cell like the Franz cell. Three 
different solutions were utilized as seen in the in vitro swelling studies (pH=2, 5.5 
and 7.4). In the receptor compartment 6 ml of the respective solution were placed. In 
the donor compartment 5 mg of MP (or FD) were placed and 300 l of the same 
solution were added; the two compartment were separated by a Millipore
®
 
membrane with pore of 0.45 µm. Drug release studies were carried out under 
magnetic stirring at 37°C up to 24 hours. At appropriate time intervals 200 l of the 
solution from the receptor compartment were withdrawn and the same amount was 
replaced with the appropriate solution to maintain sink condition. The amount of 5-
ASA released was assayed by HPLC as described before.  
The mean release profiles (cumulative drug release up to 90%) were fitting 
according to the power law equation (Eq. (2)) in order to describe the drug release 
mechanism. 
 nt Kt
M
M


                                                           (2) 
Where Mt and M∞ are the absolute amount of drug released at t and infinite time, 
respectively; K is a constant reflecting structural and geometric characteristic of the 
device, and n is the release exponent characterizing the diffusion mechanism. 
According to the criteria for release kinetics from swellable film systems, release 
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exponent values n=0.45, 0.45<n<0.89 and 0.89 indicate, respectively, Fickian (case 
I) diffusion, non-Fickian (anomalous) transport, and diffusion and zero-order (case 
II) transport [23,24]. 
 
4.2.8. Statistical analysis 
Data analysis was carried out with the software package R, version 2.10.1. Results 
are expressed as the mean ± standard deviation (S.D.). Multiple comparisons of 
means (Tukey test) were used to substantiate statistical differences between groups, 
while Student’s t-test was used for comparison between two samples. Significance 
was tested at the 0.05 level of probability (p). 
 
4.3. Results and discussion. 
 
4.3.1 Preparation of N-Succinyl-chitosan 
N-Succinyl-chitosan was successfully synthesized according to the methods reported 
in literature (Scheme 1). 
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Scheme 1. N-Succinyl-chitosan preparation 
 
IR, DSC and X-ray diffraction studies revealed the derivatization of chitosan.  
FTIR spectra of chitosan and SucCH are shown in Figure 1. CH spectrum is 
characterized by a broad absorption around 1660 cm
−1
 (Amide I, C=O stretching 
mode), 1610 cm
−1
 (amide II, N-H deformation mode) and 1650 cm
−1
 (-NH2 bending 
of non-acetylated NH2 groups). Characteristic for its saccharide structure are 
absorption bands at 1161 cm
−1
 (asymmetric stretching vibration of the C-O-C 
bridge), 1101 cm
−1
 and 1058 cm
−1
 (skeletal vibration involving C-O stretching) 
[25,26]. 
 75 
 
SucCH spectrum presents amide I and II band at 1668 and 1585 cm
−1
 respectively 
and the characteristics peaks of sugar structure at 1162, 1072 and 1035 cm
-1
. The 
new bands at 1731 and 1417 cm
-1
, which corresponds to the carboxyl group confirm 
the derivatization of the amino group [20]. 
 
 
Figure 1. FTIR spectra of 5-ASA (A), CH (B), SucCH (C), FD (D) and MP (E). 
 
DSC thermograms of chitosan and SucCH are shown in Figure 2. In general, the 
thermal properties of chitosan and its derivatives are similar to those of cellulose. 
They do not melt but degrade at elevated temperatures [27]. The spectra of chitosan 
shows a broad endothermic peak around 78°C and sharp exothermic peak at 306.3°C 
(Figure 2B). The former endothermic peak may be due to the water that the chitosan 
contains, while the latter may be attributed to the decomposition of chitosan. The 
endothermic peak of SucCH (Figure 2C) around 79°C may be due to the loss of 
water and moisture content in the polymer. The small broad exothermic peak at 
310°C corresponds to its thermal decomposition. The results indicated that the 
structure of chitosan chains has been changed due to the introduction of succinyl 
group and the reduced ability of crystallization [28]. 
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Figure 2. DSC thermograms of 5-ASA (A), CH (B), SucCH (C), FD (D) and MP (E). 
 
X-ray diffraction spectra of chitosan and its derivative (Figure 3) show that chitosan 
exhibits two reflection fall at 2= 11.0° and 2= 19.56°. Samuels et al. [29] 
reported that the reflection fall at 2= 11.0° was assigned to crystal form I and the 
strongest reflection appears at 2= 19.56° which corresponds to crystal forms II. 
However, with the N-Succinyl substitution, there are two less intense broad peaks at 
around 2= 12.02° and 18.86°. This result indicates that crystal forms have been 
destroyed in SucCH macromolecules and suggests that intermolecular hydrogen 
bindings (H-bonds) in SucCH are greatly decreased in comparison with that of 
chitosan. As a result, its solubility is higher than that of chitosan, it can be disperse 
into distilled water and obtain a transparent and stable system [30]. 
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Figure 3. X-ray diffractograms of: 5-ASA (A), CH (B), SucCH (C), FD (D) and MP (E). 
 
4.3.2. Polymers–drug interaction analysis using FTIR Spectroscopy 
According to the characteristic spectra of the polymer and 5-ASA separately, in the 
freeze-dried system and in the microparticles, an attempt was made to detect the 
eventual existence and type of interactions between the polymers and the drug. 
Chitosan and SucCH spectra have been previously discussed. Considering 5-ASA 
(Figure 1A), the characteristic IR band at 1652 cm
−1
 corresponds to the C=O 
stretching of the –COOH group, -NH2 bending is assigned to the peak at 1622 cm
−1
, 
bands at 1456 belong to the –OH bending, while C-N stretching to the peak at 1357 
cm
−1
. The bands in a range of 2000–3000 cm−1 correspond to stretching vibrations of 
the hydrogen bonds in the 5-ASA molecule [31]. Freeze-dried system’s FTIR 
spectrum presents typical bands of 5-ASA and SucCH, confirming the presence of 
both the molecules in the system, however due to the presence of interactions 
between the two molecule some bands are shifted; -COOH stretching bands of 
SucCH is present at 1720 cm
-1
 and bands at 1130, 1085 and 1053 cm
-1
 are the 
characteristics of the sugar structure. 5-ASA bands are the following: 1654 cm
-1
 
(-COOH stretching); 1641 cm
-1
 (-NH2 bending), 1456 (-OH bending) and 1357 cm
-1
 
(C-N stretching). 
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The microparticle spectrum shows typical 5-ASA bands and typical SucCH bands as 
seen for the freeze-dried system.  
 
4.3.3. Evaluation of the polymers-drug interaction and physical state of 5-ASA using 
differential scanning calorimetry (DSC) and X-ray diffraction studies 
Thermogram of 5-ASA is characterized by a sharp endothermic peak at 277°C 
(Figure 2A) and an enthalpy of 24 mW mg
-1
, which corresponds to its melting point. 
In FD and MP (Figure 2D and 2E, respectively) this endothermic peak exists at 
281°C with a broader shape and smaller enthalpy (1.41 and 1.17 mW mg
-1
 
respectively). The shift of drug melting peaks might be a result of a heat-induced 
drug-polymer interaction during DSC measurements [32]. Also the endothermic 
peak of SucCH is present at 67.1 and 67.5°C respectively. The appearance of a new 
peak at around 254 and 252°C denotes an interaction between anionic succinyl 
group of SucCH and cationic amino group of 5-ASA.  
These results were confirmed by X-ray diffractogram studies. 
The diffractogram of 5-ASA alone is shown in Figure 3A and results of several 
peaks of different intensities between 2= 6° and 45°. The diffractograms of the two 
formulations are shown in Figure 3D and 3F, respectively and they present the 
typical XRD peaks of both systems. When the drug was loaded into SucCH polymer 
in the form of microparticles or physical mixture the intensity of each peak 
markedly decreased. That means that both of two molecules are present but there are 
some interaction between them that affect the cristallinity of 5-ASA and decrease 
the intensity of the peaks. 
 
4.3.4. Particle size analysis, zeta potential and 5-ASA content  
The formulation and preparation process resulted in production of negatively 
charged particles with a dvs of 5.1±2.2 m. Zeta potentials of blank SucCH 
microparticles and 5-ASA loaded SucCH microparticles were -44.2±3.9 mV and 
-20.7±4.9 mV, respectively; while SucCH freeze-dried system zeta potential was 
-11.3±3.9 mV. No remarkable difference was found in particle size and distribution 
between blank- and drug-loaded microparticles, indicating that the loading of 
5-ASA in the microparticles substantially did not influence their size. 
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The amount of 5-ASA present in FD and MP were 50% and 49.2%, respectively. 
The results are shown in Table 1. 
 
Table 1. Content and examined parameters of 5-ASA loaded systems 
 
System 5-ASA content  
(%) 
EE (%) Yield 
( %) 
Particle size 
(m) 
Zeta pot. 
(mV) 
      
Microparticles 49.3±2.1 50.1±1.6 55.2±0.5 5.1±2.2 −44.2±3.9 
Freeze-dried  50.0±2.3 93.75±3.2 93.75±2.8 - −11.3±3.91 
 
4.3.5. Morphological analysis. 
By imaging with SEM, an acceptable spherical morphology was observed. The 
surface appeared mostly smooth with some roughness. The absence of ideal 
spherical morphology can be probably attributed to the drying process that causes 
certain invaginations in the particles. The particles tend to agglomerate, probably 
due to the specific localization of the polymers and existence of attractive 
electrostatic forces.  
 
                       
 
Figure 4. SEM pictures of blank SucCH microparticles (A) MP (B) and FD (C). 
A B 
C 
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Figure 4A depicts the surface topography of unloaded N-Succinyl-chitosan 
microparticles while Figure 4B shows 5-ASA loaded SucCH microparticles.  
In Figure 4C freeze-dried system is presented, it shows a filamentous and rough 
powder proper to a polymeric system like SucCH. 
 
4.3.6. In vitro swelling 
The swelling studies of FD and MP were performed at different pH values and are 
shown in Figure 5. The two systems showed the highest swelling at pH=7.4, while 
the swelling in acidic pH was considerably smaller as evidenced from the shown 
data. In FD (Figure 5a) there were no differences between pH=2.0 and 5.5 swelling 
with an index never reaching the 10%. On the contrary at pH=7.4 the FD sample 
constantly increased up to 25% at 24 hours showing a tendency to increase. 
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Figure 5. In vitro swelling studies of FD (a) and MP (b) in different dissolution mediums. Error 
bars represent standard deviation, n =3. 
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This property is due to the presence of carboxyl groups, which in acidic conditions 
are undissociate. At alkaline pH the carboxyl groups are negatively charged and 
their affinity for the water increases making them to swell and solubilize at this pH 
value.  
The swelling ratio of the microparticles was different at the three pH values and it 
increased as the pH increased (Figure 5b). As expected the highest ratio was at 
pH=7.4 as discussed before and it followed the same trend of FD, reaching 21% of 
swelling after 24 hours. The swelling ratio at pH=2 never surpassed the 8%. At 
pH=5.5 it was a little bit higher then that one of the freeze-dried system probably 
due to the larger specific surface area of the microparticles that let the water enter in 
a easier way. From the shown data it can be concluded that the swelling index 
depended on the presence of carboxyl groups of SucCH and their different affinity 
for the alkaline or acid pH values.  
 
4.3.7. Drug release studies 
As previously mentioned, 5-ASA formulations have to pass preferentially 
unmodified through the stomach and small intestine to reach the large intestine, 
where the drug should be released to exerts its action. For this reason drug release 
studies were performed in three different solutions: pH=2.0, 5.5 and pH=7.4. Drug 
release studies were carried out up to 24 hours because the colonic transit time goes 
from 20 to 30 hours [33]. 
In Figure 6a, 5-ASA release profiles from FD are shown; drug release was faster at 
pH=7.4 than at pH=2.0 and 5.5. Indeed after 6 hours, 5-ASA release at pH=2.0 and 
5.5 did not overpass 10%, while 30% of drug was released at pH=7.4, where after 24 
hours more than 75% of the loaded 5-ASA was released. 
Drug release studies from microparticles are shown in Figure 6b. As seen for the 
freeze-dried system the released drug percentage increased with the pH medium. In 
condition simulating gastric content (pH=2.0), 5-ASA release during the first 2 
hours (stomach transit time) was less than 10%, while at pH=7.4 the drug release 
rate was 30% showing a different affinity of the polymer for the two solutions. After 
4 hours (small intestine transit time) the percentage of drug released at pH=5.5 and 
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7.4 was respectively 25% and 51%, that is more than double of drug released at 
pH=7.4 in comparison to pH=5.5. 
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Figure 6. In vitro 5-ASA release studies from FD (a) and MP (b) in different dissolution 
mediums. Error bars represent standard deviation, n =3. 
 
At increasing pH the affinity of the SucCH to the buffer solution increases. It is due 
to the chitosan modification: the number of succinyl groups (and consequently 
-COOH moiety) present in SucCH is higher than the amino groups (-NH2). The 
carboxylic group can be deprotonated at alkaline pH but not at acidic pH and it had a 
higher affinity for pH=7.4 solution. However, under acidic conditions, the carboxyl 
moieties are either partially ionized (at pH=5.5) or predominantly unionized (at 
pH=2.2). The uncharged carboxylic acid groups are considerably less hydrophilic 
compared to their charged conjugate-bases, i.e. the carboxylate anions. Therefore the 
drug was probably released due to combined mechanisms of swelling, jelling, drug 
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diffusion in the gel layer and solubilization of the systems. The polymer firstly let 
the solvent enter into the matrix, swelled maintaining its three dimensional structure; 
then at pH=7.4 it slowly solubilized releasing the loaded drug. 
Moreover, drug release from FD is slower than that one from microparticle due to 
the different specific surface area. The larger specific surface area speeds up the 
microparticle swelling and helps the entrance of the solvent in the polymer matrix 
causing a faster drug release. 
To investigate more precisely the mechanism of drug release results were analysed 
according to Ritger–Peppas equation (Eq. (2)). The fitting results are presented in 
Table 2. As can be seen from the obtained correlations coefficient values (R≥0.975), 
the release data fit well to the empirical Eq. (2). In all cases, n values were between 
0.45 and 0.89 (Table 2) (from 0.44 to 0.80). Therefore drug release is characteristic 
for an anomalous transport, which can be regarded as an indicator of for the 
superposition of both Fickian diffusion (diffusion controlled drug release) and case-
II transport (swelling controlled drug release).  
 
Table 2. Comparison of estimate parameters from curve fitting of drug dissolution in pH media 
to power law expression. 
 
Microparticles K (h
-1
) n
 
R
2 
pH=2 8.76±0.99 0.56±0.04 0.988 
pH=5.5 14.63±2.02 0.51±0.05 0.977 
pH=7.4 24.53±3.02 0.44±0.05 0.975 
 
Freeze-dried system K (h
-1
) n
 
R
2
 
pH=2 2.89±0.59 0.66±0.07 0.980 
pH=5.5 3.37±0.62 0.73±0.06 0.987 
pH=7.4 5.99±0.47 0.80±0.03 0.998 
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4.4. Conclusion 
In conclusion the 5-ASA loaded SucCH microparticles and freeze-dried system were 
prepared as new formulations for the controlled and delivered release of 5-
aminosalicylic acid. SucCH was chosen as carrier due to its favorable 
pharmaceutical properties. DSC, FTIR, X-ray diffraction studies were useful to 
show the derivatization of chitosan and to confirm the effective loading of the drug 
into the polymer. Results from physical characterization (morphology, particle size, 
zeta potential) and drug loading of the prepared microparticles and freeze-dried 
system are in favour of their localization and prolonged presence time in colon. In 
vitro swelling behaviour and release studies showed the usefulness of both 
formulations for the 5-ASA delivery, showing that both systems released the drug 
preferentially at colonic pH (pH=7.4). Therefore, these systems might be good 
candidates for further research aimed to evaluate their effects on the inflammatory 
response in an experimental chronic model of induced colitis in Wistar rats. 
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Abstract 
5-Aminosalicylic acid (5-ASA) loaded N-Succinyl-chitosan (SucCH) microparticle 
and freeze-dried system were prepared as potential delivery systems to the colon. 
Physicochemical characterization and in vitro release and swelling studies were 
previously assessed and showed that the two formulations appeared to be good 
candidates to deliver the drug to the colon. In this work the effectiveness of these 
two systems in the treatment of inflammatory bowel disease was evaluated. In vitro 
mucoadhesive studies showed excellent mucoadhesive properties of both the 
systems to the inflamed colonic mucosa. Experimental colitis was induced by rectal 
instillation of 2,4,6-trinitrobenzene sulfonic acid (TNBS) into male Wistar rats. 
Colon/body weight ratio, clinical activity score system, mieloperoxydase activity 
and histological evaluation were determined as inflammatory indices. The two 
formulations were compared with drug suspension and SucCH suspension. The 
results showed that the loading of 5-ASA into SucCH polymer markedly improved 
efficacy in the healing of induced colitis in rats. 
 
5.1. Introduction 
 
Colon-targeting drug delivery systems have applications in several therapeutic areas 
[1-4]. These include topical treatment of colon diseases and systemic delivery of 
therapeutic peptide and proteins (that are normally degraded in the upper 
gastrointestinal tract). Additionally, colonic delivery of drugs may be extremely 
useful when a delay in drug absorption is required from a therapeutic point of view, 
e.g. in case of diurnal asthma, angina pectoris and arthritis. One of the important 
therapeutic applications of colon targeting delivery systems is the treatment of large 
intestine disorders, such as irritable bowel syndrome, ulcerative colitis, Crohn’s 
disease, colon cancer and amebiasis. Chron’s disease and ulcerative colitis are two 
related but distinct chronic inflammatory disorders of the gastrointestinal tract, 
commonly denoted as inflammatory bowel disease (IBD). The exact causes remain 
uncertain but thus far, IBD is thought to be the result of an appropriate and ongoing 
activation of the mucosal immune system driven by the normal luminal flora in a 
genetically susceptible host [5,6]. This paradigm has emerged, to a great extent, 
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from studies in animal models of mucosal inflammation [7]. Several animal models 
of intestinal inflammation have been developed and can be divided into four 
categories: spontaneous colitis, inducible colitis, genetically engineered and 
adoptive transfer models [8]. Among them trinitrobenzene sulfonic acid (TNBS)-
induced colitis have been widely used [9-11]. TNBS is thought to be hapten, 
because it is presumed to bind endogenous proteins in the colonic mucosa and to 
induce a local immunologic response through macrophage and T cell activation [12]. 
5-Aminosalycilic acid (5-ASA) is an anti-inflammatory drug largely used to treat 
inflammatory bowel disease [13]. 5-ASA oral administration is limited due to its 
rapid absorption in the upper part of the gastrointestinal (GI) tract [14] and there is a 
little localization of the drug in the site of action (colon). The efficacy of treatment 
depends on providing the therapeutical concentration of the drug at the site of 
inflammation. For this reason three methods have been widely used for 5-ASA 
targeting: a prodrug concept, enteric coating and/or prolonged release of the drug 
through semipermeable membrane [15]. Controlled release preparation are 
specifically designed to minimize systemic absorption and to achieve optimum 
delivery of the biologically active 5-ASA to the distal small intestine and the colon. 
Thus relatively high concentrations of free 5-ASA can be achieved in the intestinal 
lumen without producing systemic exposure and subsequent toxicity. 
Chitosan and some of its various synthetic derivatives have recently attracted great 
interest for colon delivery. Chitosan (CH) is a polycationic polysaccharide derived 
from naturally occurring chitin by alkaline deacetylation. Chemically, it is formed 
by β-(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine 
(acetylated unit) [16]. It has favorable biological properties but it rapidly dissolves 
in the gastric cavity. To overcome its solubility at acidic pH, enteric coated chitosan 
capsules and microparticles were prepared [17,18], pH-sensitive based chitosan 
hydrogels systems [19] and chitosan polyelectrolyte complexes [20] as well as 
chitosan salts [21] and derivative [22] have been developed for drug the targeting to 
the colon.  
N-Succinyl-chitosan (SucCH) is a derivative of chitosan that could be obtained by 
introducing succinyl groups into N-terminals of chitosan glucosamine units [23-25]. 
It is reported to have favorable drug carrier properties such as biocompatibility and 
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low toxicity [26]. Due to the presence of carboxyl groups it exhibits pH dependent 
swelling behavior and it is insoluble at acidic pH value. It possesses mucoadhesive 
properties because of its hydrophilicity leading to hydrogen bond formation, 
swelling characteristics, and sufficient chain flexibility. Moreover, it is a negatively 
charged polymer and it adheres more easily to the inflamed tissues due to the 
presence in the ulcerative tissues of a high number of positively charged proteins 
[27]. All these advantages endowed this material with huge potential for the 
application as site-specific or controlled-release drug delivery systems. 
Recently we have developed 5-ASA loaded N-Succinyl-chitosan microparticles and 
freeze-dried systems as a targeted colon delivery system against IBD [28]. 
Physicochemical characterizations, including FTIR, DSC, X-ray diffraction studies, 
zeta potential, drug loading and microparticles size were performed. In vitro 
swelling and release studies were also carried out and the obtained results from in 
vitro characterization showed that the two systems could be suitable candidate for 
colon delivery of 5-ASA. 
In the present studies the therapeutic efficiency of these drug carrier system was 
evaluated using experimental TNBS colitis rat model. Initially ex vivo 
mucoadhesion studies were performed. To demonstrate the efficiency of the 
systems, rats were also treated with 5-ASA suspension, as well as SucCH 
suspension. The efficacy of all formulations was determined by the colon/body 
weight ratio, clinical activity score system, myeloperoxidase activity and 
histological evaluation. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Chitosan of medium molecular weight, succinic anhydride and 5-ASA were 
obtained from Sigma-Aldrich, (Milan, Italy). 2,4,6-trinitrobenzenesulfonic acid 
(TNBS), hexadecyltrimethylammonium bromide (HTAB), 3,3
’
,5,5
’
-
tetramethylbenzidine (TMB), hydrogen peroxide 30% and peroxidase from 
horseradish were purchased form Sigma-Aldrich (Spain). Spectra-por
®
 dialysis 
membrane (MWCO 12000-14000 Dalton, regenerated cellulose) was purchased 
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from Spectrum Lab (Inc, USA). All the products and solvents were of analytical 
grade. 
 
5.2.2. Preparation of N-Succinyl-chitosan and 5-ASA loaded SucCH systems 
Chitosan medium molecular weight was succinylated according to the method 
reported by Hirano et al. [25] with some modifications. 
5-ASA/SucCH system (FD) was prepared at 1:1 molar ratio using freeze-drying 
technique (Freeze-dryer Criotecnica, MM Cota, Rome, Italy). 
5-ASA loaded SucCH microparticles (MP) were obtained using spray-drying 
method, (Minispray Dryer, Büchi B-290, Switzerland) at 1:1.25 ratio (5-
ASA:SucCH). The conditions of the spray-drying process were: nozzle diameter 0.7 
mm, aspiration: 80%, inlet temperature: 150°C, outlet temperature: 100°C. Blank 
SucCH microparticles were prepared using the same conditions as for the drug-
loaded particles. 
 
5.2.3. Physiscochemical Characterization of MP and FD 
FTIR, DSC and X-ray diffractogram spectra were performed for 5-ASA, chitosan, 
SucCH, FD and MP. 
FTIR measurements were taken at an ambient temperature using Bruker Equinox 55 
(Germany). About 2 mg of the samples were ground thoroughly with KBr and 
pellets were formed under a hydraulic pressuse of 600 kg/cm
2
.  
DSC studies were performed using a DSC Mettler Toledo model 821e 
(Switzerland). The samples (2-5 mg) were scanned in sealed aluminium pans under 
nitrogen atmosphere. DSC thermograms were scanned in the first heating run at a 
constant rate of 10°C/min and a temperature range of 0-325°C.  
X-ray diffractograms pattern were recorded with Bragg–Brentano geometry on a 
Bruker AXS D5005 (DRXP, Germany) in the 2θ range from 5° to 45° in steps of 
0.02° at 6 s per step. 
Shape and surface morphology of the empty and 5-ASA loaded SucCH 
microparticles were examined using a scanning electron microscope (SEM, S-4100 
Hitachi, Madrid, Spain).  
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Measurement of the particle size and diameter of the microparticles was carried out 
with Analysette 22 Micro tec plus (Fritsch, Germany) after suspending the particles 
in distilled water and sonicating the suspension for 10 min in ultrasonic bath. The 
average particle size was expressed as the volume surface diameter, dvs (m).  
The zeta potential of the systems was recorded using Malvern Zeta Sizer apparatus 
(model Zen 3600, Malvern, UK). Each sample was analysed at least six times to 
obtain an average value and a standard deviation. Samples of blank SucCH 
microparticles were also submitted to this study. 
5-ASA content in the two systems was assayed by HPLC as it was described 
previously [28]. 
 
5.2.4. In vitro swelling and drug release studies 
Swelling and drug release studies were carried out in three different solutions in 
order to simulate the gastro-intestinal tract pH values: stomach (pH=2), small 
intestine (pH=5.5) and large intestine (pH=7.4). The in vitro release studies were 
performed under sink conditions and the amount of 5-ASA released was assayed by 
HPLC as described elsewhere [28].  
 
5.2.5. Preparation of GI tissues and mucoadhesive test 
Wistar rats (13-week old) had been fasted for 24 h. The fasted conditions were set to 
minimize the contents in the GI tract, which disturbed the washing process for the 
following use. The tissues (i.e. duodenum and colon) were excised from rats that 
were sacrificed. Each section of tissues was then slowly washed with a large amount 
of normal saline solution. Then, the tissues (duodenum, healthy colon and inflamed 
colon) were immediately used for this study. Inflamed colon was obtained by 
inducing the model of chronic inflammation in the rat colon as described below. 
Samples were placed in a closed flat bottom tube with 1 ml of buffer and in a 
thermostated bath at 37.0° C. pH=5.5 solution was used for the mucoadhesion in the 
duodenum and pH=7.4 was used for the mucoadhesion in the colon. At scheduled 
time intervals the mucoadhesion studies were done using different part of rat 
intestine tissue. At 120 min the mucoadhesion using duodenum tissue was studied 
and at 150 min using colon. The mucoadhesion study was done using a universal 
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tensile tester (Lloyd Instruments, LR 50K model, UK). The stainless steel plate (L-
shape) was fitted by one of its side into the upper and lower jaws of the instrument 
so as the other surfaces of the plates were facing each other. The rat tissue was stuck 
at the upper plate surface with the glue, while the sample was placed on the lower 
plate. Then the upper jaw with tissue stuck on the plate was lowered slowly so that it 
just touched the sample surface. No external force was applied. The sample was kept 
in contact with the tissue for 5 minutes and then the upper jaw was slowly moved 
upward at the speed of 3 mm/min. All the experiments were done in triplicate. The 
maximum detachment force (Fmax), i.e. the force required for separating the sample 
from the tissue surface was obtained directly from NimaST518.vi software (Nima 
Technology Ltd., Coventry, England) and the total amount of forces involved in the 
probe withdrawal from the tissue (work of adhesion, Wad) was then calculated from 
the area under the force versus distance curve. These parameters were used to 
compare the different formulations tested. 
 
5.2.6. Induction of colonic inflammation 
These studies were carried out on Wistar male rats aged 8–12 weeks and weighing 
230–250 g. Animals were housed in an air-conditioned room at 22±3 °C, 55±5% 
humidity, 12 h light/dark cycles and allowed free access to water and laboratory 
chow for the duration of the studies. To induce the model of chronic inflammation in 
the rat colon, the method described by Morris et al. [29] was followed with some 
slight modifications. Briefly, rats were arbitrarily separated into treatment groups, 
fasted for 48 h with free access to water and then anaesthetized with isoflurane. A 
graduated rubber canula was inserted rectally into the colon such that the tip was 8 
cm proximal to the anus. 0.5 ml of a solution of TNBS (81 mg/kg body weight) 
dissolved in 50% ethanol v/v was instilled into the lumen of the colon through the 
rubber probe (total volume 0.5 ml solution). A control group received 0.5 ml 50% 
ethanol v/v administered as before. The induction and development of inflammation 
were monitored every day during 13 days. Rats (in groups of 5) were sacrificed with 
an overdose of anesthesia the days 3,5,7,9 and 13 after TNBS administration. The 
development of inflammation was evaluated in respect to colon /body weight ratio, 
clinical activity score, myeloperoxidase activity and histological changes. 
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5.2.7. Treatment studies design 
Rats were divided into 4 groups: to group one was administered SucCH suspension, 
group two received 5-ASA suspension, group three received 5-ASA loaded freeze-
dried system (FD) and finally to group four microparticles (MP) was administered. 
A dose of 120 mg/kg/day of 5-ASA calculated from the dose from humans (70 kg) 
[30] were administered by oral gavage once a day for three days in the period of the 
most intensive inflammation (days 3,4 and 5 after TNBS administration).  
 
5.2.8. Assesment of colonic injury and inflammation 
The rats were killed with an overdose of anesthesia then the abdomen was opened 
and the distal colon was removed. The samples of inflamed tissue were excised to 
measure the ratios of distal colon weight to body weight (C/B ratio), the criteria for 
scoring the gross morphologic damage (clinical activity score system), the 
myeloperoxidase activities and histological evaluation. 
 
5.2.8.1. Determination of colon/body weight ratio 
The rats were killed with an overdose of anesthesia, then the abdomen was opened 
and the distal colon was rapidly excised and opened longitudinally along the 
mesenteric edge. The colon was washed with 0.9% (w/v) saline and placed with the 
mucosal surface upward over a glass plate chilled with ice and then weighted. The 
ratio of the 8 cm segment distal colon weight was calculated as an index of colonic 
tissue edema. 
 
5.2.8.2. Clinical activity score system  
Colitis activity was quantified with a clinical score assessing weight loss, stool 
consistency and rectal bleeding [31,32]. No weight loss was counted as 0 point, 1–
5% as 1 point, 5–10% as 2 points, 10–20% as 3 points and >20% as 4 points. For 
stool consistency, 0 point was given for well-formed pellets, 2 points for pasty and 
semiformed stools that did not stick to the anus and 4 points were given for liquid 
stools that stick to the anus. Bleeding was scored as 0 point for no blood, 2 points 
for positive finding and 4 points for gross bleeding. The sum of these scores was 
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forming the clinical score ranging from 0 (healthy) to 12 (maximal activity of 
colitis). 
 
5.2.8.3. Myeloperoxidase activity  
The measurement of the myeloperoxidase activity was performed to quantify the 
severity of the colitis. It is a peroxidase enzyme reliable index of inflammation 
caused by infiltration of activated neutrophils into the inflamed tissue. Activity was 
analyzed according to De Young et al. [33,34]. Briefly, colon specimen was added 
to 750 l of HTAB buffer (0.5% in 80 mM phosphate buffer pH=5.4) on ice and 
homogenized. The homogenate was centrifuged (Heraeus Fresco 17 Centrifuge, 
Thermo Electron Corporation, Spain) at -4°C and at 10000 rpm for 15 min 
(Eppendorf AG 22331, Germany). Myeloperoxidase activity in the supernatant was 
measured spectrophotometrically. Supernatant (25 l) was incubated with 75 l of 
phosphate buffers pH=7.4 and 10 l of phosphate buffer pH=5.4 and 0.026% 
hydrogen peroxide (10 l) at 37°C for 5 minutes. Then 20 l of TMB 18 mM 
(dissolved in 8% DMF) were added to the previous mixture and incubated for 10 
minutes. Finally the reaction was stopped by the adding of 15 l of sodium acetate 
1.5 M (pH=3.0) and the absorbance was measured at 620 nm. 
 
5.2.8.4. Histological evaluation 
Two tissue samples (3 cm samples distal and proximal) were excised from each 
colon and maintained in formaldehyde (10% v/v) for microscopic studies. These 
tissue samples were processed routinely and embedded in paraffin. Longitudinal 
sections (5 m) were stained with haemotoxylin and eosin. Microscopic assessment 
by light microscope was performed blind on coded slices. 
 
5.2.9. Statistical analysis 
Data analysis was carried out with the software package R, version 2.10.1. Results 
are expressed as the mean ± standard deviation (S.D.). Multiple comparisons of 
means (Tukey test) were used to substantiate statistical differences between groups, 
while Student’s t-test was used for comparison between two samples. Significance 
was tested at the 0.05 level of probability (p). 
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5.3. Results and discussion. 
5-ASA loaded microparticles and freeze-dried system were prepared according to 
the previously stated formulations and subjected to further characterization [28]. 
 
5.3.1. Physiscochemical characterization of the systems 
N-Succinyl-chitosan was successfully synthesized according to the methods reported 
in literature. FTIR, DSC and X-ray diffractograms spectra revealed the 
derivatization of chitosan and confirmed the loading of the drug into 5-ASA/SucCH 
systems, denoting that some interaction between the polymer and the drug are 
present. 
Negatively charged particles with a dvs of 5.1±2.2 m were prepared. No remarkable 
differences was found in particle size and distribution between blank- and drug-
loaded microparticles, indicating that 5-ASA loading in the microparticles 
substantially did not influence their size. 
Zeta potentials of blank SucCH microparticles and 5-ASA loaded SucCH 
microparticles and freeze-dried system were -44.2±3.94 mV, -20.7±4.89 mV and 
-11.3±3.91 mV, respectively. 
By imaging with SEM, an acceptable spherical morphology was observed. The 
surface appeared mostly smooth with some roughness. 
The amount of 5-ASA present in 5-ASA/SucCH freeze-dried system and 
microparticles were 50% and 49.2% respectively.  
 
5.3.2. In vitro swelling and drug release studies 
As shown previously, the two systems showed the highest swelling at pH=7.4, while 
the swelling at acidic pH was considerably smaller as a consequence of the physico-
chemical properties of the SucCH [28]. 
The in vitro release studies were in accordance with the swelling studies. They 
showed that drug release rate from freeze-dried system and microparticles increased 
with the increase of pH. The maximum drug release percentage was reached at 
pH=7.4, as expected. Drug release from FD was slower than that from 
microparticles due to the different specific surface area. The higher specific surface 
area speeded up the microparticles swelling and helped the solvent penetration into 
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the polymer matrix causing a faster drug release. As results show, FD and MP could 
be useful for the preparation of new 5-ASA formulation. 
 
5.3.3. Mucoadhesion studies 
Mucoadhesive polymers are used to immobilize a drug delivery device on a specific 
site for targeted release and optimal drug delivery due to intimacy and duration of 
contact. It has been proposed that the interaction between the mucus and 
mucoadhesive polymers is a result of physical entanglement and secondary bonding, 
mainly H-bonding and van der Waals attraction. These forces are related to the 
chemical structure of the polymers and chemical groups of mucoadhesive polymers 
that contribute to mucoadhesion include hydroxyl, carboxyl, amine, and amide 
groups in the structure. Polymer characteristics that are necessary for mucoadhesion 
are: strong H-bonding groups, strong anionic charges, high molecular weight, 
sufficient chain flexibility, and surface energy properties favoring spreading onto 
mucus [35]. 
N-Succinyl-chitosan presents all of these properties, and therefore it could be a good 
mucoadhesive polymer. The in vitro mucoadhesive properties of 5-ASA loaded 
SucCH systems were studied using rat’s stomach, duodenum, healthy and inflamed 
colon (induced by TNBS administration as seen before). The maximum detachment 
force (Fmax), i.e. the force required for separating the system from the tissue surface 
and the total amount of forces involved in the probe withdrawal from the tissue 
(work of adhesion, Wad) of both formulations on different GI mucosa are shown in 
Figure 1.  
Large intestinal mucosa showed a stronger mucoadhesion than small intestinal 
mucosa. This is probably due to the fact that there is a difference in the functional 
histology of epithelia of small and large intestinal mucosa. The absence of villi in 
large intestine, at the tissue level, may be a benefit for the mucoadhesion as the 
adhesion between the sample and mucosa or epithelia can occur easily. Moreover, at 
cellular level, the ratio of goblet cells in large intestine is higher than in other parts 
of GI tract resulting in higher mucin level, and thus in higher mucoadhesion onto the 
large intestinal mucosa [35]. 
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Mucoadhesion of the two systems to the inflamed colonic mucosa resulted higher 
than healthy mucosa; it has been previously suggested by other authors that a 
possible cause for the affinity of negatively charged systems to the ulcerated mucosa 
of the rat was the high concentration of positively charged proteins in the inflamed 
regions [27].  
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Fig. 1. Ex vivo mucoadhesive performance of 5-ASA systems. Effect of GI mucosa on (a) 
maximum detachment force (Fmax) and (b) work of adhesion (Wad). Error bars represent 
standard deviation, n =3. 
 
No significant mucoadhesion differences between microparticles and freeze-dried 
systems were observed. 
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5.3.4. Induction of colonic inflammation. 
TNBS was chosen as a model of inflammatory bowel disease; IBD can be induced 
by the administration of an enema containing the contact sensitizing allergen 
trinitrobenzene sulfonic acid (TNBS) in ethanol 50%. The main advantages of this 
model were: simplicity, reproducibility and time and dose related development of 
inflammation [36,37]. 
First of all, to select an optimal schedule to induce the inflammation by TNBS, we 
examined the development of the inflammation process at different days after 
intracolonic administration of TNBS in comparison to the control group that 
received ethanol 50% (v/v). 
The development of the inflammation was monitored daily; rats suffered from 
diarrhea and weight-lost and during the first days of TNBS administration, rats 
suffered from rectal bleeding. Figures 2A and B show respectively opened colon of 
control rats that received ethanol 50% (v/v) and of rats after induction of colitis with 
TNBS, killed on day 9. The group of animals sacrificed 9
th
 day after colonic 
administration of TNBS showed necrotic changes and presented thick and rigid 
bowel. 
 
 
Figure 2. Photographs of the colon of rat after the induction of colitis with TNBS sacrificed on 
day 9: A control (ethanol receiving group ), B (untreated TNBS group), C (SucCH treated group 
1) D (5-ASA treated group 2) E (freeze-dried system treated group 3) and F (microparticles 
treated group 4) 
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Figures 3, 4 and 5 show respectively colon/body (C/B) weight ratio, clinical activity 
score system, and myeloperoxidase (MPO) activity in TNBS induced colitis on days 
3, 5, 7, 9 and 13. All of the three experiments had a maximum at day 9 after the 
administration of TNBS, and recovered on the day 13. 
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Figure 3. Index of colonic tissue edema (colon/body weight ratio) of animals with TNBS induced 
colitis . Each bar is an average value±S.D. of five animals. 
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Figure 4. Clinical activity score system of animals with TNBS induced colitis. Each bar is an 
average value±S.D. of five animals 
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Figure 5. Myeloperoxidase activity of animals with TNBS induced colitis. Each bar is an average 
value±S.D. of five animals 
 
5.3.5. Treatment studies design 
Afterward, the effectiveness of 5-ASA for the treatment of the inflammation was 
evaluated by administrating 5-ASA formulations daily on days 3, 4 and 5. Rats were 
killed on day 9 because it was the day of maximal inflammation, as seen before. C/B 
ratio, clinical activity score and myeloperoxidase activity were compared with 
induced TNBS colitis untreated rats.  
In Figure 2 (C,D,E and F) opened colons of groups 1, 2, 3 and 4 are presented, 
respectively, and compared to the untreated TNBS induced colitis rat on day 9 and 
control rats that received just ethanol 50% (v/v). Colons from groups 1 (Fig. 2C) and 
2 (Fig. 2D) are very similar to the untreated TNBS ones with the presence of 
necrotic zone and thick and rigid bowel. Colons from groups 3 (Fig. 2E) and 4 (Fig. 
2F) present just a little necrotic tissue and it mostly appear healthy and more similar 
to the control group that received ethanol 50% (v/v). 
After FD and MP administration, rats from group 3 and 4 started to gain weight and 
have normal stool without the presence of bleeding; on the contrary after 5-ASA or 
SucCH administration rats from group 1 and 2 continued to lose weight and had 
diarrhea during all the experiment long. 
The effects of 5-ASA, SucCH and the two 5-ASA formulations on the C/B ratio and 
clinical activity score and myeloperoxidase activity after oral administration are 
shown in Figures 6, 7 and 8, respectively. The colon body weight ratio markedly 
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decreased in rats of group 3 and 4 compared to the control that received only 
intracolonic TNBS (untreated rats). On the other hand no marked effect was 
observed on the C/B ratio of the rats of group 1 and 2 (Fig. 6). It confirms that 5-
ASA alone when taken orally is almost completely absorbed before it reaches the 
site of action, and that it is necessary to load the drug into a new formulation that 
prevents its absorption and carry the drug to the large intestine. SucCH did not have 
any therapeutic effect for IBD. 
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Figure 6. Colon/body weight ratio of animals with TNBS induced colitis after treatment with 
SucCH suspension (SucCH) group 1, 5-ASA suspension (5ASA) group 2, 5-ASA/SucCHT freeze-
dried system (FD) group 3, 5-ASA/SucCH microparticles (M) group 4 and compared with 
induced TNBS colitis untreated rats (TNBS) and healthy (ethanol receiving rats, Control). Each 
bar is an average value±S.D. of five animals. 
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Figure 7. Clinical activity score of animals with TNBS induced colitis after treatment with 
SucCH suspension (SucCH) group 1, 5-ASA suspension (5ASA) group 2, 5-ASA/SucCH freeze-
dried system (FD) group 3, 5-ASA/SucCH microparticles (M) group 4 and compared with 
induced TNBS colitis untreated rats (TNBS) and healthy (ethanol receiving rats, Control). Each 
bar is an average value±S.D. of five animals. 
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Figure 8. Myeloperoxidase activity of TNBS induced colitis at rats after treatment of SucCH 
suspension (SucCH) group 1, 5-ASA suspension (5ASA) group 2, 5-ASA/SucCH freeze-dried 
system (FD) group 3, 5-ASA/SucCH microparticles (M) group 4 and compared with induced 
TNBS colitis untreated rats (TNBS) and healthy (ethanol receiving rats, Control). Each bar is an 
average value±S.D. of five animals. 
 
Similar results were also observed in the experiments of clinical activity score 
systems and MPO activity (Fig. 7 and 8, respectively). Myeloperoxidase activity 
markedly decreased after oral administration of FD and MP in the animal groups 3 
and 4, showing and confirming that the inflammation decreased after the oral 
administration of the two formulations. 
 
5.3.6. Histological evaluation. 
Histological examination was made for the 50% ethanol receiving rats (healthy 
control), untreated TNBS induced colitis rats and treated group 1, 2, 3, and 4 rats. 
All the samples were taken from rats sacrificed on the 9
th
 day after administration of 
TNBS. 
The control group shows normal colon structure: healthy mucosa with both 
enterocytes and goblet cells and between them connective tissue (lamina propria, 
Figure 10A), muscularis mucosae and normal submucosa and muscularis externa. 
Untreated animals showed necrosis, loss of the necrotic mucosa and substitution 
with granulation tissue. A strong inflammatory process was present in the lamina 
propria, submucosa and muscularis externa. As can be seen in figure 10B process of 
ulceration with fibrinoid necrosis of the mucosal surface and granulation tissue 
below the necrotic tissue were observed. 
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Animals treated with SucCH suspension showed necrosis, loss of the mucosa, 
intense transmural inflammation and granulation tissue appearance. Histologiacal 
findings indicated also the presence of ulceration with fibrinoid material on the 
surface of the mucosa and granulation tissue that involves the whole submucosa. 
(Figure 10C). Moreover the muscularis propria presented cronic inflammation and 
fibrosis.  
Animals treated with 5-ASA suspension presented superficial erosion, thinning of 
the mucosa accompanied by thickening of the muscularis mucosae, and a cronic 
inflammatory process that affects the mucosa and submucosa with early 
development of lymphoid follicles. A few parts with normal mucosa structure but 
presence of strong follicular hyperplasia in the muscularis externa and parts with 
necrosis, loss of mucosa and substitution with granulation tissue and inflammation 
process were also observed (Figure 10D). 
Animals treated with FD showed substantially normal mucosal structure with slight 
presence of chronic inflammation in the muscularis propria (Figure 10E) 
Animals treated with MP showed normal mucosa structure (Figure 10F). 
Histological findings indicated that untreated TNBS group showed presence of 
strong inflammation accompanied with necrosis and loss of the mucosa. Similar 
results were also obtained with SucCH suspension receiving group and 5-ASA 
suspension receiving group. Indeed histological findings FD and MP showed 
decreasing of inflammation followed by intensive regeneration and normal mucosal 
structure. 
Histological evaluation provides additional information in addition to these obtained 
by the clinical activity score, colon/body weight ratio, and myeloperoxydase 
activity, thus confirming the usefulness of the two 5-ASA/SucCH systems in the 
treatment of inflammatory bowel disease. 
                       
A Zoom: 10x 
Zoom: 20x 
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Figure 10. Histology of a representative colon specimen of a rat after the induction of colitis with 
TNBS sacrificed on day 9: A control (ethanol receiving group), B (untreated TNBS group), C 
(SucCH treated group 1), D (5-ASA treated group 2), E (freeze-dried system treated group 3) and 
F (microparticles treated group 4). 
 
5.4. Conclusion 
Two new systems for the controlled and delivered release of 5-aminosalicylic acid 
were prepared and their efficacy in the treatment of IBD was evaluated with TNBS 
colitis rat model. In our previous work, 5-ASA loaded microparticles and 
freeze-dried system were subjected to physicochemical characterization and in vitro 
swelling and release studies. Physical properties of the evaluated systems were in 
favor of drug accumulation in the site of action. In this work, mucoadhesive studies 
showed that the mucoadhesive properties of the two formulations extended the 
residence of the systems in the targeted inflamed area. The TNBS model confirmed 
Zoom: 4x 
B C 
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D Zoom: 10x Zoom: 4x E 
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that both formulations could serve as new drug delivery systems for 5-ASA. 
Colon/body weight ratio, clinical activity score systems, myeloperoxidase activity, 
and histology evaluation showed that the animals treated with the two formulations 
had an improvement in the pathology.  
5-ASA loaded SucCH MP and FD compared with 5-ASA and SucCH suspension 
markedly improved efficacy of 5-ASA in the healing of induced colitis in rats. 
In conclusion, we demonstrated that 5-ASA can be specifically delivered to the site 
of action and that the described systems may be useful for the treatment of 
inflammatory bowel disease. 
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Abstract 
The aim of the present study was to develop a colon targeted delivery system for 
metronidazole using polymeric prodrug formulation. Two chitosan amide conjugates 
of metronidazole were prepared by using two different spacers to covalently link the 
drug to the amino group of the chitosan glucosamine units. Glutaric and succinic 
hemiesters of metronidazole were thus prepared and then coupled to chitosan to 
obtain metronidazole-glutaryl- and metronidazole-succinyl-chitosan conjugates. 
Polymeric prodrugs were characterized by solid state NMR method, namely carbon 
13 cross polarization magic angle spinning (
13
C NMR CPMAS). Prodrug stability 
study was carried out in acid (pH=1.2) and in alkaline (pH=7.4) buffers in a 
thermostatic bath at 37°C. Drug release from the two prodrugs was studied by 
incubating each of them with 10% w/v cecal and colonic content of rats. Obtained 
results showed that both prodrugs were adequately stable in acid environment, while 
the succinyl conjugate was more stable than the glutaryl one in alkaline buffer. Both 
the prodrugs released the drug in cecal and colonic content, showing that the two 
systems could serve as colon specific delivery systems of metronidazole.  
 
6.1. Introduction 
The oral route has always been considered the most convenient way for drug 
administration. This is supported by several advantages that oral administration 
shows in comparison with other routes. In particular, high patient acceptance and a 
high degree of flexibility in dosage form design as well as on dosing. However, oral 
administration leads to drug absorption along the gastrointestinal tract (GIT) 
according to the physicochemical properties of the administered drug. This is a 
drawback when drugs show a preferential site of absorption or when an appropriate 
concentration is required in a specific portion of the GIT such as the colon is. In 
these conditions, formulation of a delivery systems capable of reaching the specific 
site of drug activity is required. 
During last decades, the colon has received a great deal of attention in the delivery 
of drugs for the treatment of local diseases associated with this portion of the GIT 
but also for its potential for the delivery of proteins and therapeutic peptides 
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sensitive to the enzymes in both the stomach and small intestine. The proximal or 
ascendant colon is considered as the optimum site for colon-target delivery of drugs 
[1]. A variety of approaches have been used to deliver drugs locally to colon. They 
include: pH dependent, time dependent or enzyme dependent systems [2-4].  
Recently, prodrugs in which a drug is covalently bound to a carrier have been 
proposed as a source of colon targeting [5-7]. Prodrugs usually improve drug 
physicochemical properties in order to increase the drug concentration at the action 
site, to prolong the effect, decrease toxicity and undesirable side effects. The 
prodrug should be stable in the stomach and in the small intestine, non-toxic, 
biodegradable, and biocompatible. It can be a small molecule (aminoacid, 
carbohydrate) or a macromolecule (polymers) [8]. The prodrug takes advantage of 
some specific colon characteristics that make the drug to be released specifically in 
the last part of the GIT. It is well known that the colon has a large and specific 
enzyme concentration, which is not present in the rest of the GIT [9,10]. Then a 
prodrug, which passes unmodified the stomach and the upper intestine, can reach the 
colon where the drug can be released by the action of the colonic enzymes.  
Chitosan (CHT) is a natural and cationic high molecular weight polysaccharide. It is 
composed of randomly distributed β-(1-4)-linked D-glucosamine (deacetylated unit) 
and N-acetyl-D-glucosamine (acetylated unit). CHT is produced commercially by 
deacetylation of chitin (60-100%), which is the structural element in the exoskeleton 
of crustaceans (crabs, shrimp, etc.) and cell walls of fungi. It has favourable 
biological properties such as biodegradability and biocompatibility. For this reason 
it has attracted a lot of attention in the pharmaceutical and medical fields [11-17] 
and several chitosan-based gastrointestinal delivery systems have been prepared [18-
23]. CHT is not absorbed in the upper part of the GIT, but it is selectively degraded 
by some enzymes of the colonic microflora [24-26]. These characteristics make the 
CHT a suitable carrier for the preparation of a polymeric prodrug [8, 26], generally 
obtained by linking the drug to CHT through a spacer [15]. Therefore, the prodrug 
can be prepared by linking the drug to the CHT through an amide bond formed with 
the amino group on position 2 of the glucosamine units.  
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In this work, as a model drug, metronidazole (MTZ) was used. MTZ is a 
nitroimidazole derivative particularly used in the treatment of anaerobic bacteria and 
Protozoa infections. MTZ is the drug of choice for the treatment of Amoebiasis, an 
infection of the large intestine caused by Entamoeba histolytica [27,28].  
The parasite reaches preferentially the colon and causes haemorrhage and ulceration. 
Therefore, MTZ must be released in the colon to assure its effective activity against 
the parasite but, after oral administration, it is completely and promptly absorbed. 
As a result, only a minimal amount of the drug reaches the colon (< 10%) [29,30] 
and considerable side effects are also induced [31,32]. 
The aim of this study was to develop a colon targeted delivery system for MTZ 
using polymeric prodrug formulation. To this purpose, two amide conjugates of 
CHT and MTZ were synthesized using a succinyl and glutaryl spacer respectively. 
Different spacers were used to evaluate the influence of the pro-moiety on the 
physicochemical properties of the prodrugs as well as on their rate of bioconversion 
to MTZ. Firstly, metronidazole hemiesters (hemisuccinate and hemiglutarate) were 
synthesized and then coupled with the amino group of the CHT glucosamine units to 
obtain the amide conjugates.  
The hemiester intermediates were characterized by spectroscopic and analytical 
methods (
1
H and 
13
C NMR, IR, and CHNO) while the prodrugs were mainly 
characterized by solid state NMR (
13
C NMR CPMAS). In vitro prodrug stability and 
ex vivo evaluation of drug release were also carried out.  
 
6.2. Experimental 
6.2.1. General Methods 
Metronidazole, succinic and glutaric anhydride, 4-dimethylaminopyridine, 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride, chitosan of medium 
molecular weight and Ultrafree-MC microcentrifuge filters (pore size 30000 Dalton, 
PLTK cellulosic membrane) were obtained from Aldrich (Milan, Italy). Spectra-
Por
®
 dialysis membrane (MWCO 12000-14000 Dalton, regenerated cellulose) was 
purchased from Spectrum Labs, Inc. (USA). Solvents for HPLC were obtained from 
Merck (Milan, Italy). All the products and solvents were of analytical grade. 
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Male Sprague-Dawley rats, weighing 250-275 g were purchased from Charles River 
(Calco, Italy) and were housed in a temperature- and humidity-controlled room with 
a 12-h light/dark cycle (light from 7:00 am to 7:00 pm). Animal used in this study 
were maintained in facilities fully accredited by the American Association for the 
Accreditation of Laboratory Animal Care and all experimentation was conducted in 
accordance with the guidelines of the Institutional Care and Use Committee of 
NIDA, NIH, and of the Guide for Care and Use of Laboratory Animals (National 
Res. Council, 1996) and the Council of the European Communities (86/809/EEC). 
High-resolution liquid 
1
H NMR experiments were recorded at 25 °C on a Varian 
Unity Inova spectrometer operating at 300 MHz in DMSO-d6 using 
tetramethylsilane (TMS) as internal standard reference. The experiments were 
carried out with the sample contained in a 5 mm tube using 7 μs pulse (90°), 2 s 
repetition time, and spectral with of 4 kHz. Solid state NMR spectra were collected 
using a Varian Unity Inova spectrometer with a 9.39 T wide-bore Oxford magnet. 
13
C Cross Polarization Magic Angle Spinning (CPMAS) spectra were collected with 
a probe configured for 4 mm Si3N4 rotors. The contact times for cross polarization 
was 0.5, 1 and 2 ms and recycle time of 2 s. 
13
C chemical shifts were referenced 
externally to hexamethylbenzene (CH3 = 17.4 ppm).  
Melting points were carried out in a Köfler apparatus. FTIR spectra were recorded 
on a Perkin Elmer System 2000 spectrophotometer using KBr mulls. CHNS 
analyses were carried out on a Fisons model EA 1108 Elemental Microanalyser. 
Eppendorf centrifuge was used for centrifugation. Thin layer chromatography (TLC) 
was performed on plates precoated with silica gel 60 F254 (Merck). The amount of 
MTZ released was assayed by HPLC at 320 nm, using a HP 1100 LC equipped with 
a Photodiode Array detector 996. The mobile phase consisted of citrate buffer 
(pH=2.6) : acetonitrile (80:20 v/v) and was filtered through a 0.45 m membrane 
filter before use. The mobile phase was eluted at a flow rate of 1 ml/min. The 
column was a Hypersil ODS 5.0 m (4.6 x 200 mm, HP). Retention times of MTZ, 
metronidazole hemisuccinate and hemiglutarate were 4.5, 6.5 and 9.0 min, 
respectively. Their concentrations in samples were calculated from the calibration 
curve constructed at the concentration range of 0.02-0.002 mg/ml (correlation 
coefficients, R
2
 between 0.999 and 0.994). 
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6.2.2. Chemistry 
6.2.2.1. General procedure for preparation of metronidazole hemiesters (2-3)  
Hemiesters 2 (MTZ-SUC) and 3 (MTZ-GLU) were obtained according to literature 
procedures with slight modifications [33]. Briefly, MTZ (11.7 mmol) and succinic 
or glutaric anhydride (13.7 mmol) were dissolved in 80 ml of acetonitrile. The 
obtained solutions were stirred at room temperature respectively for 72 or 120 hours 
in presence of 4-dimethylaminopyridine (DMAP) as catalyst. The reaction was 
monitored by TLC. The solvent was evaporated in a rotary evaporator to give a 
residue that was washed three times with 25 ml of hot water (60 °C) and let to 
crystallize as a white solid powder. The precipitate was filtered off and dried in a 
P2O5 desiccator under vacuum to give the hemiesters (2-3). 
4-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid (2).  
Yield: 90%, m.p.: 109 °C. IR (nujol) cm
-1
: 1746 cm
-1
 (ester, C=O), 1716 cm
-1
 
(carboxylic acid C=O), 1538 cm
-1
 (C=N), 1457 and 1377 cm
-1
 (NO2). 
1
H NMR 
(DMSO-d6) (ppm) 2.42 (t, 2H, J=3.3 Hz, H9), 2.44 (t, 2H, J=3.3 Hz, H8), 2.46 (s, 
3H, H7), 4.37 (t, 2H, J=5.1 Hz, H4), 4.57 (t, 2H, J=5.1 Hz, H5), 8.02 (s, 1H, H2). 
13
C 
NMR (DMSO-d6) (ppm) 14.1 (C7), 28.8 (C8), 28.9 (C9), 44.9 (C4), 62.5 (C5), 133.2 
(C2), 138.7-135.4 (C3) 151.8 (C1), 172.05 (C6), 173.52 (C10). CHN: calculated from 
(C10H13N3O6) C: 44.28; H: 4.83; N: 15.49; found C: 44.45; H: 4.84; N: 15.44. 
5-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-5-oxopentanoic acid (3).  
Yield: 60%, m.p.: 102 °C. ). IR (nujol) cm
-1
: 1738 cm
-1
 (ester, C=O), 1719 cm
-1
 
(carboxylic acid C=O), 1538 cm
-1
 (C=N), 1470 and 1380 cm
-1
 (NO2). 
1
H NMR 
(DMSO-d6) (ppm) 1.77 (m, 2H, J=7.2 Hz, H9), 2.31 (t, 2H, J=7.5 Hz, H8), 2.39 (t, 
2H, J=7.5 Hz, H10), 2.57 (s, 3H, H7), 4.49 (t, 2H, J=4.8 Hz, H4), 4.69 (t, 2H, J=4.8 
Hz, H
5
), 8.14 (s, 1H, H2), 12.22 (s, 1 H, OH). 
13
C NMR (DMSO-d6) (ppm) 14.0 
(C7), 19.8 (C9), 32.5 (C8), 32.6 (C10) 44.8 (C4), 62.2 (C5), 133.1 (C2), 138.6 (C3) 
151.6 (C1), 172.2 (C6), 174.0 (C11). CHN: calculated from (C11H15N3O6) C: 46.32; 
H: 5.30; N: 14.73; found C: 46.46; H: 5.28; N: 14.74.  
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6.2.2.2. General procedure for preparation of metronidazole-spacer-chitosan 
conjugates (4, 5) 
Metronidazole-succinyl-chitosan (MTZ-SUC-CHT, 4) and metronidazole-glutaryl-
chitosan (MTZ-GLU-CHT, 5) amide conjugates were prepared by coupling CHT 
with carboxyl groups of the hemiesters 2 or 3. Each hemiester (2 or 3, 1 mmol) were 
dissolved in 10 ml of acetonitrile and 1-ethyl-3-(3-dimethlaminopropyl) 
carbodiimide hydrochloride (EDAC, 1.25 mmol) was added. The reaction mixture 
was stirred at room temperature for 2 hours to activate the carboxyl group of 2 or 3, 
then a CHT solution (1 mmol in 15 ml of 5% acetic acid) was slowly added. The 
reaction was left under stirring at room temperature for 5 days. Part of the solvent 
was then removed under vacuum and the residue was dialyzed against distilled water 
for 48 hours. Finally the amide conjugates 4 and 5 were obtained as slightly yellow 
cotton-like powders by freeze-drying the dialyzed solution.  
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-4-(2-chitosan)-4-oxobutanoate (4).  
Yield: 50%. IR (KBr mull) cm
-1
: 3423 cm
-1
 (NH2 and OH), 1731 cm
-1
 (ester C=O), 
1651 cm
-1
 (amide I) 1558 cm
-1
 (amide II), 1155 cm
-1
, 1067 cm
-1
, 897 cm
-1
 (chitosan 
sugar structure). 
13
C CPMAS NMR (ppm): 15.8 (C8-CHT), 31.5-22.5 (C7-, C8-, C9-
MTZ-SUC), 49.0 (C2-CHT), 52,1 (C6-CHT), 68.2 (C3-, C5-CHT), 73.2 (C4-CHT), 
95.5 (C1-CHT), 165.0-175.0 (C7-CHT, C6-, C10-MTZ-SUC).  
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-5-(2-chitosan)-5-oxopentanoate (5)  
Yield: 45%). IR (KBr mull) cm
-1
: 3423 cm
-1
 (NH2 and OH), 1731 cm
-1
 (ester C=O), 
1651 cm
-1
 (amide I) 1557 cm
-1
 (amide II), 1157 cm
-1
, 1067 cm
-1
, 897 cm
-1
 (chitosan 
sugar structure). 
13
C CPMAS NMR (ppm): 15.8 (C8-CHT), 35.0-20.0 (C7-, C8-, C9-, 
C10-MTZ-GLU), 49.6 (C2-CHT), 52,7 (C6-CHT), 68.0 (C3-, C5-CHT), 72.8 (C4-
CHT), 94.5 (C1-CHT), 166.5 (C7-CHT), 173.5 (C6-, C11-MTZ-GLU).  
 
6.2.3. Determination of drug content in conjugates 
Drug content was determined following alkaline hydrolysis of the conjugates.  
Each conjugate (10 mg) was added to 10 ml borate buffer (pH=9.5) [34] and stirred 
at 50 °C for 48 hours. An aliquot of the solution (0.4 ml) was then placed in an 
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Ultrafree-MC centrifugal filter tube with Ultrafiltration membrane (30000 Dalton) to 
separate the MTZ solution from the polymer. MTZ content in the purified solutions 
was assayed by HPLC as reported above.  
 
6.2.4. Stability studies 
The conjugate stability was checked in two different media: acid (pH=1.2) and 
alkaline (pH=7.4) buffers [34] in a thermostatic bath at 37 °C. 10 mg of each 
conjugate were placed in a membrane dialysis bag; which was closed and transferred 
into a flask containing 40 ml of the buffer solution. The external solution was 
continuously stirred and the system was maintained at 37 °C for 24 hours. At 
appropriate time intervals, 1 ml solution was removed from the external solution and 
replaced with the same buffer. 20 L of the withdrawn solution was assayed by 
HPLC as reported above to determine the percentage of the released drug. 
 
6.2.5. Drug release studies 
Rats were anaesthetized by chloral hydrate (300 mg/Kg ip), the abdomen was 
opened and the cecum and colon were traced, legated at both ends, dissected and 
immediately transferred into pH=7.4 buffer. Part of the cecal and colonic bags was 
immediately used for the experiment (content A) while another part of the cecal and 
colonic bags was frozen and stored at -80 °C (content B).  
The cecal or colonic bags were opened and their contents were individually 
weighted, pooled, and then suspended in the buffer to give 10% w/v dilution. The 
release studies were performed by incubating each conjugate or hemiester with a 
10% w/v cecal and colonic content of rats. These studies were carried out using both 
cecum and colon contents A and B. 5 mg of each conjugate were added to 5 ml of 
the 10% w/v suspension of cecal and colonic contents (A or B) and the mixture was 
stirred and incubated at 37 °C under N2 flow to maintain the anaerobic condition as 
the cecum and the colon are naturally anaerobic. At appropriate time intervals, 0.5 
ml of the suspension were withdrawn, diluted to 1 ml with buffer and centrifuged at 
5000 rpm for 3 minutes. To 0.2 ml portion of the supernatant, 0.8 ml of methanol 
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were added to precipitate the protein, vortexed for 2 minutes and centrifuged at 
10260 rpm for 5 minutes.  
The concentration of MTZ was determined in 20 L of the supernatant by HPLC as 
described above. Each experiment was carried out in triplicate. 
 
6.2.6. Statistical analysis 
Data analysis was carried out with the software package R, version 2.10.1. Results 
are expressed as the mean ± standard deviation (S.D.). Multiple comparisons of 
means (Tukey test) were used to substantiate statistical differences between groups, 
while Student’s t-test was used for comparison between two samples. Significance 
was tested at the 0.05 level of probability (p). 
 
6.3. Results and discussion 
6.3.1. Chemistry 
In this work, two MTZ-spacer-CHT amide conjugates were studied as potential 
colon specific prodrugs of MTZ. Preparation of the conjugates was achieved as 
shown in Scheme 1 and 2.  
The first step (Scheme 1) consisted in the synthesis of the metronidazole 
hemisuccinate (2) and hemiglutarate (3). This process was performed to introduce a 
carboxyl, essential group for coupling the drug to the CHT [33].  
Then, in a second step (Scheme 2) activation of the hemiester carboxyl group was 
achieved by coupling it with the water soluble 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDAC) [35].  
EDAC was chosen because CHT is insoluble in all the organic solvents and it just 
dissolves in water only at acidic pH. Moreover, it is stable in water and mostly used 
to form an amide bond for peptide synthesis. After the activation of the carboxyl 
group, a solution of CHT in 5% acetic acid was added and the mixture was stirred 
for 5 days to obtain the respective MTZ-spacer-CHT conjugate 4 and 5.  
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Scheme 1. Synthesis of metronidazole hemiesters 2 and 3 
 
 
N
N
NH
O
O
OH
OH
O
CH2
O
O
CH2
NO2
N
N
N
N
N
NO2
O
O
CH2
COOH
CH2
O
O
N
N
NO2
O
O
NH
N
N
CH3CN
O
O
NH
OHO
OH
O
O O
NH2
OH
OH
n
n
n
CHITOSAN
2
+
n=2 SUC
n=3 GLU
CH3COOH 5%
mx
y
2,3
4,5  
Scheme 2. Synthesis of metronidazole-spacer-chitosan conjugates (4 - 5) 
 
The hemiester intermediates and the conjugates were spectroscopically and 
analytically characterized to confirm their structures. 
Main information on the interaction between metronidazole hemiesters and chitosan 
were obtained from analysis with solid state NMR method, namely carbon 13 cross 
polarization magic angle spinning (
13
C NMR CPMAS). In figure 1, as an example, 
the 
13
C CPMAS spectra for the commercial CHT (a), MTZ-GLU (b) and MTZ-
GLU-CHT(c) are reported since following discussion will focus only on these 
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compounds while assignments for products 2 and 4 are shown in the experimental 
section. 
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Figure 1. 13C CPMAS NMR spectra for (a) CHT, cntct 2ms; (b) MTZ-GLU, cntct 2ms; (c) MTZ-
GLU-CHT, cntct 0.5ms; *experimental artefacts [41]. 
 
For the sake of clarity, in the figure 2, glucosamine, acetylglucosamine repetitive 
units (~ 15%), and MTZ-GLU structure are also sketched with the used labeling of 
C atoms. The attribution of CHT carbons was made by comparison with literature 
data [36].  
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Figure 2. Schematic representation of glucosamine (a), acetylglucosamine (b), and hemiester 
MTZ-GLU 3 (c) with the used labeling of C atoms. 
 
At 97.6 ppm, the resonance of anomeric carbon C1 of the glucosamine unit is 
observed. At 167.3 ppm and 16.4 ppm, weak resonances, respectively due to the 
carbonyl C7 and to methyl C8 of the N-acetylglucosamine units, are noticed. These 
signals, C7 and C8, are visible despite the fact that the N-acetylglucosamine is only 
15% of the polymeric molecule, because the cross-polarization (CP) efficiency 
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depends strongly on the internuclear distance of the two involved nuclei as well as 
on their mobility, and also because usually the signal intensity does not provide 
quantitative information [37,38]. Thus, C6 resonates at 53.3 ppm while the nearby 
resonance at 49.6 ppm is due to C2. At 68.1 ppm, a set of overlapped resonances is 
due both to C3 and C5. In the frequency range 73-78 ppm, the resonance due to C4 
is split in different peaks. Splittings in the order of 1-2 ppm, observed in carbon 
resonances, may be ascribed either to differences in the polymeric chain packing or 
to different internal torsion angles. In this case, the observed splittings are possibly 
due to both effects. In fact, the resonance of C4 is sensitive to the ω torsion angle 
while it is also well known that CHT exhibits polymorphism [39]. The 
13
C NMR 
CPMAS spectrum for MTZ-GLU is reported in figure 1b. The attribution of the 
carbon resonance was made by comparison with the 
13
C NMR spectrum in liquid 
state.  
 
Table 1. 13C CPMAS chemical shifts of CHT, 13C NMR and 13C CPMAS NMR chemical shifts of 
MTZ-GLU (3) 
 
Carbon CHT  
13
C CPMAS NMR Carbon MTZ-GLU 
13
C NMR 
13
C CPMAS NMR 
(see fig. 2b) 
 
(ppm) 
 
(see fig. 2c) 
 
(ppm) 
 
(ppm) 
 
1 97.6 1 151.6 152.0 
2 49.6 2 133.1 131.4 
3/5 68.1 3 138.6 135.6/134.1 
4 75.5 4 44.8 44.9/41.7 
6 53.3 5 62.2 64.4/61.2 
7 167.3 6 172.2 172.1 
8 16.4 7 14.0 13.7/11.6 
   8 32.5 31.1/28.5 
   9 19.8 19/16.8 
   10 32.6 31.1/28.5 
    11 174.0 174.2 
 
Table 1 shows the 
13
C CPMAS NMR signals assigned to CHT and MTZ-GLU as 
well as the 
13
C NMR chemical shifts for MTZ-GLU in the liquid state. In the 
13
C 
CPMAS NMR of the MTZ-GLU, seven out of eleven carbon resonances show 
evidence of fine structure in the form of splitting. This suggests the presence of two 
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environments for these carbon sites and reflects the existence of two conformations. 
In the liquid state, this cannot be observed because rapid motions remove dipolar 
and quadrupolar couplings as well as average anisotropic value so that most of the 
information contained in these spin interaction is lost [40]. 
 
Table 2. 13C CPMAS NMR chemical shifts and respective attributions to MTZ-GLU-CHT 
carbons.  
Carbon MTZ-GLU-CHT (ppm) Attributions 
(see fig. 1c)  
173.5 C6/11 MTZ-GLU 
166.5 C7 CHT 
144.9 C1 MTZ-GLU 
131.9 C2/3 MTZ-GLU 
94.5 C1 CHT 
49.6 C2 CHT 
68.0 C3/5 CHT 
72.8 C4 CHT 
52.7 C6 CHT 
35.0-20.0 C7/8/9/10 MTZ-GLU 
15.8 C8 CHT 
 
The 
13
C CPMAS NMR spectrum of the sample MTZ-GLU-CHT is shown in figure 
1c. As can be seen, the presence of CHT is clear, but the signals are broad in 
comparison to the pure polymer (~1 ppm). This is the consequence of the MTZ-
GLU that is bounded to CHT thus creating a structural disorder in the polymer [41]. 
The evidence of MTZ-GLU conjugation to chitosan is given by the spectrum that 
also demonstrates the resonance of the MTZ-GLU carbons: at 173.5 ppm, resonance 
corresponding to the C6 and C11 carbonyl are observed while the broad signals at 
131.9 ppm are due to the C2/3. As can be seen in the figure 1c, in the range between 
20-35 ppm, below the two sharp spikes (marked with an asterisk since they are 
experimental artifacts, i.e. rotor frequency lines) [42], weak overlapped signals are 
present, which can be probably due to the chemical shift of carbons C7, C8, C9 and 
C10 of the MTZ-GLU. In table 2 chemical shifts and their corresponding 
attributions to MTZ-GLU-CHT carbons are reported. 
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Therefore, these analyses confirmed that MTZ was linked to the amino group of the 
CHT glucosamine units through a succinyl or glutaryl spacer, which was linked to 
the drug and to the polymer by an ester and an amide bond, respectively. Both these 
bonds are susceptible to hydrolysis by amidase and esterase enzymes present in the 
colonic microflora, thus causing the drug release in the colon.  
The drug loading was studied by HPLC determination after alkaline hydrolysis of 
the prodrugs 4 and 5. Obtained results indicated that 10 mg of the MTZ-SUC-CHT 
prodrug contained 1.5 ± 0,01 mg of MTZ, while 10 mg of MTZ-GLU-CHT prodrug 
contained 1.05 ± 0.06 mg of MTZ. Therefore, a loading efficiency of 17.65 and 
11.75% respectively was achieved.  
 
6.3.2. Stability studies 
Colon-targeting prodrugs have to survive passage through stomach and small 
intestine as an intact form to reach the colon, where they have to be degraded by the 
enzymes of the colonic microflora. Therefore, to have information on the prodrug 
behaviour in acidic and alkaline environment, the prodrug stability was studied in 
vitro in acid and basic buffers. In fact, on the basis of their chemical structures, both 
ester and amide bond of the prodrugs are susceptible to hydrolysis. Therefore, 
following incubation in different buffer solutions, the drug and the hemiesters could 
be released. In order to evaluate the stability of the prodrugs, the amount of MTZ 
and hemiesters released from the prodrugs 4 and 5 were quantified during 24 hours 
experiments. In particular, the in vitro stability study was carried out at pH=1.2 and 
pH=7.4. Results are shown in Figure 3. 
As can be seen, the prodrug 4 was adequately stable at both acidic (Fig. 3a) and 
basic pH (Fig. 3b). Indeed, a similar small amount of hemiester 2 and MTZ (20%) 
was released after 8 hours, thus showing no difference between ester and amide 
bond stability in both tested media. 
On the contrary, the prodrug 5 showed a different behaviour: it was adequately 
stable (as the prodrug 4) at acid pH (Fig. 3a) for the first two hours but its stability 
decreased at pH 7.4 (Fig. 3b). After 6 hours (when the conjugate is supposed to 
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reach the colon), more than 40% of hemiester 3 and only less than 16% of MTZ 
were released (Fig. 3b). 
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Figure 3. Stability studies of prodrugs 4 and 5 in acid (pH=1.2) and alkaline (pH=7.4) buffers at 
37°C: a) buffer at pH 1.2; b) buffer at pH 7.4. Error bars represent standard deviation, n =3. 
 
Therefore, in this case the hydrolysis rate of the ester and amide bonds was 
different: results clearly show that the amide bond was hydrolysed faster than the 
ester one when the spacer was the glutaryl moiety. Hence, outcomes of this stability 
study show that length of the spacer affects the amide bond stability especially in 
alkaline environment. Indeed, comparison of results obtained with succinyl and 
glutaryl moieties indicates that the longer the spacer chain the higher the hydrolysis 
rate of the prodrug in alkaline buffer. 
 
6.3.3. Drug release studies 
In order to verify the actual capability of the prodrugs 4 and 5 to release the drug 
into the target area [43], an ex vivo release study was carried out using cecum and 
a 
b 
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colon contents A (immediately used) and B (previously frozen and stored at -80 °C). 
Figure 4 shows comparison of the results obtained from prodrugs 4 and 5 in the 
release experiments with both cecum and colon contents A.  
As can be seen, in the presence of both cecum and colon contents, the prodrug 4 
released very small amount of both MTZ and hemiester 2, especially in colon. In 
fact, the amount of MTZ and 2 increased only up to about 15% (cecum) and 5% 
(colon) in the first 30 minutes of the experiments to decrease and disappear after 4 
and 2 hours in cecum and colon, respectively. However, it is well known that MTZ 
is metabolized in the colon: N-(2-hydroxyethyl)-oxamic acid [44] and acetamide 
[45] are formed when the drug is reduced as a result of the colonic anaerobic 
bacteria activity.  
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Figure 4. Cumulative release of 1 (MTZ), 2 (MTZ-SUC) and 3 (MTZ-GLU) from prodrugs 4 and 
5 during incubation with fresh contents A of cecum (a) and colon (b) at 37°C. Error bars 
represent standard deviation, n =3. 
 
Therefore, these results could be the consequence of a very fast metabolic process 
that involves the released MTZ in the last portions of the GIT content. Incubation of 
a 
b 
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prodrug 5 with both cecum and colon content A led to a similar release profile but, 
in this case, the maximum amount of released hemiester 3 was much greater than 
MTZ ( 68% in cecum and  42% in colon). This result could be due to a slower 
hydrolysis process of this hemiester in the presence of both cecum (Fig. 4a) and 
colon (Fig. 4b) content A.  
Different results were obtained when the release study was carried out in cecum and 
colon content B (Fig. 5).  
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Figure 5. Cumulative release of 1 (MTZ), 2 (MTZ-SUC) and 3 (MTZ-GLU) from prodrugs 4 and 
5 during incubation with frozen contents B of cecum (a) and colon (b) at 37°C. Error bars 
represent standard deviation, n =3. 
 
In fact, after 30 minutes from the starting of the experiments with cecum content 
(Fig. 5a), the prodrug 4 released a maximum amount of 13% of hemiester 2 that 
rapidly decreased. On the contrary, increasing amount (up to 60%) of MTZ were 
released during the experiments. A similar release profile was obtained also in the 
colon content (Fig. 5b).  
b 
a 
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A different behaviour was shown by the prodrug 5 in both B contents. Just after 30 
minutes from the starting of the experiments, approximately 45% of the 
corresponding hemiester 3 was released and its amount increased up to more than 
60% at the end of the study in both cecum and colon content. The amount of 
released MTZ, on the contrary, was lower (30% in cecum, 25% in colon) even than 
that released from the prodrug 4 thus confirming the hypothesis of a slower 
conversion of the hemiester 3 in comparison with the 2 one (Fig. 7).  
Therefore, overall results of the release experiments from the hemiesters 2 and 3 
showed a reduced release process in media B in comparison to media A and they led 
us to suppose that the freezing procedure had reduced the activity of some enzymes 
[46,47].  
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Figure 6. Metronidazole (MTZ) release and 2 (MTZ-SUC) and 3 (MTZ-GLU) disappearance 
during incubation of hemiesters 2 and 3 with freshly prepared contents A of cecum (a) and colon 
(b) at 37°C. Error bars represent standard deviation, n =3. 
To verify the hypothesis of a different susceptibility to enzymatic hydrolysis of the 
amide and ester bonds, the drug release from the hemiesters 2 and 3 was also 
a 
b 
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studied. Results obtained in the presence of fresh cecum and colon content A are 
shown in Figure 6.  
As can be seen, neither in cecum (Fig. 6a) nor in colon (Fig. 6b) MTZ was 
appreciably detected while the two hemiesters underwent hydrolysis and 
progressively disappeared. Therefore, the observed degradation of the two 
hemiesters confirms that the released MTZ is metabolized in the colon.  
On the contrary, when the studies were performed with frozen contents B, MTZ 
could be quantified (Fig. 7) and degradation of the two hemiesters 2 and 3 occurred 
much more slowly than in fresh cecum and colon contents.  
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Figure 7. Metronidazole (MTZ) release and 2 (MTZ-SUC) and 3 (MTZ-GLU) disappearance 
during incubation of hemiesters 2 and 3 and with frozen contents B of cecum (a) and colon (b) at 
37°C. Error bars represent standard deviation, n =3. 
 
In particular, in both cecum and colon (Fig. 7) a good correlation between the 
hemiester disappearance and drug release could be found. Indeed, in cecum at the 
end of the experiments,  80% of hemiester 2 was hydrolyzed thus leading to  80% 
a 
b 
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of delivered MTZ while only  20% of hemiester 3 was degraded with a 
corresponding release of MTZ in the medium.  
However, comparison of the figures 6 and 7 shows some differences in the 
behaviour of the two hemiesters. In fact, although the compounds 2 and 3 were 
rapidly converted to MTZ with both contents A, the enzymatic hydrolysis of 2 was a 
little bit faster than that of 3 especially in cecum where the hemiester 2 disappeared 
after only 4 hours. In addition, for both prodrugs 2 and 3, the conversion rate was 
slightly faster in cecum content (Fig. 6a) than in that of colon (Fig. 6b) and MTZ 
was not detected in both systems A. When treated with both frozen contents B, the 
hemiester 2 showed again a MTZ release faster in cecum content (Fig. 7a) than in 
the colon one (Fig. 7b) while the hemiester 3 was very slowly converted to MTZ in 
both media (Fig. 7a-b). Furthermore, release experiments from the hemiesters 
confirmed a reduced release process in media B in comparison to media A and 
further support the hypothesis of a reduced activity of some enzymes as a 
consequence of the freezing procedure [46,47]. Nevertheless, the experiments in 
media B were useful to demonstrate the actual MTZ release in cecum and colon 
content from both prodrugs. In fact, when contents A (immediately used) were used 
the drug release rate was faster than in contents B as shown by the faster 
disappearance of MTZ-SUC and MTZ-GLU. However, in contents A, MTZ was 
metabolized and could not be detected. When the previously frozen contents B were 
tested, MTZ was detected thus showing that the drug was released both in cecum 
and colon contents. 
In summary, results of these ex vivo experiments showed no substantial differences 
in the release behaviour of the two prodrugs in cecum and colon content: in both 
cases the hemiester conversion is slightly faster in the cecum than in the colon 
although a higher stability of the prodrug 5 can be observed in both media. 
Therefore, results obtained in this work show that both prodrugs can be potential 
colon specific delivery systems for MTZ since the prodrug 4 is able to give a fast 
and complete drug release by enzymatic hydrolysis in cecum and colon. On the 
other side, the slower conversion rate of the prodrug 5 could be useful for both 
delayed and sustained MTZ release. 
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6.4. Conclusion  
In conclusion, the prepared prodrugs were adequately stable at acidic pH (pH=1.2) 
while the prodrug 5 was more sensitive to the alkaline hydrolysis than prodrug 4. 
However, both 4 and 5 conjugates demonstrated their capability to release MTZ in 
the content of the cecum and the colon, showing that these compounds are 
susceptible to enzymatic hydrolysis although the glutaryl prodrug 5 showed slower 
drug release profiles. For this reason, both MTZ-SUC-CHT and MTZ-GLU-CHT 
seem to be suitable prodrugs for the development of a colonic drug delivery system 
for MTZ: the prodrug 4 could be used as a delayed drug delivery system while the 
second one (5) could guarantee a sustained drug release. 
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7. METRONIDAZOLE-SUCCINYL-CYCLODEXTRIN ESTER  
AS COLON SPECIFIC PRODRUGS: SYNTHESIS, 
CHARACTERIZATION AND EX VIVO RELEASE STUDIES 
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7.1. Introduction 
 
Native cyclodextrins (CDs) are cyclic oligosaccharides consisting of six (-
cyclodextrin), seven (-cyclodextrin), eight (-cyclodextrin) glucopyranose units 
linked by -(1,4) bonds [1]. They have been widely used in pharmaceutical field 
because of their ability to alter physical, chemical, and biological properties of guest 
molecules through the formation of inclusion complexes. Recently, various kinds of 
CD derivatives have been prepared so as to extend the physicochemical properties 
and inclusion capacity of natural CDs as novel drug carriers [2]. Among the 
chemically modified CDs, the hydrophilic or ionizable CDs will enhance drug 
absorption [3,4], while hydrophobic CDs may have broad applicability [5,6], and 
could serve as novel slow-release carriers of water soluble drugs, including peptide 
and protein drugs. Moreover, the biodegradation property of CDs is particularly 
useful for colon-targeting of drugs. CDs are known to undergo minimal hydrolysis 
in the stomach and small intestine, while they are selectively fermented into small 
saccharides by the colonic microflora [7]. These biodegradable properties of CDs 
make them to be good carrier candidates for preparation of colon specific delivery 
prodrugs. Indeed, prodrugs are designed to be neither hydrolysed nor absorbed in the 
upper gastrointestinal (GI) tract but to undergo enzymatic hydrolysis in the colon, 
releasing the active drug moiety from the carrier. [8]. For this reason several CD-
drug conjugates have been prepared and studied as colon specific drug delivery 
systems [9-13]. 
Metronidazole (MTZ) is an antibiotic drug particularly used against anaerobic 
bacteria and protozoa. It is the drug of choice for intestinal amoebiasis [14], an 
infection of the large intestine caused by Entamoeba histolytica, a single celled 
protozoan parasite [15]. The trophozoites of E. histolytica can invade the colonic 
epithelium, causing amoebic colitis, resulting in hemorrhage and ulceration. MTZ 
must be delivered to the colon for its effective action against the parasite, but its 
pharmacokinetic profile indicates that the drug is completely and promptly absorbed 
after oral administration [16,17]. The administration of this drug in conventional 
tablet dosage forms provides minimal amount of metronidazole for local action in 
the colon, causing unwanted systemic effects. Thus, there is a strong clinical need 
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and a potential market for a delivery system capable of delivering maximum amount 
of MTZ to the colon in a controlled manner. Various approaches for colon specific 
drug delivery have been developed and they include: coating with pH sensitive 
polymer systems, design of timed release dosage forms, and use of prodrugs and 
carriers that are degraded exclusively by colonic bacteria [18-20]. 
In this work, metronidazole-CD prodrugs were prepared as colon specific drug 
delivery system. The strategy for the prodrug production consisted of linking the 
drug to CDs through a succinyl spacer.  
Metronidazole hemiester [21] was firstly prepared and then the carboxyl group of 
this derivative and hydroxyl group of CDs were coupled via ester linkage. 
Therefore, MTZ-succinyl--, -and -CD conjugates were prepared. The prodrugs 
were characterized by spectroscopic and analytical methods (IR, CHN, 
1
H and 
13
CNMR, and ROESY). In vitro stability studies of the prodrugs were performed at 
acid (pH=1.2) and alkaline (pH=7.4) pH values. Ex vivo drug release studies from 
the conjugates were carried out with cecum and colon content of rats. 
 
7.2. Materials and methods 
7.2.1. Materials 
Metronidazole, succinic anhydride, 4-dimethylaminopyridine (DMAP), 1,1'-
carbonyldiimidazole (CDI), -, - and -CD, Corning® Spin-X UF 500 (10 kDa 
MWCO) and DIAION HP-20 were obtained from Aldrich (Milan, Italy). All the 
products and solvents were of analytical grade.  
Male Sprague-Dawley rats, weighing 250-275 g were purchased from Charles River 
(Calco, Italy) and were housed in a temperature- and humidity-controlled room with 
a 12-h light/dark cycle (light from 7:00 am to 7:00 pm). Animals used in this study 
were maintained in facilities fully accredited by the American Association for the 
Accreditation of Laboratory Animal Care and all experimentation was conducted in 
accordance with the guidelines of the Institutional Care and Use Committee of 
NIDA, NIH, and of the Guide for Care and Use of Laboratory Animals (National 
Res. Council, 1996) and the Council of the European Communities (86/809/EEC). 
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7.2.2. Methods  
High-resolution liquid NMR 
1
H and 
13
C experiments were recorded at 25°C on a 
Varian Unity Inova spectrometer operating at 300 MHz in DMSO-d6 using 
tetramethylsilane (TMS) as internal standard reference. Phase-sensitive rotating 
frame nuclear Overhauser effect (ROESY) spectra were recorded at 25 °C on Varian 
Unity INOVA 400 MHz spectrometer, operating at 400 MHz for 
1
H and 100 MHz 
for 
13
C respectively, and measured under the following conditions: sweep width, 
3700 Hz; carrier frequency, 399.94 MHz; spin-lock field, 11 kHz; mixing time, 250 
ms. Melting points were carried out in a Köfler apparatus. FTIR spectra were 
recorded on a Perkin Elmer System 2000 spectrophotometer using KBr mulls. 
CHNS analyses were carried out on a Fisons model EA 1108 Elemental 
Microanalyser. Eppendorf centrifuge was used for centrifugation. Thin layer 
chromatography (TLC) was performed on plates precoated with silica gel 60 F254 
(Merck) and an eluent of ethyl acetate/2-propanol/water = 3,5 : 2,5 : 2,5 (indicator p-
anisaldehyde).  
The amount of released MTZ was assayed by HPLC at 320 nm, using a HP 1100 LC 
equipped with a Photodiode Array detector 996. The mobile phase consisted of 
citrate buffer (pH=2.6): acetonitrile (80:20 v/v) and was filtered through a 0.45 m 
membrane filter before use. The mobile phase was eluted at a flow rate of 1 ml/min. 
The column was a Hypersil ODS 5.0 m (4.6 x 200 mm, HP). Retention times of 
cyclodextrin conjugates, MTZ, and metronidazole hemisuccinate were 2.6, 3.5 and 
5.5 minutes, respectively. Their concentrations in samples were calculated from the 
calibration curve constructed at the concentration range of 0.03-0.003 mg/ml for 
MTZ and metronidazole hemisuccinate and 0.1-0.01 mg/ml for CD conjugates 
(correlation coefficients, R
2
 between 0.999 and 0.997). 
 
7.2.3. General procedure for preparation of metronidazole-succinyl-α-, β-, and γ-
cyclodextrin conjugates (3, 4, 5) 
Metronidazole hemisuccinate (MTZ-SUC, 2) compound was obtained according to 
previously reported procedures [30]. The metronidazole-succinyl-cyclodextrin 
(MTZ-SUC--CD, 3; MTZ-SUC--CD, 4; MTZ-SUC--CD, 5) ester conjugates 
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were prepared by coupling CDs with carboxyl groups of hemiesters 2. The 
hemiester (2, 1.2 mmol) was dissolved in 5 ml of anhydrous dimethyl sulfoxide and 
1,1'-carbonyldiimidazole (CDI, 1.25 mmol) was added. The reaction mixture was 
stirred at room temperature for 90 minutes under N2 flow to activate the carboxyl 
group of 2, and then CDs and 5 ml of triethylamine were added. The reaction was 
left under stirring at room temperature for 48 hours. Subsequently, a large amount of 
acetone (200 ml) was added to the solution, and the resulting precipitates were 
collected by filtration through a 0.45 m membrane filter (Alltech, Italy). The 
conjugates were purified by column chromatography using porous polystyrene resin 
DIAION HP-20 (5 x 20 cm) and eluting with methanol and 0.1 M acetic acid with 
increasing methanol content. The elutes were monitored by TLC and the prodrugs 
appeared in the 40-60% methanol in acetic acid fraction. The fractions containing 
the conjugates were collected, part of the solvent was removed under reduced 
pressure and the product was precipitated by adding 200 ml of acetone anhydrous; 
the resulting precipitate was collected by filtration (0.45 m) and let to dry in a 
desiccator under vacuum. Finally, the ester conjugates 3, 4 and 5 were obtained as 
white powders. 
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-4-(-cyclodextrin)-4-oxobutanoate (3) 
Yield: 24.5%; m.p.: 260°C. IR (KBr mull) cm
-1
: 3389 cm
-1
 (OH), 1731 cm
-1
 (ester 
CO), 1651 cm
-1
, 1151 cm
-1
 1023 cm
-1
, 951 cm
-1
 (CD sugar structure). 
1
H NMR 
(DMSO-d6) (ppm) 2.59-2.62 (m, overlaps with DMSO- d6, H8-, H9-, H7-MTZ-
SUC), 3.41-3.91 (m, 36 H, H2-, H4-, H5-, H6-, H3-CD), 4.12 (t, H3’-CD), 4.38-4.42 
(dd, H2’-CD), 4.49-4.51 (t, 2H, H4-MTZ-SUC), 4.58-4.63 (d, 6H, OH6-CD, D2O 
exchange), 4.68-4.70 (t, 2H, H5-MTZ-SUC), 4.89-4.95 (m, 5H, H1-CD), 5.12-5.13 
(d, 1H, H1’-CD), 5.58-5.82 (m, 11H, OH2-3-CD, D2O exchange), 8.16 (s, 1H, H2-
MTZ-SUC). 
13
C NMR (ppm) 14.06 (C7-MTZ-SUC), 28.46 (C8-MTZ-SUC), 30.81 
(C9-MTZ-SUC), 44.83 (C4-MTZ-SUC), 59.86-60.33 (C6-CD), 62.50 (C5-MTZ-
SUC), 69.56 (C3’-CD), 71.58 (C5-CD), 72.23-72.48 (C2-CD), 72.87-73.36 (C3-CD), 
73.67 (C2’-CD), 81.86-82.50 (C4-CD), 98.60 (C1’-CD), 102.2-102.9 (C1-CD), 133.9 
(C2-MTZ-SUC), 138.6 (C3-MTZ-SUC), 151.8 (C1-MTZ-SUC), 171.9 (C6-MTZ-
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SUC), 172.2 (C10-MTZ-SUC). CHN: calculated from (C46H71N3O35) C: 45.05; H: 
5.80; N: 3.43; found C: 44.59; H: 5.91; N: 3.37.  
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-4-(-cyclodextrin)-4-oxobutanoate (4)  
Yield: 25.2%; m.p.: 278°C. IR (KBr mull) cm
-1
: 3382 cm
-1
 (OH), 1740 cm
-1
 (ester 
CO), 1638 cm
-1
, 1156 cm
-1
, 1029 cm
-1
, 947 cm
-1
 (CD sugar structure). 
1
H NMR 
(DMSO-d6) (ppm) 2.59-2.66 (m, overlaps with DMSO- d6, H8-, H9-, H7-MTZ-
SUC), 3.44-3.75 (m, H2-, H4-, H5-, H6-, H3-CD), 3.99 (t, H3’-CD), 4.40-4.50 (t, 2H, 
H4-MTZ-SUC), 4.58-4.60 (d, 7H, OH6-CD, D2O exchange), 4.69 (t, 2H, H5-MTZ-
SUC), 4.93 (s, 6H, H1-CD), 5.15 (s, 1H, H1’-CD), 5.58-5.62 (t, H2’-CD), 5.7-6.04 
(m, 13H, OH2-3-CD, D2O exchange), 8.16 (s, 1H, H2-MTZ-SUC). 
13
C NMR (ppm) 
14.04 (C7-MTZ-SUC), 28.47 (C8-MTZ-SUC), 30.79 (C9-MTZ-SUC), 44.81 (C4-
MTZ-SUC), 60.05 (C6-CD), 62.49 (C5-MTZ-SUC), 69.50 (C3’-CD), 71.58 (C5-CD), 
72.12-72.5 (C2-CD), 73.16 (C3-CD), 73.20 (C2’-CD), 81.22-81.81 (C4-CD), 98.32 
(C1’-CD), 101.40-102.01 (C1-CD), 133.12 (C2-MTZ-SUC), 138.54 (C3-MTZ-SUC), 
151.70 (C1-MTZ-SUC), 171.74 (C6-MTZ-SUC), 172.03 (C10-MTZ-SUC). CHN: 
calculated from (C52H81N3O40) C: 44.95; H: 5.83; N: 3.02; found C: 43.20; H: 6.89; 
N: 2.72. 
2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-4-(-cyclodextrin)-4-oxobutanoate (5) 
Yield: 24.3%; m.p.: 280°C. IR (KBr mull) cm
-1
: 3380 cm
-1
 (OH), 1737 cm
-1
 (ester 
CO), 1635 cm
-1
, 1152 cm
-1
, 1021 cm
-1
, 950 cm
-1
 (CD sugar structure). 
1
H NMR 
(DMSO-d6) (ppm) 2.58-2.74 (m, overlaps with DMSO- d6, H7-, H8-, H9-MTZ-
SUC), 3.32-3.72 (m, 48H, H2-, H3-, H4-, H5-, H6-CD), 3.91 (t, H3’-CD), 4.46-4.50 (t, 
2H, H4-MTZ-SUC), 4.55-4.62 (d, 8H, OH6-CD, D2O exchange), 4.67 (t, 2H, H5-
MTZ-SUC), 4.83 (s, 7H, H1-CD), 5.15 (s, 1H, H1’-CD), 5.58-5.62 (t, H2’-CD), 5.71-
6.00 (m, 15H, OH2-3-CD, D2O exchange), 8.16 (s, 1H, H2-MTZ-SUC). 
13
C NMR 
(ppm) 14.03 (C7-MTZ-SUC), 28.50 (C8-MTZ-SUC), 30.79 (C9-MTZ-SUC), 44.83 
(C4-MTZ-SUC), 59.74 (C6-CD), 62.54 (C5-MTZ-SUC), 69.21 (C3’-CD), 71.89 (C5-
CD), 72.26-73.00 (C2-CD), 73.32 (C3-CD), 73.84 (C2’-CD), 78.38-81.49 (C4-CD), 
97.54 (C1’-CD), 101.0-102.1 (C1-CD), 133.1 (C2-MTZ-SUC), 138.6 (C3-MTZ-
SUC), 151.7 (C1-MTZ-SUC), 171.4 (C6-MTZ-SUC), 171.9 (C10-MTZ-SUC). CHN: 
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calculated from (C58H91N3O45) C: 44.91; H: 5.92; N: 2.71; found C: 44.68; H: 5.87; 
N: 2.73. 
 
7.2.4. Stability studies 
The conjugates stability was checked in two different media: acid (pH=1.2) and 
alkaline (pH=7.4) buffers [22] in a thermostatic bath at 37 °C. 3.5 mg of each 
conjugate were placed in a closed flat bottom tube containing 25 ml of the buffer 
solution. The solution was continuously stirred and the system was maintained at 37 
°C for 24 hours. At appropriate time intervals, 1 ml solution was removed and 
replaced with the same buffer. 20 l of the withdrawn solution was assayed by 
HPLC as reported above to determine the percentage of the released drug and the 
disappearance of the conjugates. 
 
7.2.5. Drug release studies 
Rats were anaesthetized by chloral hydrate (300 mg/Kg ip), the abdomen was 
opened and the cecum and colon were traced, legated at both ends, dissected and 
immediately transferred into pH=7.4 buffer. A portion of the cecal and colonic bag 
was immediately used for the experiment (content A) while another one was frozen 
and stored at -80 °C (content B). The cecal or colonic bags were opened and their 
contents were individually weighed, pooled, and then suspended in the buffer to give 
10% w/v dilution. The release studies were performed by incubating each conjugate 
or hemiester with a 10% w/v cecal and colonic content of rats. These studies were 
carried out using both cecum and colon contents A and B. 2 mg of each conjugate 
were added to 5 ml of the 10% w/v suspension of cecal and colonic contents (A or 
B) and the mixture was stirred and incubated at 37 °C under N2 flow to maintain the 
anaerobic condition as the cecum and the colon are naturally anaerobic. At 
appropriate time intervals, 0.5 ml of the suspension were withdrawn, acidified by 
addition of 1.0 M HCl solution (0.3 ml) and centrifuged at 7000 rpm for 5 minutes. 
0.4 ml of the supernatant was ultrafiltered using a membrane filter (Corning
®
 Spin-
X
®
, a centrifugation of 5000 rpm for 20 min). The concentration of conjugates, 
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MTZ, and MTZ-SUC was determined in 20 l of the filtrate by HPLC as described 
above. Each experiment was carried out in triplicate. 
 
7.2.5. Statistical analysis 
Data analysis was carried out with the software package R, version 2.10.1. Results 
are expressed as the mean ± standard deviation (S.D.). Multiple comparisons of 
means (Tukey test) were used to substantiate statistical differences between groups, 
while Student’s t-test was used for comparison between two samples. Significance 
was tested at the 0.05 level of probability (p). 
 
7.3. Results and discussion 
7.3.1. Preparation and characterization of the ester conjugates and their 
intermediates 
CDs are natural oligosaccharide with a considerable number of hydroxyl groups 
(-CD: 18 OH; -CD: 21 OH and -CD: 24 OH), which could be esterified with 
carboxylic groups of different drugs to prepare CD-drug conjugates. Since MTZ 
does not have any carboxylic acid group, succinic anhydride was used to insert a 
spacer capable of interacting with the OH group of MTZ [23]. This reaction was 
catalyzed by 4-dimethylaminopyridine (DMAP), as previously reported by other 
authors [21]. Then, MTZ-SUC was directly conjugated to CD by the activated ester 
method. Carbonyldiimidazole (CDI) was chosen as coupling agents because it 
allows one-pot ester formation (Scheme 1). Practically, the acylimidazole (activated 
species, 2’) is formed in 1 hour by reacting the metronidazole hemiester and CDI in 
anhydrous dimethyl sulfoxide and then the cyclodextrin is added directly to the 
reaction mixture to give the final ester conjugate [24]. The reaction mixture should 
be kept under N2 flow because both CDI and the acylimidazole are instable in water. 
It is believed that the excess of triethylamine activates the cyclodextrin hydroxyl 
groups through general base catalysis [21]. The MTZ-CD conjugate was separated 
by column chromatography. The chemical structure of the conjugates (3, 4, 5) 
(Figure 1) was determined by IR, CHN, and 
1
H and 
13
C NMR spectroscopy.  
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Scheme 1. Synthesis of metronidazole-succinyl-α-, β-, γ-CD conjugates (3, 4, 5). 
 
Elemental analysis and NMR studies showed that the conjugate was monosubtituted 
and 
1
H NMR spectroscopy indicated that MTZ-SUC was introduced at the 
secondary O2 or O3 hydroxyl group of the CD. 
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Figure 1. Chemical structures of metronidazole-succinyl-α-, β-, γ-CD conjugates (3, 4, 5). 
 
This was demonstrated by the NMR. In fact, in the 
1
H NMR spectrum of the -CD 
derivative, the H2 and H3 protons of the CD gave new signals at 4.12 and 4.4 ppm 
(peaks H3’-CD and H2’-CD) respectively, in addition to the original signals at 3.412-
3.9 ppm (H3-CD and H2-CD). In the 
13
C NMR spectrum (Figure 2) the appearance 
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of new signals at 69.56 and 73.67 ppm (peaks C3’-CD and C2’-CD, respectively) 
besides the original signals at 72.3 and 73.0 ppm (peaks C3-CD and C2-CD, 
respectively) confirmed what 
1
H NMR let us to suppose. Moreover, the C6 carbon 
(C6-CD) located at the primary hydroxyl side gave no additional 
13
C signals. These 
results indicate that MTZ-SUC was introduced at the secondary O2 (prevalently) and 
O3 hydroxyl group of -CD. Similar results were obtained with -CD and -CD 
conjugates. They are in accordance with the results obtained by Yano et al. [11].  
The esterification reaction involved mainly the secondary hydroxyl group in C2 of 
CD [25] because it is more acid than that of C6 [26] and it is not as sterically 
hindered as that of C3 [27].  
 
 
Figure 2. 13C NMR spectrum of MTZ-SUC-a-CD conjugate. See Figure 1 for the atom 
numbering of MTZ-SUC and CD. 
 
To verify if the drug was completely or partially included in the cyclodextrin cavity, 
NMR ROESY spectroscopic studies were conducted. Figure 3 shows ROESY 
spectra of MTZ-SUC--CD. In particular, it was evaluated if the H2 and the –CH3 
substituent of the imidazole ring gave correlation peaks with H3-CD and H5-CD 
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located inside the cyclodextrin cavity, indicating that the ring is included in the CD 
cavity. As can be seen, the interactions are too weak to conclude that the drug is 
completely or partially included in the CD.  
 
Figure 3. ROESY spectrum of MTZ-SUC-a-CD. See Figure 2 for the atom numbering of MTZ-
SUC and CD. 
 
 
This is confirmed by the 3D simulation (Chem 3D Ultra 8.0) of the conjugate that 
revealed that MTZ cannot be accommodated in the cyclodextrin cavity probably 
because of the steric hindrance of the two substituents in position 1 (methyl) and 3 
(nitro) of the imidazole ring (Figure 4).  
The physicochemical properties of MTZ, MTZ-SUC and 3, 4 and 5 conjugates are 
presented in Table 1. 
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Table 1. Physicochemical properties of MTZ, MTZ-SUC and MTZ-SUC-CD conjugates (3, 4, 5). 
Compound Molecular weight Melting point (°C) Yield % 
    
MTZ 171.13  160 - 
MTZ-SUC  271.22 109 90.0 
MTZ-SUC--CD 1225.22 260 24.5 
MTZ-SUC--CD 1388.23 278 25.2 
MTZ-SUC--CD 1550.34 280 24.3 
 
 
                       Figure 4. 3D simulation of MTZ-SUC--CD 
 
7.3.2. Stability studies 
Both esteric bonds of the prodrugs (between drug and spacer and between spacer 
and cyclodextrin) are susceptible to hydrolysis. The hydrolysis could be catalysed by 
acidic or alkaline media or by an enzyme. The colon targeting prodrug should be 
stable in the stomach and small intestine to pass unmodified and reach the colon, 
where the enzymes catalyze the drug-carrier bond hydrolysis thus releasing the drug 
in the site of action. Therefore, stability studies of the cyclodextrin conjugates in 
both acidic and alkaline media were firstly carried out in two different solutions 
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(pH=1.2 and 7.4). The disappearance of the cyclodextrin conjugate and the 
appearance of the released MTZ and MTZ-SUC were monitored during 24 hours 
experiments by HPLC. Results are shown in Figure 5, which shows results of the 
stability studies for -CD conjugate (- and -CD conjugates gave similar results). 
None of the prodrugs released the carried drug during the 24 h experiments in 
aqueous buffers (pH=1.2, Fig 5a and pH=7.4, Fig. 5b). Neither MTZ nor MTZ-SUC 
were released from the prodrugs, and only the MTZ-CD conjugate was detected by 
HPLC thus indicating that both the estereal bonds in conjugates 3, 4 and 5 were 
stable in acid and alkaline pH and that the prepared prodrugs were chemically stable 
in the pH environment of the gastrointestinal tract. 
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Figure 5. Stability studies of MTZ-SUC-α-CD in acid (pH=1.2) and alkaline (pH=7.4) buffers at 
37°C. 5(a) buffer at pH 1.2; 5(b) buffer at pH 7.4. Error bars represent standard deviation, n =3. 
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7.3.3. Drug release studies 
It is expected that the esteric bonds could be hydrolysed by the esterases of the 
cecum and colon. Therefore, we studied the drug release behaviour of the conjugates 
in cecum and colon contents of rats. In a previous work we found that when these 
studies were carried out in cecum or colon contents A (immediately used) neither 
MTZ nor MTZ-SUC were detected by HPLC. However, it is well known that MTZ 
is metabolized in the colon: N-(2-hydroxyethyl)-oxamic acid [28] and acetamide 
[29] are formed when the drug is reduced as a result of the colonic anaerobic 
bacteria activity. Also MTZ-SUC was found to disappear in cecum and colon 
content content A. On the other hand, when these studies were carried out in cecum 
or colon content B (previously frozen and stored at -80 °C) MTZ and MTZ-SUC 
were detected. We concluded that most likely the freezing procedure reduced the 
activity of some enzymes [30].  
Also in this study, the drug release behaviour was studied in both contents A 
(immediately used) and B (previously frozen and stored at -80 °C). In this case the 
disappearance of the cyclodextrin conjugates was monitored. Figures 6, 7 and 8 
show drug release from 3, 4 and 5 in rat cecum and colon content A. As can be seen, 
the conjugates rapidly disappeared (after four hours) but no appreciable amounts of 
MTZ and MTZ-SUC were detected due to their fast metabolization by the colonic 
anaerobic bacteria activity. Release profiles indicated that the amount of MTZ and 
MTZ-SUC increased only up to 8% in the first two hours of the experiments to 
decrease and disappear after 4 hours. This is in accordance with the previously 
obtained results [30]. 
No substantial differences were observed in the release behaviour of the three 
prodrugs in cecum and colon content A but all the three products were rapidly 
hydrolysed. 
However, some differences were observed in the hydrolysis rate of the three 
cyclodextrin conjugates during the first two hours and especially in the beginning of 
the experiments. In fact, after 30 minutes in the colon content A, -CD conjugate 
amount was 65% (Fig. 6b), while  (Fig.7b) and -CD (Fig.8b) conjugates were 60 
and 40%, respectively. Therefore, it seems that as the cyclodextrin ring increases, 
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the rate of hydrolysis is faster (the bigger the CD ring is, the faster the rate of 
hydrolysis). It was no possible to gain insight the mechanism of hydrolysis due to 
the subsequent metabolization of MTZ and MTZ-SUC. 
Preliminary overall obtained results showed that the conjugates are able to reach the 
cecum and colon without significant degradation, while they are selectively 
hydrolysed in the large intestine to release metronidazole. 
Ex vivo hydrolysis studies in the content of cecum and colon of rats B are still in 
progress to verify the effective metronidazole release. 
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Figure 6. MTZ and MTZ-SUC release and MTZ-SUC--CD (3) disappearance during incubation 
of conjugate 3 with freshly prepared contents A of cecum (a) and colon (b) at 37°C. Error bars 
represent standard deviation, n =3 
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Figure 7. MTZ and MTZ-SUC release and MTZ-SUC-β-CD (4) disappearance during incubation 
of conjugate 4 with freshly prepared contents A of cecum (a) and colon (b) at 37°C. Error bars 
represent standard deviation, n =3 
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Figure 8. MTZ and MTZ-SUC release and MTZ-SUC-γ-CD (5) disappearance during incubation 
of conjugate 5 with freshly prepared contents A of cecum (a) and colon (b) at 37°C. Error bars 
represent standard deviation, n =3 
 
7.4. Conclusion 
MTZ-SUC was selectively conjugated via an ester bond to one of the secondary 
hydroxyl group of -, - and -CD. These conjugates were chemically stable in acid 
and alkaline media (pH=1.2 and 7.4), while they were hydrolyzed in cecum and 
colon contents of rats by the action of the enzymes produced by the microflora. In 
conclusion, the present data suggest that metronidazole-succinyl-cyclodextrin 
conjugates could serve as colon-specific prodrugs. 
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Several colon specific delivery systems were prepared, characterized and subjected 
to in vitro, ex vivo and in vivo studies. 
N-Succinyl-chitosan showed that it could be a good carrier candidate for the 
preparation of matrices for colon specific drug delivery. It showed pH-dependent 
swelling behaviour and good mucoadhesivness. Due to its favorable 
physicochemical properties it was able to release the loaded drug selectively at 
colonic pH (pH=7.4). 
The introduction of CD into the matrices resulted in a reduction of drug release from 
the swollen polymeric matrices, while an increase of drug release from the inert 
polymers.  
Moreover 5-ASA loaded N-Succinyl-chitosan microparticles and freeze-dried matrix 
markedly improved efficacy 5-ASA in the healing of induced colitis in rats, 
demonstrating the usefulness of these two formulations in the treatment of 
inflammatory bowel disease. 
On the other hand chitosan and cyclodextrin resulted good carrier systems for the 
preparation of metronidazole-spacer prodrugs. They were basically stable at acidic 
and alkaline pH, while they selectively released the drug in the content of cecum and 
colon of rats, showing that these compounds are susceptible to enzymatic 
hydrolysis. 
Both MTZ-SUC-CHT and MTZ-GLU-CHT seemed to be suitable prodrugs for the 
development of a colonic drug delivery system for MTZ: the first one could be used 
as a delayed drug delivery system while the second one could guarantee a sustained 
drug release. 
MTZ-SUC-CD prodrugs were rapidly hydrolysed after incubation with cecum and 
colon contents of rats. Some differences were observed in the hydrolysis rate of the 
three conjugates especially in the beginning of the experiments. MTZ-SUC--CD 
conjugate hydrolysis rate was the slowest, while MTZ-SUC--CD one was the 
fastest. Obtained results suggested that as the cyclodextrin ring increases, the rate of 
hydrolysis is faster. 
Summarizing the results of this study we may conclude that all the prepared 5-ASA 
and MTZ drug delivery systems are potential carriers for targeting the model drug to 
colon. 
